Magnetic liposomes and related treatment and imaging methods

Bifunctional RNA-loaded nanoparticles with DOTAP and cholesterol enhance DC migration and enable MRI-based tracking, addressing the limitations of cancer vaccine biomarkers and imaging complexity.

JP2024160224AActive Publication Date: 2024-11-13UNIV OF FLORIDA RESEARCH FOUNDATION INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024110694
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-05-08
Filing Date
2024-07-10
Publication Date
2024-11-13
Estimated Expiration
2039-05-08

AI Technical Summary

Technical Problem

The lack of effective biomarkers for tracking dendritic cell migration and the complexity of nuclear medicine-based imaging limit the widespread utilization of cancer vaccines, necessitating a method to enhance DC migration and enable non-radioactive tracking.

Method used

Development of bifunctional RNA-loaded nanoparticles comprising liposomes with DOTAP and cholesterol, optionally containing iron oxide nanoparticles, to enhance DC migration and enable MRI-based tracking.

Benefits of technology

The nanoparticles effectively enhance DC migration to lymph nodes, improve vaccination responses, and allow for MRI-based tracking, providing a non-radioactive method for monitoring therapeutic response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160224000007
    Figure 2024160224000007
  • Figure 2024160224000008
    Figure 2024160224000008
  • Figure 2024160224000009
    Figure 2024160224000009
Patent Text Reader

Abstract

To provide a liposome that leads to the development of bi-functional RNA-loaded nanoparticles (RNA-NPs), enhancing DC migration to lymph nodes and enabling MRI-based tracking of DC migration in vivo.SOLUTION: Provided herein is a liposome comprising ribonucleic acid (RNA) molecules, and a lipid mixture comprising DOTAP and cholesterol, wherein the DOTAP and cholesterol are present in the lipid mixture at a DOTAP:cholesterol ratio of about 3:1 by mass.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 668,608, filed May 8, 2018, the contents of which are incorporated by reference in their entirety.

[0002] Grant Disclosure This invention was made with Government support under CA195563 awarded by the National Institutes of Health. The Government has certain rights in this invention. [Background technology]

[0003] Cancer vaccines are a promising approach to personalized cancer immunotherapy, but the lack of meaningful biomarkers in patients' response to treatment limits their development. In a randomized, double-blind, placebo-controlled study, RNA-pulsed dendritic cells (DCs) were reported to extend progression-free and overall survival in patients with glioblastoma (Mitchell et al, Nature 519:366-369 (2015)). Furthermore, DC migration to lymph nodes, assessed by SPECT / CT imaging, was demonstrated to strongly correlate with clinical outcome. This finding could provide a novel imaging biomarker for responding to DC vaccines, but the complexity and regulatory requirements of nuclear medicine-based imaging of radiolabeled cells limit the widespread utilization of this technology. Thus, there is a need in the art for methods to track DC migration to lymph nodes without the use of radioactivity, and to enhance migration to improve vaccination responses. Summary of the Invention

[0004] Herein, data are presented for the first time that lead to the development of bifunctional RNA-loaded nanoparticles (RNA-NPs) that enhance DC migration to lymph nodes and enable MRI-based tracking of DC migration in vivo. Thus, the present disclosure provides liposomes that include ribonucleic acid (RNA) molecules and a lipid mixture that includes DOTAP and cholesterol. In various embodiments, the liposomes include iron oxide nanoparticles (IONPs). In various aspects, the DOTAP and cholesterol are present in the lipid mixture at a DOTAP:cholesterol mass ratio of about 3:1. Various advantages of the liposomes of the present disclosure are described in more detail below.

[0005] The present disclosure also provides cells comprising the liposomes of the present disclosure, for example, immune cells (e.g., antigen-presenting cells, dendritic cells) comprising the liposomes of the present disclosure. In various embodiments, the cells are transfected with the liposomes. In various examples, the cells take up the liposomes of the present disclosure by endocytosis or pinocytosis. The cells comprising the liposomes of the present disclosure are not limited to any particular mechanism by which the liposomes are taken up by the cells. Also provided are populations of cells, at least 50% of which are cells comprising the liposomes of the present disclosure, for example, cells transfected with the liposomes of the present disclosure.

[0006] The present disclosure further provides compositions, comprising a liposome, a cell (eg, a dendritic cell), or a population of cells, or any combination thereof, of the present disclosure, and a pharma- ceutically acceptable carrier, excipient, or diluent.

[0007] The present disclosure further provides a method of making liposomes. In an exemplary embodiment, the method includes: (A) mixing DOTAP and cholesterol in a DOTAP:cholesterol mass ratio of about 3:1 to form a lipid mixture; (B) drying the lipid mixture; (C) rehydrating the lipid mixture with a rehydration solution to form a rehydrated lipid mixture; and (D) drying the lipid mixture. ) incubating the rehydrated lipid mixture at a temperature above about 40° C. and vortexing the rehydrated lipid mixture intermittently to form liposomes. Liposomes made by the methods of the present disclosure are also provided. Further provided herein are (e.g., transfected) cells comprising liposomes made by the methods of the present disclosure. Also provided are populations of cells, at least 50% of the population being (e.g., transfected) cells comprising liposomes made by the methods of the present disclosure. The present disclosure provides compositions comprising liposomes made by the methods of the present disclosure, cells comprising liposomes, or cell populations described herein, or any combination thereof, and a pharma- ceutically acceptable carrier, excipient, or diluent.

[0008] The present disclosure further provides a method of delivering an RNA molecule to a cell. In an exemplary embodiment, the method includes incubating a cell with a liposome of the present disclosure. In various aspects, the cell is an immune cell. In various examples, the immune cell is an antigen-presenting cell, e.g., a dendritic cell. In various aspects, the immune cell is located in a tumor microenvironment, e.g., the tumor environment of a brain tumor. The liposome of the present disclosure in some aspects activates the immune cell. In various examples, the RNA molecule is an antisense molecule, e.g., an siRNA, that targets a protein of an immune checkpoint pathway. For example, the protein of the immune checkpoint pathway may be PDL1. Thus, in various aspects, an siRNA that targets PDL1 is delivered to the immune cell of the microenvironment. Without being bound to a particular theory, the liposome activates the immune cell of the microenvironment and reduces the expression of a protein of the immune checkpoint pathway to enhance the immune response against the tumor. In various aspects, the RNA molecule encodes a protein, e.g., a tumor antigen. In various aspects, the RNA molecule is an mRNA that encodes a tumor antigen.

[0009] The present disclosure provides a method for treating a subject with a disease.In an exemplary embodiment, the method comprises delivering RNA molecules to the cells of the subject by the method of delivering RNA molecules to cells of the present disclosure.In another exemplary embodiment, the method comprises administering the composition of the present disclosure, which comprises liposomes, cells, populations of cells, or any combination thereof, as described herein, in an amount effective for treating the disease in the subject.

[0010] The present disclosure further provides a method of enhancing an immune response against a tumor or cancer in a subject. In an exemplary embodiment, the method comprises administering to a subject a liposome of the present disclosure in an amount effective to enhance an immune response in the subject. In an exemplary aspect, the enhanced immune response is evident by increased activation of dendritic cells, as demonstrated, for example, by enhanced expression of genes associated with DC activation, enhanced expression of costimulatory molecules on the surface of DCs, increased production of antiviral cytokines (e.g., IFNα), increased T cell stimulation (e.g., as shown by increased IFN-γ production by T cells upon contact with activated DCs), increased migration to lymph nodes, and enhanced inhibition of tumor growth. Thus, the present disclosure further provides a method of increasing activation of DCs or activating DCs. In an exemplary embodiment, the method comprises administering to a subject a liposome of the present disclosure in an amount effective to increase activation of DCs or in an amount effective to activate DCs. Thus, the present disclosure also provides a method of increasing production of antiviral cytokines (e.g., IFNα). In an exemplary embodiment, the method includes administering to a subject a liposome of the present disclosure in an amount effective to increase production of anti-viral cytokines in the subject. Additionally, a method of increasing T cell stimulation in a subject is provided. In an exemplary embodiment, the method includes administering to a subject a liposome of the present disclosure in an amount effective to increase T cell stimulation in the subject. In various aspects, the increased T cell stimulation is evidenced by increased T cell production of IFN-γ. The present disclosure further provides a method of increasing T cell production of IFN-γ. In an exemplary embodiment, the method includes contacting a T cell with a dendritic cell (DC) of the present disclosure, optionally wherein the liposome comprises IONPs and the DC is magnetically coupled to a dendritic cell (DC) of the present disclosure. The liposome is transfected in the presence of a field. Further provided herein is a method for increasing dendritic cell (DC) migration to lymph nodes in a subject. In an exemplary embodiment, the method comprises administering to a subject a composition of the present disclosure in an amount effective to increase DC migration to lymph nodes. Further provided herein is a method for inhibiting tumor growth. In an exemplary embodiment, the method comprises administering to a subject a liposome of the present disclosure in an amount effective to inhibit tumor growth in the subject.

[0011] The present disclosure also provides a method of tracking migration of dendritic cells (DCs) to lymph nodes in a subject. In an exemplary embodiment, the method includes (i) treating the subject according to the treatment method of the present disclosure, where the cells are DCs and the liposomes include IONPs, and (ii) performing magnetic resonance imaging (MRI) on one or more lymph nodes of the subject. In an exemplary aspect, the method includes measuring T2 * Emphasis (T2 * weighted) MRI intensity of control untreated lymph nodes. * Compared with the weighted MRI intensity, T2 * Lymph nodes that show a decrease in enhanced MRI intensity represent lymph nodes to which DCs have migrated. In an exemplary embodiment, a method of tracking DC migration to lymph nodes in a subject includes incubating DCs obtained from the subject with liposomes of the present disclosure and administering the liposome-containing DCs to the subject. The method further includes performing MRI on one or more lymph nodes of the subject following administration of the DCs to the subject. In various aspects, the MRI is performed about 2 days after administration. As further described herein, the method in some aspects includes measuring the T2 * Measure the weighted MRI intensity and T2 * This involves comparing the T2 *A decrease in the weighted MRI intensity is associated with a positive outcome (e.g., a positive therapeutic response) of DC administration. Thus, a method for determining a subject's therapeutic response to a dendritic cell (DC) vaccination therapy in a subject is provided by the present disclosure. In an exemplary embodiment, the method includes (i) treating a subject according to the treatment method of the present disclosure, where the cells are DCs and the liposomes comprise IONPs, and (ii) tracking DC migration to lymph nodes according to the method of tracking DC migration of the present disclosure, where the T2 * If the enhanced MRI intensity decreases, it is determined that the DC vaccination therapy results in a positive therapeutic response in the subject, and following up.

[0012] The present disclosure also provides a method for monitoring a therapeutic response to a dendritic cell (DC) vaccination therapy in a subject. In an exemplary embodiment, the method includes tracking DC migration to lymph nodes according to the disclosed method of tracking DC migration to lymph nodes at a first time point and a second time point, and measuring the T2 * Weighted MRI intensity was T2 of treated lymph nodes at the first time point * A reduction compared to the enhanced MRI intensity indicates an effective therapeutic response to the DC vaccination therapy.

[0013] The present disclosure provides a method of delivering RNA to cells within the microenvironment of a tumor, optionally a brain tumor, comprising intravenously administering a composition of the present disclosure, wherein the composition comprises a liposome. [Brief description of the drawings]

[0014] [Figure 1A] 1 is a graph of the percentage of DCs transfected with GFP RNA containing liposomes with different amounts of cholesterol. [Figure 1B] Graph of % of dendritic cells loaded with RNA delivered by liposomes containing 0% cholesterol (Std-RNA-NP) or 25% cholesterol (Chol-RNA-NP). [Figure 1C]FIG. 1 is a graph of the % of viable dendritic cells loaded with RNA delivered by liposomes containing 0% cholesterol (Std-RNA-NP) or 25% cholesterol (Chol-RNA-NP). [Figure 1D] Graph of IFNγ produced by T cells incubated with dendritic cells transfected with liposomes containing 0% cholesterol and tumor-derived RNA (Std-RNA-NP DCs) or with liposomes containing 25% cholesterol and tumor-derived RNA (Chol-RNA-NP DCs). As controls, non-transfected DCs (naive DCs) and T cells were used in this experiment. [Figure 2A] Immunofluorescence images of the cortex. [Figure 2B] Immunofluorescence images of tumors. [Figure 2C] Graph of Cy5+ cells in brain tumors in mice bearing KR158B-luciferase tumors and injected with liposomes containing 25% cholesterol (Chol-RNA-NP), liposomes with 0% cholesterol (RNA-NP), RNA only, or untreated. [Figure 2D] 1 is a graph of Cy5+ cells in brain tumors in mice bearing GL261 tumors and injected with liposomes containing 25% cholesterol (Chol-RNA-NP), liposomes with 0% cholesterol (RNA-NP), or untreated mice. [Diagram 3] Graph of Cy3+ cells in tumors from mice bearing KR158B-luciferase tumors and injected with liposomes containing 1%, 12.5%, 25%, or 37% cholesterol, plotted as a function of cholesterol content. [Figure 4] A series of fluorescent microscopy images of the tumor or cortex stained with CD31 fluorescent antibody (left column) or liposomes containing Cy3-labeled RNA (middle column) or overlaid (right column). [Figure 5A]Graph of Cy5+CD45+ cells in brain tumors in mice injected with liposomes containing 25% cholesterol (Chol-RNA-NP), liposomes with 0% cholesterol (RNA-NP), RNA only, or untreated. [Figure 5B] FIG. 13 is a graph of the % of CD45+ cells that are Cy5+ in brain tumors of mice injected with liposomes containing 25% cholesterol (Chol-RNA-NP) or 0% cholesterol (RNA-NP). [Figure 5C] FIG. 13 is a graph of MHC class II+CD45+ cells that are Cy5+ in brain tumors of mice injected with liposomes containing 25% cholesterol (Chol-RNA-NP) or liposomes with 0% cholesterol (RNA-NP). [Figure 6A] Graph of Cy5+ cells in the lungs of mice injected with liposomes containing 25% cholesterol (Chol-RNA-NP), liposomes with 0% cholesterol (RNA-NP), untreated, or RNA only (Cy5). [Figure 6B] Graph of Cy5+ cells in the spleens of mice injected with liposomes containing 25% cholesterol (Chol-RNA-NP), liposomes with 0% cholesterol (RNA-NP), untreated, or RNA only (Cy5). [Figure 6C] Graph of Cy5+ cells in livers of mice injected with liposomes containing 25% cholesterol (Chol-RNA-NP), liposomes with 0% cholesterol (RNA-NP), untreated, or RNA only (Cy5). [Figure 6D] Graph of Cy5+ cells in brain tumors of mice injected with liposomes containing 25% cholesterol (Chol-RNA-NP, circles) and liposomes with 0% cholesterol (RNA-NP, squares), plotted as a function of Cy5+ cells in the lungs. [Figure 6E]Graph of Cy5+ cells in brain tumors of mice injected with liposomes containing 25% cholesterol (Chol-RNA-NP, ◯) or liposomes with 0% cholesterol (RNA-NP, □), plotted as a function of Cy5+ cells in the spleen. [Figure 6F] Graph of Cy5+ cells in brain tumors of mice injected with liposomes containing 25% cholesterol (Chol-RNA-NP, ◯) or liposomes with 0% cholesterol (RNA-NP, □), plotted as a function of Cy5+ cells in the liver. [Figure 7A] FIG. 1 is a schematic diagram of the basic steps for making liposomes containing iron oxide nanoparticles. [Figure 7B] Cryo-TEM images of iron oxide liposomes. [Figure 7C] 1 is a graph of particle concentration plotted as a function of particle size. [Figure 7D] Image of an agarose gel where IO-RNA-NPs containing various amounts of iron oxide were loaded into the wells. In this image, bright bands indicate the presence of unbound mRNA. The absence of bands in the column indicates that all of the RNA was bound by the particle formulation. [Figure 7E] Graph of the % of cells transfected with liposomes containing green fluorescent protein (GFP) RNA with (IO-RNA-NP) or without iron oxide (RNA-NP), iron oxide particles alone, nanoparticles alone, or untreated cells. [Figure 7F] Graph of % of DCs transfected with liposomes containing iron oxide and cholesterol (Chol-IO-RNA-NP) or iron oxide but no cholesterol (IO-RNA-NP). [Figure 7G] Bright field images of DCs transfected with Cy3-labeled IO-RNA-NPs. [Figure 7H] Fluorescence images of DCs transfected with Cy3-labeled IO-RNA-NPs. [Figure 7I]1 is a graph of the percentage of DCs transfected with GFP RNA containing liposomes containing cholesterol and different amounts of carboxylated iron oxide nanoparticles. [Figure 8A] Graph of the percentage of DCs transfected with GFP RNA containing iron oxide liposomes in the presence (magnet) or absence (no magnet) of a magnetic field. [Figure 8B] 1 is a graph of the percentage of DCs transfected with GFP RNA containing iron oxide liposomes with various amounts of iron oxide in the presence of a magnetic field. [Figure 8C] Graph of the percentage of DCs transfected with GFP RNA containing magnetic liposomes in the presence of a magnetic field for 30 minutes (30 min + magnet), or in the absence of a magnetic field for 30 minutes (30 min), or overnight in the absence of a magnetic field (18 hours). [Figure 8D] Photograph of a tube containing DCs placed on a magnetic separator for 30 min, showing visible clumps of cells attracted to the side of the tube where the magnetic field is strongest. [Figure 8E] Graph of % of Cy5+ positive bone marrow DC incubated with magnetic liposomes in the presence (static magnet) or absence (no magnet) of a magnetic field. [Figure 8F] Graph of the percentage of DCs transfected with GFP RNA containing IO liposomes in the presence of a magnetic field for 30 minutes (static magnet), or in the absence of a magnetic field for 30 minutes (no magnet), or in the absence of a magnetic field overnight (no magnet, overnight). [Figure 9A] FIG. 1 is a diagram of the pathway showing the effect of RNA-loaded magnetic liposomes on cytokine production. [Figure 9B] Graph of IFNα produced by DCs electroporated with GFP RNA (Electro), DCs incubated with RNA- and IO-loaded liposomes (GFP mRNA+NP), untreated or treated simply with nanoparticles (NP only). [Figure 9C]1 is a graph of IFNγ produced by unstimulated or T cells stimulated with DCs incubated with RNA-loaded liposomes. [Figure 9D] Graph of DsRed+ cells in lymph nodes of mice injected with DsRed DCs loaded with Cy3-labeled OVA RNA (18 h) or Cy3-labeled GFP RNA via electroporation (left) or IO-RNA-NPs (right) at 18, 48, or 72 h. [Figure 10A] Representative images of treated and untreated lymph nodes in T2*-weighted images with TR / TE of 207 / 17 and T2_RARE-weighted images for each set of imaging parameters. [Figure 10B] Quantification of the data in FIG. 10A. [Figure 10C] Graph of the number of cells in each lymph node plotted against the relative change in intensity in T2* weighted images with fat saturation. [Figure 10D] 1 is a graph of the mean relative change in lymph node size. [Figure 11A] Graph of tumor size plotted as a function of days after tumor implantation in untreated or IO-RNA-NP-treated mice. [Figure 11B] Graph of tumor size plotted as a function of days after tumor implantation for untreated or IO-RNA-NP-treated mice divided into two groups: responders and non-responders. [Figure 11C] 13 is a graph of tumor size in responders and non-responders at day 27 in mice treated with IO-RNA-NP. [Figure 11D] 13 is a graph of T2* fat suppressed (T2*fatsat) image intensity of responders and non-responders on day 2 in mice treated with IO RNA NPs. [Figure 11E] 1 is a table of sequences that did not correlate with survival. [Figure 11F] 2 is a graph of T2* fat-suppressed image intensity on day 2 plotted as a function of tumor volume on day 27. [Figure 12A] We show that Chol-RNA-NPs deliver mRNA to brain tumors. Figure 12A is a representative immunofluorescence microscopy image of KR158b-luciferase tumors 24 hours after injection with Cy3-labeled Chol-RNA-NPs. Figures 12B-12C are graphs of flow cytometry-based quantification of Cy5-labeled RNA in intracranial KR158b (Figure 12B) or GL261 (Figure 12C) tumors 24 hours after injection with Cy5-labeled liposomes. Figure 12D is a graph of RNA delivery to brain tumors after vaccination with RNA-NPs containing various amounts of cholesterol. [Figure 12B] We show that Chol-RNA-NPs deliver mRNA to brain tumors. Figure 12A is a representative immunofluorescence microscopy image of KR158b-luciferase tumors 24 hours after injection with Cy3-labeled Chol-RNA-NPs. Figures 12B-12C are graphs of flow cytometry-based quantification of Cy5-labeled RNA in intracranial KR158b (Figure 12B) or GL261 (Figure 12C) tumors 24 hours after injection with Cy5-labeled liposomes. Figure 12D is a graph of RNA delivery to brain tumors after vaccination with RNA-NPs containing various amounts of cholesterol. [Figure 12C] We show that Chol-RNA-NPs deliver mRNA to brain tumors. Figure 12A is a representative immunofluorescence microscopy image of KR158b-luciferase tumors 24 hours after injection with Cy3-labeled Chol-RNA-NPs. Figures 12B-12C are graphs of flow cytometry-based quantification of Cy5-labeled RNA in intracranial KR158b (Figure 12B) or GL261 (Figure 12C) tumors 24 hours after injection with Cy5-labeled liposomes. Figure 12D is a graph of RNA delivery to brain tumors after vaccination with RNA-NPs containing various amounts of cholesterol. [Figure 12D]We show that Chol-RNA-NPs deliver mRNA to brain tumors. Figure 12A is a representative immunofluorescence microscopy image of KR158b-luciferase tumors 24 hours after injection with Cy3-labeled Chol-RNA-NPs. Figures 12B-12C are graphs of flow cytometry-based quantification of Cy5-labeled RNA in intracranial KR158b (Figure 12B) or GL261 (Figure 12C) tumors 24 hours after injection with Cy5-labeled liposomes. Figure 12D is a graph of RNA delivery to brain tumors after vaccination with RNA-NPs containing various amounts of cholesterol. [Figure 13A] We show that Chol-RNA-NPs transfect perivascular TAMs. Figure 13A shows representative immunofluorescence images of KR15b tumors and cortex of mice treated with Cy3-labeled Chol-RNA-NPs. Figures 13B-13H show flow cytometry graphs of tumors vaccinated or not with fluorescently labeled Chol-RNA-NPs. Data are presented as the percentage of total cells that are CD45+ (Figures 13B, 13C), the percentage of CD45+ cells that are macrophages (Figures 13D-13E), the percentage of CD45+ cells that are antigen presenting cells (Figures 13F-G), and the percentage of CD45+ cells that are CD11b+Ly6G / 6C+ (Figure 13H) for untreated tumors, treated tumors (Chol(Bulk)), and RNA+ cells within treated tumors (Chol(RNA+)) from mice bearing intracranial GL261 (13B, 13D, 13F, 13H) or KR158b-luciferase (13C, 13E, 13G). [Figure 13B]We show that Chol-RNA-NPs transfect perivascular TAMs. Figure 13A shows representative immunofluorescence images of KR15b tumors and cortex of mice treated with Cy3-labeled Chol-RNA-NPs. Figures 13B-13H show flow cytometry graphs of tumors vaccinated or not with fluorescently labeled Chol-RNA-NPs. Data are presented as the percentage of total cells that are CD45+ (Figures 13B, 13C), the percentage of CD45+ cells that are macrophages (Figures 13D-13E), the percentage of CD45+ cells that are antigen presenting cells (Figures 13F-G), and the percentage of CD45+ cells that are CD11b+Ly6G / 6C+ (Figure 13H) for untreated tumors, treated tumors (Chol(Bulk)), and RNA+ cells within treated tumors (Chol(RNA+)) from mice bearing intracranial GL261 (13B, 13D, 13F, 13H) or KR158b-luciferase (13C, 13E, 13G). [Figure 13C] We show that Chol-RNA-NPs transfect perivascular TAMs. Figure 13A shows representative immunofluorescence images of KR15b tumors and cortex of mice treated with Cy3-labeled Chol-RNA-NPs. Figures 13B-13H show flow cytometry graphs of tumors vaccinated or not with fluorescently labeled Chol-RNA-NPs. Data are presented as the percentage of total cells that are CD45+ (Figures 13B, 13C), the percentage of CD45+ cells that are macrophages (Figures 13D-13E), the percentage of CD45+ cells that are antigen presenting cells (Figures 13F-G), and the percentage of CD45+ cells that are CD11b+Ly6G / 6C+ (Figure 13H) for untreated tumors, treated tumors (Chol(Bulk)), and RNA+ cells within treated tumors (Chol(RNA+)) from mice bearing intracranial GL261 (13B, 13D, 13F, 13H) or KR158b-luciferase (13C, 13E, 13G). [Figure 13D]We show that Chol-RNA-NPs transfect perivascular TAMs. Figure 13A shows representative immunofluorescence images of KR15b tumors and cortex of mice treated with Cy3-labeled Chol-RNA-NPs. Figures 13B-13H show flow cytometry graphs of tumors vaccinated or not with fluorescently labeled Chol-RNA-NPs. Data are presented as the percentage of total cells that are CD45+ (Figures 13B, 13C), the percentage of CD45+ cells that are macrophages (Figures 13D-13E), the percentage of CD45+ cells that are antigen presenting cells (Figures 13F-G), and the percentage of CD45+ cells that are CD11b+Ly6G / 6C+ (Figure 13H) for untreated tumors, treated tumors (Chol(Bulk)), and RNA+ cells within treated tumors (Chol(RNA+)) from mice bearing intracranial GL261 (13B, 13D, 13F, 13H) or KR158b-luciferase (13C, 13E, 13G). [Figure 13E] We show that Chol-RNA-NPs transfect perivascular TAMs. Figure 13A shows representative immunofluorescence images of KR15b tumors and cortex of mice treated with Cy3-labeled Chol-RNA-NPs. Figures 13B-13H show flow cytometry graphs of tumors vaccinated or not with fluorescently labeled Chol-RNA-NPs. Data are presented as the percentage of total cells that are CD45+ (Figures 13B, 13C), the percentage of CD45+ cells that are macrophages (Figures 13D-13E), the percentage of CD45+ cells that are antigen presenting cells (Figures 13F-G), and the percentage of CD45+ cells that are CD11b+Ly6G / 6C+ (Figure 13H) for untreated tumors, treated tumors (Chol(Bulk)), and RNA+ cells within treated tumors (Chol(RNA+)) from mice bearing intracranial GL261 (13B, 13D, 13F, 13H) or KR158b-luciferase (13C, 13E, 13G). [Figure 13F]We show that Chol-RNA-NPs transfect perivascular TAMs. Figure 13A shows representative immunofluorescence images of KR15b tumors and cortex of mice treated with Cy3-labeled Chol-RNA-NPs. Figures 13B-13H show flow cytometry graphs of tumors vaccinated or not with fluorescently labeled Chol-RNA-NPs. Data are presented as the percentage of total cells that are CD45+ (Figures 13B, 13C), the percentage of CD45+ cells that are macrophages (Figures 13D-13E), the percentage of CD45+ cells that are antigen presenting cells (Figures 13F-G), and the percentage of CD45+ cells that are CD11b+Ly6G / 6C+ (Figure 13H) for untreated tumors, treated tumors (Chol(Bulk)), and RNA+ cells within treated tumors (Chol(RNA+)) from mice bearing intracranial GL261 (13B, 13D, 13F, 13H) or KR158b-luciferase (13C, 13E, 13G). [Figure 13G] We show that Chol-RNA-NPs transfect perivascular TAMs. Figure 13A shows representative immunofluorescence images of KR15b tumors and cortex of mice treated with Cy3-labeled Chol-RNA-NPs. Figures 13B-13H show flow cytometry graphs of tumors vaccinated or not with fluorescently labeled Chol-RNA-NPs. Data are presented as the percentage of total cells that are CD45+ (Figures 13B, 13C), the percentage of CD45+ cells that are macrophages (Figures 13D-13E), the percentage of CD45+ cells that are antigen presenting cells (Figures 13F-G), and the percentage of CD45+ cells that are CD11b+Ly6G / 6C+ (Figure 13H) for untreated tumors, treated tumors (Chol(Bulk)), and RNA+ cells within treated tumors (Chol(RNA+)) from mice bearing intracranial GL261 (13B, 13D, 13F, 13H) or KR158b-luciferase (13C, 13E, 13G). [Figure 13H]We show that Chol-RNA-NPs transfect perivascular TAMs. Figure 13A shows representative immunofluorescence images of KR15b tumors and cortex of mice treated with Cy3-labeled Chol-RNA-NPs. Figures 13B-13H show flow cytometry graphs of tumors vaccinated or not with fluorescently labeled Chol-RNA-NPs. Data are presented as the percentage of total cells that are CD45+ (Figures 13B, 13C), the percentage of CD45+ cells that are macrophages (Figures 13D-13E), the percentage of CD45+ cells that are antigen presenting cells (Figures 13F-G), and the percentage of CD45+ cells that are CD11b+Ly6G / 6C+ (Figure 13H) for untreated tumors, treated tumors (Chol(Bulk)), and RNA+ cells within treated tumors (Chol(RNA+)) from mice bearing intracranial GL261 (13B, 13D, 13F, 13H) or KR158b-luciferase (13C, 13E, 13G). [Figure 14A] Chol-RNA-NPs activate CD45+ cells in brain tumors. Figures 14A-14D are flow cytometry graphs of activation markers on antigen-presenting cells in intracranial KR158b tumors 24 hours after vaccination. Figure 14A, MHCII expression on F4 / 80+CD45+, Figure 14B, CD80 expression on MHCII+CD45+ cells, Figure 14C, CD86 expression on MHCII+CD45+ cells. [Figure 14B] Chol-RNA-NPs activate CD45+ cells in brain tumors. Figures 14A-14D are flow cytometry graphs of activation markers on antigen-presenting cells in intracranial KR158b tumors 24 hours after vaccination. Figure 14A, MHCII expression on F4 / 80+CD45+, Figure 14B, CD80 expression on MHCII+CD45+ cells, Figure 14C, CD86 expression on MHCII+CD45+ cells. [Figure 14C]Chol-RNA-NPs activate CD45+ cells in brain tumors. Figures 14A-14D are flow cytometry graphs of activation markers on antigen-presenting cells in intracranial KR158b tumors 24 hours after vaccination. Figure 14A, MHCII expression on F4 / 80+CD45+, Figure 14B, CD80 expression on MHCII+CD45+ cells, Figure 14C, CD86 expression on MHCII+CD45+ cells. [Figure 15A] Chol-RNA-NPs deliver PDL1 siRNA to brain tumors. Figures 15A-15B, Expression of GFP (15A) and PDL1 (15B) 48 hours after transfection of DC2.4 with Chol-RNA-NPs carrying GFP mRNA and siRNA targeting PDL1. Figure 15C, Uptake of Cy5-labeled PDL1-siRNA in KR158b brain tumors 24 hours after intravenous injection of Chol-RNA-NPs. Figures 15D-15F, Flow cytometry characterizing transfected cells by expression of MHCII, F4 / 80, and CD11b and Ly6G / 6C (MDSC). [Figure 15B] Chol-RNA-NPs deliver PDL1 siRNA to brain tumors. Figures 15A-15B, Expression of GFP (15A) and PDL1 (15B) 48 hours after transfection of DC2.4 with Chol-RNA-NPs carrying GFP mRNA and siRNA targeting PDL1. Figure 15C, Uptake of Cy5-labeled PDL1-siRNA in KR158b brain tumors 24 hours after intravenous injection of Chol-RNA-NPs. Figures 15D-15F, Flow cytometry characterizing transfected cells by expression of MHCII, F4 / 80, and CD11b and Ly6G / 6C (MDSC). [Figure 15C]Chol-RNA-NPs deliver PDL1 siRNA to brain tumors. Figures 15A-15B, Expression of GFP (15A) and PDL1 (15B) 48 hours after transfection of DC2.4 with Chol-RNA-NPs carrying GFP mRNA and siRNA targeting PDL1. Figure 15C, Uptake of Cy5-labeled PDL1-siRNA in KR158b brain tumors 24 hours after intravenous injection of Chol-RNA-NPs. Figures 15D-15F, Flow cytometry characterizing transfected cells by expression of MHCII, F4 / 80, and CD11b and Ly6G / 6C (MDSC). [Figure 15D] Chol-RNA-NPs deliver PDL1 siRNA to brain tumors. Figures 15A-15B, Expression of GFP (15A) and PDL1 (15B) 48 hours after transfection of DC2.4 with Chol-RNA-NPs carrying GFP mRNA and siRNA targeting PDL1. Figure 15C, Uptake of Cy5-labeled PDL1-siRNA in KR158b brain tumors 24 hours after intravenous injection of Chol-RNA-NPs. Figures 15D-15F, Flow cytometry characterizing transfected cells by expression of MHCII, F4 / 80, and CD11b and Ly6G / 6C (MDSC). [Figure 15E] Chol-RNA-NPs deliver PDL1 siRNA to brain tumors. Figures 15A-15B, Expression of GFP (15A) and PDL1 (15B) 48 hours after transfection of DC2.4 with Chol-RNA-NPs carrying GFP mRNA and siRNA targeting PDL1. Figure 15C, Uptake of Cy5-labeled PDL1-siRNA in KR158b brain tumors 24 hours after intravenous injection of Chol-RNA-NPs. Figures 15D-15F, Flow cytometry characterizing transfected cells by expression of MHCII, F4 / 80, and CD11b and Ly6G / 6C (MDSC). [Figure 15F]Chol-RNA-NPs deliver PDL1 siRNA to brain tumors. Figures 15A-15B, Expression of GFP (15A) and PDL1 (15B) 48 hours after transfection of DC2.4 with Chol-RNA-NPs carrying GFP mRNA and siRNA targeting PDL1. Figure 15C, Uptake of Cy5-labeled PDL1-siRNA in KR158b brain tumors 24 hours after intravenous injection of Chol-RNA-NPs. Figures 15D-15F, Flow cytometry characterizing transfected cells by expression of MHCII, F4 / 80, and CD11b and Ly6G / 6C (MDSC). [Figure 15G] We show that siPDL1 reduces the expression of PDL1 in KLuc brain tumors. Figure 15G-15I, PDL1 expression in CD45+MHCII+ cells 24 hours after vaccination with Chol-RNA-NPs carrying siPDL1. Figure 15J, PDL1 expression in CD11b+Ly6G / 6C+ cells (MDSCs) in intracranial KR158b-luciferase tumors 24 hours after completing 3x daily vaccination with Chol-RNA-NPs carrying siPDL1. [Figure 15H] We show that siPDL1 reduces the expression of PDL1 in KLuc brain tumors. Figure 15G-15I, PDL1 expression in CD45+MHCII+ cells 24 hours after vaccination with Chol-RNA-NPs carrying siPDL1. Figure 15J, PDL1 expression in CD11b+Ly6G / 6C+ cells (MDSCs) in intracranial KR158b-luciferase tumors 24 hours after completing 3x daily vaccination with Chol-RNA-NPs carrying siPDL1. [Figure 15I] We show that siPDL1 reduces the expression of PDL1 in KLuc brain tumors. Figure 15G-15I, PDL1 expression in CD45+MHCII+ cells 24 hours after vaccination with Chol-RNA-NPs carrying siPDL1. Figure 15J, PDL1 expression in CD11b+Ly6G / 6C+ cells (MDSCs) in intracranial KR158b-luciferase tumors 24 hours after completing 3x daily vaccination with Chol-RNA-NPs carrying siPDL1. [Figure 15J] We show that siPDL1 reduces the expression of PDL1 in KLuc brain tumors. Figure 15G-15I, PDL1 expression in CD45+MHCII+ cells 24 hours after vaccination with Chol-RNA-NPs carrying siPDL1. Figure 15J, PDL1 expression in CD11b+Ly6G / 6C+ cells (MDSCs) in intracranial KR158b-luciferase tumors 24 hours after completing 3x daily vaccination with Chol-RNA-NPs carrying siPDL1. [Figure 16] Schematic diagram showing that IO-RNA-NPs were generated by combining commercially available IONPs and tumor antigen-encoding mRNA with a combination of previously translated lipids with exceptional capacity for mRNA delivery and DC activation. Incubation of these particles with DCs in the presence or absence of a magnetic field led to significant DC activation, characterized by dramatic changes in RNA expression and enhanced ability to stimulate antigen-specific T cells. IO-RNA-NPs enabled MRI-based detection of DC migration to lymph nodes, which directly correlated with survival in mouse tumor models. [Figure 17A]Figure 17 shows the development and characterization of iron oxide loaded RNA nanoparticles. Figure 17A, Representative cryo-TEM of RNA-NPs with and without iron oxide (IO). Figure 17B, Size distribution of RNA-NPs with and without IO (100 μg IO:1 mg lipid) assessed by Nanosight. Figure 17C, Saturation magnetization of IO-RNA-NPs (100 μg IO:1 mg lipid) assessed by SQUID magnetometer. Figure 17D, Agarose gel electrophoresis demonstrating RNA binding to different formulations of IO-RNA-NPs (labeled as mass of IONPs in each formulation per mg lipid) after 15 min incubation with RNA at different lipid:RNA ratios. Figure 17E, RNA binding capacity of RNA-NPs containing various amounts of iron oxide. Values ​​on graphs are p-values ​​obtained from one-way ANOVA and Tukey's test, n=4 per group. Figure 17F: DC2.4 viability after 24 hours of incubation with RNA-NPs assessed by flow cytometry (n=3). Figure 17G: DC2.4 uptake of Cy5-labeled RNA after overnight incubation with RNA-NPs assessed by flow cytometry (n=3). [Figure 17B]Figure 17 shows the development and characterization of iron oxide loaded RNA nanoparticles. Figure 17A, Representative cryo-TEM of RNA-NPs with and without iron oxide (IO). Figure 17B, Size distribution of RNA-NPs with and without IO (100 μg IO:1 mg lipid) assessed by Nanosight. Figure 17C, Saturation magnetization of IO-RNA-NPs (100 μg IO:1 mg lipid) assessed by SQUID magnetometer. Figure 17D, Agarose gel electrophoresis demonstrating RNA binding to different formulations of IO-RNA-NPs (labeled as mass of IONPs in each formulation per mg lipid) after 15 min incubation with RNA at different lipid:RNA ratios. Figure 17E, RNA binding capacity of RNA-NPs containing various amounts of iron oxide. Values ​​on graphs are p-values ​​obtained from one-way ANOVA and Tukey's test, n=4 per group. Figure 17F: DC2.4 viability after 24 hours of incubation with RNA-NPs assessed by flow cytometry (n=3). Figure 17G: DC2.4 uptake of Cy5-labeled RNA after overnight incubation with RNA-NPs assessed by flow cytometry (n=3). [Figure 17C]Figure 17 shows the development and characterization of iron oxide loaded RNA nanoparticles. Figure 17A, Representative cryo-TEM of RNA-NPs with and without iron oxide (IO). Figure 17B, Size distribution of RNA-NPs with and without IO (100 μg IO:1 mg lipid) assessed by Nanosight. Figure 17C, Saturation magnetization of IO-RNA-NPs (100 μg IO:1 mg lipid) assessed by SQUID magnetometer. Figure 17D, Agarose gel electrophoresis demonstrating RNA binding to different formulations of IO-RNA-NPs (labeled as mass of IONPs in each formulation per mg lipid) after 15 min incubation with RNA at different lipid:RNA ratios. Figure 17E, RNA binding capacity of RNA-NPs containing various amounts of iron oxide. Values ​​on graphs are p-values ​​obtained from one-way ANOVA and Tukey's test, n=4 per group. Figure 17F: DC2.4 viability after 24 hours of incubation with RNA-NPs assessed by flow cytometry (n=3). Figure 17G: DC2.4 uptake of Cy5-labeled RNA after overnight incubation with RNA-NPs assessed by flow cytometry (n=3). [Figure 17D]Figure 17 shows the development and characterization of iron oxide loaded RNA nanoparticles. Figure 17A, Representative cryo-TEM of RNA-NPs with and without iron oxide (IO). Figure 17B, Size distribution of RNA-NPs with and without IO (100 μg IO:1 mg lipid) assessed by Nanosight. Figure 17C, Saturation magnetization of IO-RNA-NPs (100 μg IO:1 mg lipid) assessed by SQUID magnetometer. Figure 17D, Agarose gel electrophoresis demonstrating RNA binding to different formulations of IO-RNA-NPs (labeled as mass of IONPs in each formulation per mg lipid) after 15 min incubation with RNA at different lipid:RNA ratios. Figure 17E, RNA binding capacity of RNA-NPs containing various amounts of iron oxide. Values ​​on graphs are p-values ​​obtained from one-way ANOVA and Tukey's test, n=4 per group. Figure 17F: DC2.4 viability after 24 hours of incubation with RNA-NPs assessed by flow cytometry (n=3). Figure 17G: DC2.4 uptake of Cy5-labeled RNA after overnight incubation with RNA-NPs assessed by flow cytometry (n=3). [Fig. 17E-17F]Figure 17 shows the development and characterization of iron oxide loaded RNA nanoparticles. Figure 17A, Representative cryo-TEM of RNA-NPs with and without iron oxide (IO). Figure 17B, Size distribution of RNA-NPs with and without IO (100 μg IO:1 mg lipid) assessed by Nanosight. Figure 17C, Saturation magnetization of IO-RNA-NPs (100 μg IO:1 mg lipid) assessed by SQUID magnetometer. Figure 17D, Agarose gel electrophoresis demonstrating RNA binding to different formulations of IO-RNA-NPs (labeled as mass of IONPs in each formulation per mg lipid) after 15 min incubation with RNA at different lipid:RNA ratios. Figure 17E, RNA binding capacity of RNA-NPs containing various amounts of iron oxide. Values ​​on graphs are p-values ​​obtained from one-way ANOVA and Tukey's test, n=4 per group. Figure 17F: DC2.4 viability after 24 hours of incubation with RNA-NPs assessed by flow cytometry (n=3). Figure 17G: DC2.4 uptake of Cy5-labeled RNA after overnight incubation with RNA-NPs assessed by flow cytometry (n=3). [Figure 17G]Figure 17 shows the development and characterization of iron oxide loaded RNA nanoparticles. Figure 17A, Representative cryo-TEM of RNA-NPs with and without iron oxide (IO). Figure 17B, Size distribution of RNA-NPs with and without IO (100 μg IO:1 mg lipid) assessed by Nanosight. Figure 17C, Saturation magnetization of IO-RNA-NPs (100 μg IO:1 mg lipid) assessed by SQUID magnetometer. Figure 17D, Agarose gel electrophoresis demonstrating RNA binding to different formulations of IO-RNA-NPs (labeled as mass of IONPs in each formulation per mg lipid) after 15 min incubation with RNA at different lipid:RNA ratios. Figure 17E, RNA binding capacity of RNA-NPs containing various amounts of iron oxide. Values ​​on graphs are p-values ​​obtained from one-way ANOVA and Tukey's test, n=4 per group. Figure 17F: DC2.4 viability after 24 hours of incubation with RNA-NPs assessed by flow cytometry (n=3). Figure 17G: DC2.4 uptake of Cy5-labeled RNA after overnight incubation with RNA-NPs assessed by flow cytometry (n=3). [Figure 18A]We show that iron oxide enhances dendritic cell transfection and activation. Figure 18A, Representative images of GFP expression in DC2.4 after 24 h incubation with RNA-NPs synthesized with various amounts of iron oxide per mg lipid. Figure 18B, Quantification of transfection efficiency from (a) using flow cytometry. For statistical analysis, we used analysis of variance with Pearson's correlation and Tukey's test. Figure 18C, Fluorescence in BMDCs after transfection with GFP-RNA-loaded liposomes with no iron oxide, iron oxide encapsulated in liposomes (IO-liposomes), or iron oxide added to the medium outside the liposomes. For statistical analysis, we used analysis of variance with Tukey's test. Figures 18D-18E, ELISA of IFN-γ produced after 2 days of co-culture of DCs loaded with OVA RNA via RNA-NPs or IO-RNA-NPs combined with naïve splenocytes (d) or antigen-experienced OVA T cells (e) from OT1 mice. FIG. 18F, Transfection efficiency in DC2.4 after 30 min incubation with IO-RNA-NPs in the presence or absence of a magnetic field. Pearson's correlation coefficient was used for statistical analysis. FIG. 18G, Viability of BMDCs 24 h after 30 min incubation with IO-RNA-NPs in the presence or absence of a magnetic field. FIG. 18H, GFP expression in BMDCs after 30 min incubation with IO-RNA-NPs (100 μg IONP:1 mg lipid) in the presence or absence of a magnetic field or overnight incubation in the absence of a magnetic field. One-way ANOVA with Tukey's test was used for statistical analysis. FIG. 18I, ELISA of IFN-γ produced during 2 days of co-culture of antigen-naive OT1 T cells with BMDCs treated with IO-RNA-NPs with OVA mRNA in the presence of a magnetic field for either overnight or 30 min. For all experiments, n=3, error bars represent standard deviation from the mean, and values ​​are P values ​​calculated from two-tailed unpaired two-group t-tests or Tukey's test, as appropriate. Results in Figures 18A-18C and 18F-18I each represent at least two replicate experiments. ns=not significantly different. [Figure 18B] We show that iron oxide enhances dendritic cell transfection and activation. Figure 18A, Representative images of GFP expression in DC2.4 after 24 h incubation with RNA-NPs synthesized with various amounts of iron oxide per mg lipid. Figure 18B, Quantification of transfection efficiency from (a) using flow cytometry. For statistical analysis, we used analysis of variance with Pearson's correlation and Tukey's test. Figure 18C, Fluorescence in BMDCs after transfection with GFP-RNA-loaded liposomes with no iron oxide, iron oxide encapsulated in liposomes (IO-liposomes), or iron oxide added to the medium outside the liposomes. For statistical analysis, we used analysis of variance with Tukey's test. Figures 18D-18E, ELISA of IFN-γ produced after 2 days of co-culture of DCs loaded with OVA RNA via RNA-NPs or IO-RNA-NPs combined with naïve splenocytes (d) or antigen-experienced OVA T cells (e) from OT1 mice. FIG. 18F, Transfection efficiency in DC2.4 after 30 min incubation with IO-RNA-NPs in the presence or absence of a magnetic field. Pearson's correlation coefficient was used for statistical analysis. FIG. 18G, Viability of BMDCs 24 h after 30 min incubation with IO-RNA-NPs in the presence or absence of a magnetic field. FIG. 18H, GFP expression in BMDCs after 30 min incubation with IO-RNA-NPs (100 μg IONP:1 mg lipid) in the presence or absence of a magnetic field or overnight incubation in the absence of a magnetic field. One-way ANOVA with Tukey's test was used for statistical analysis. FIG. 18I, ELISA of IFN-γ produced during 2 days of co-culture of antigen-naive OT1 T cells with BMDCs treated with IO-RNA-NPs with OVA mRNA in the presence of a magnetic field for either overnight or 30 min. For all experiments, n=3, error bars represent standard deviation from the mean, and values ​​are P values ​​calculated from two-tailed unpaired two-group t-tests or Tukey's test, as appropriate. Results in Figures 18A-18C and 18F-18I each represent at least two replicate experiments. ns=not significantly different. [Figure 18C] We show that iron oxide enhances dendritic cell transfection and activation. Figure 18A, Representative images of GFP expression in DC2.4 after 24 h incubation with RNA-NPs synthesized with various amounts of iron oxide per mg lipid. Figure 18B, Quantification of transfection efficiency from (a) using flow cytometry. For statistical analysis, we used analysis of variance with Pearson's correlation and Tukey's test. Figure 18C, Fluorescence in BMDCs after transfection with GFP-RNA-loaded liposomes with no iron oxide, iron oxide encapsulated in liposomes (IO-liposomes), or iron oxide added to the medium outside the liposomes. For statistical analysis, we used analysis of variance with Tukey's test. Figures 18D-18E, ELISA of IFN-γ produced after 2 days of co-culture of DCs loaded with OVA RNA via RNA-NPs or IO-RNA-NPs combined with naïve splenocytes (d) or antigen-experienced OVA T cells (e) from OT1 mice. FIG. 18F, Transfection efficiency in DC2.4 after 30 min incubation with IO-RNA-NPs in the presence or absence of a magnetic field. Pearson's correlation coefficient was used for statistical analysis. FIG. 18G, Viability of BMDCs 24 h after 30 min incubation with IO-RNA-NPs in the presence or absence of a magnetic field. FIG. 18H, GFP expression in BMDCs after 30 min incubation with IO-RNA-NPs (100 μg IONP:1 mg lipid) in the presence or absence of a magnetic field or overnight incubation in the absence of a magnetic field. One-way ANOVA with Tukey's test was used for statistical analysis. FIG. 18I, ELISA of IFN-γ produced during 2 days of co-culture of antigen-naive OT1 T cells with BMDCs treated with IO-RNA-NPs with OVA mRNA in the presence of a magnetic field for either overnight or 30 min. For all experiments, n=3, error bars represent standard deviation from the mean, and values ​​are P values ​​calculated from two-tailed unpaired two-group t-tests or Tukey's test, as appropriate. Results in Figures 18A-18C and 18F-18I each represent at least two replicate experiments. ns=not significantly different. [Figure 18D]We show that iron oxide enhances dendritic cell transfection and activation. Figure 18A, Representative images of GFP expression in DC2.4 after 24 h incubation with RNA-NPs synthesized with various amounts of iron oxide per mg lipid. Figure 18B, Quantification of transfection efficiency from (a) using flow cytometry. For statistical analysis, we used analysis of variance with Pearson's correlation and Tukey's test. Figure 18C, Fluorescence in BMDCs after transfection with GFP-RNA-loaded liposomes with no iron oxide, iron oxide encapsulated in liposomes (IO-liposomes), or iron oxide added to the medium outside the liposomes. For statistical analysis, we used analysis of variance with Tukey's test. Figures 18D-18E, ELISA of IFN-γ produced after 2 days of co-culture of DCs loaded with OVA RNA via RNA-NPs or IO-RNA-NPs combined with naïve splenocytes (d) or antigen-experienced OVA T cells (e) from OT1 mice. FIG. 18F, Transfection efficiency in DC2.4 after 30 min incubation with IO-RNA-NPs in the presence or absence of a magnetic field. Pearson's correlation coefficient was used for statistical analysis. FIG. 18G, Viability of BMDCs 24 h after 30 min incubation with IO-RNA-NPs in the presence or absence of a magnetic field. FIG. 18H, GFP expression in BMDCs after 30 min incubation with IO-RNA-NPs (100 μg IONP:1 mg lipid) in the presence or absence of a magnetic field or overnight incubation in the absence of a magnetic field. One-way ANOVA with Tukey's test was used for statistical analysis. FIG. 18I, ELISA of IFN-γ produced during 2 days of co-culture of antigen-naive OT1 T cells with BMDCs treated with IO-RNA-NPs with OVA mRNA in the presence of a magnetic field for either overnight or 30 min. For all experiments, n=3, error bars represent standard deviation from the mean, and values ​​are P values ​​calculated from two-tailed unpaired two-group t-tests or Tukey's test, as appropriate. Results in Figures 18A-18C and 18F-18I each represent at least two replicate experiments. ns=not significantly different. [Figure 18E] We show that iron oxide enhances dendritic cell transfection and activation. Figure 18A, Representative images of GFP expression in DC2.4 after 24 h incubation with RNA-NPs synthesized with various amounts of iron oxide per mg lipid. Figure 18B, Quantification of transfection efficiency from (a) using flow cytometry. For statistical analysis, we used analysis of variance with Pearson's correlation and Tukey's test. Figure 18C, Fluorescence in BMDCs after transfection with GFP-RNA-loaded liposomes with no iron oxide, iron oxide encapsulated in liposomes (IO-liposomes), or iron oxide added to the medium outside the liposomes. For statistical analysis, we used analysis of variance with Tukey's test. Figures 18D-18E, ELISA of IFN-γ produced after 2 days of co-culture of DCs loaded with OVA RNA via RNA-NPs or IO-RNA-NPs combined with naïve splenocytes (d) or antigen-experienced OVA T cells (e) from OT1 mice. FIG. 18F, Transfection efficiency in DC2.4 after 30 min incubation with IO-RNA-NPs in the presence or absence of a magnetic field. Pearson's correlation coefficient was used for statistical analysis. FIG. 18G, Viability of BMDCs 24 h after 30 min incubation with IO-RNA-NPs in the presence or absence of a magnetic field. FIG. 18H, GFP expression in BMDCs after 30 min incubation with IO-RNA-NPs (100 μg IONP:1 mg lipid) in the presence or absence of a magnetic field or overnight incubation in the absence of a magnetic field. One-way ANOVA with Tukey's test was used for statistical analysis. FIG. 18I, ELISA of IFN-γ produced during 2 days of co-culture of antigen-naive OT1 T cells with BMDCs treated with IO-RNA-NPs with OVA mRNA in the presence of a magnetic field for either overnight or 30 min. For all experiments, n=3, error bars represent standard deviation from the mean, and values ​​are P values ​​calculated from two-tailed unpaired two-group t-tests or Tukey's test, as appropriate. Results in Figures 18A-18C and 18F-18I each represent at least two replicate experiments. ns=not significantly different. [Figure 18F] We show that iron oxide enhances dendritic cell transfection and activation. Figure 18A, Representative images of GFP expression in DC2.4 after 24 h incubation with RNA-NPs synthesized with various amounts of iron oxide per mg lipid. Figure 18B, Quantification of transfection efficiency from (a) using flow cytometry. For statistical analysis, we used analysis of variance with Pearson's correlation and Tukey's test. Figure 18C, Fluorescence in BMDCs after transfection with GFP-RNA-loaded liposomes with no iron oxide, iron oxide encapsulated in liposomes (IO-liposomes), or iron oxide added to the medium outside the liposomes. For statistical analysis, we used analysis of variance with Tukey's test. Figures 18D-18E, ELISA of IFN-γ produced after 2 days of co-culture of DCs loaded with OVA RNA via RNA-NPs or IO-RNA-NPs combined with naïve splenocytes (d) or antigen-experienced OVA T cells (e) from OT1 mice. FIG. 18F, Transfection efficiency in DC2.4 after 30 min incubation with IO-RNA-NPs in the presence or absence of a magnetic field. Pearson's correlation coefficient was used for statistical analysis. FIG. 18G, Viability of BMDCs 24 h after 30 min incubation with IO-RNA-NPs in the presence or absence of a magnetic field. FIG. 18H, GFP expression in BMDCs after 30 min incubation with IO-RNA-NPs (100 μg IONP:1 mg lipid) in the presence or absence of a magnetic field or overnight incubation in the absence of a magnetic field. One-way ANOVA with Tukey's test was used for statistical analysis. FIG. 18I, ELISA of IFN-γ produced during 2 days of co-culture of antigen-naive OT1 T cells with BMDCs treated with IO-RNA-NPs with OVA mRNA in the presence of a magnetic field for either overnight or 30 min. For all experiments, n=3, error bars represent standard deviation from the mean, and values ​​are P values ​​calculated from two-tailed unpaired two-group t-tests or Tukey's test, as appropriate. Results in Figures 18A-18C and 18F-18I each represent at least two replicate experiments. ns=not significantly different. [Figure 18G]We show that iron oxide enhances dendritic cell transfection and activation. Figure 18A, Representative images of GFP expression in DC2.4 after 24 h incubation with RNA-NPs synthesized with various amounts of iron oxide per mg lipid. Figure 18B, Quantification of transfection efficiency from (a) using flow cytometry. For statistical analysis, we used analysis of variance with Pearson's correlation and Tukey's test. Figure 18C, Fluorescence in BMDCs after transfection with GFP-RNA-loaded liposomes with no iron oxide, iron oxide encapsulated in liposomes (IO-liposomes), or iron oxide added to the medium outside the liposomes. For statistical analysis, we used analysis of variance with Tukey's test. Figures 18D-18E, ELISA of IFN-γ produced after 2 days of co-culture of DCs loaded with OVA RNA via RNA-NPs or IO-RNA-NPs combined with naïve splenocytes (d) or antigen-experienced OVA T cells (e) from OT1 mice. FIG. 18F, Transfection efficiency in DC2.4 after 30 min incubation with IO-RNA-NPs in the presence or absence of a magnetic field. Pearson's correlation coefficient was used for statistical analysis. FIG. 18G, Viability of BMDCs 24 h after 30 min incubation with IO-RNA-NPs in the presence or absence of a magnetic field. FIG. 18H, GFP expression in BMDCs after 30 min incubation with IO-RNA-NPs (100 μg IONP:1 mg lipid) in the presence or absence of a magnetic field or overnight incubation in the absence of a magnetic field. One-way ANOVA with Tukey's test was used for statistical analysis. FIG. 18I, ELISA of IFN-γ produced during 2 days of co-culture of antigen-naive OT1 T cells with BMDCs treated with IO-RNA-NPs with OVA mRNA in the presence of a magnetic field for either overnight or 30 min. For all experiments, n=3, error bars represent standard deviation from the mean, and values ​​are P values ​​calculated from two-tailed unpaired two-group t-tests or Tukey's test, as appropriate. Results in Figures 18A-18C and 18F-18I each represent at least two replicate experiments. ns=not significantly different. [Figure 18H] We show that iron oxide enhances dendritic cell transfection and activation. Figure 18A, Representative images of GFP expression in DC2.4 after 24 h incubation with RNA-NPs synthesized with various amounts of iron oxide per mg lipid. Figure 18B, Quantification of transfection efficiency from (a) using flow cytometry. For statistical analysis, we used analysis of variance with Pearson's correlation and Tukey's test. Figure 18C, Fluorescence in BMDCs after transfection with GFP-RNA-loaded liposomes with no iron oxide, iron oxide encapsulated in liposomes (IO-liposomes), or iron oxide added to the medium outside the liposomes. For statistical analysis, we used analysis of variance with Tukey's test. Figures 18D-18E, ELISA of IFN-γ produced after 2 days of co-culture of DCs loaded with OVA RNA via RNA-NPs or IO-RNA-NPs combined with naïve splenocytes (d) or antigen-experienced OVA T cells (e) from OT1 mice. FIG. 18F, Transfection efficiency in DC2.4 after 30 min incubation with IO-RNA-NPs in the presence or absence of a magnetic field. Pearson's correlation coefficient was used for statistical analysis. FIG. 18G, Viability of BMDCs 24 h after 30 min incubation with IO-RNA-NPs in the presence or absence of a magnetic field. FIG. 18H, GFP expression in BMDCs after 30 min incubation with IO-RNA-NPs (100 μg IONP:1 mg lipid) in the presence or absence of a magnetic field or overnight incubation in the absence of a magnetic field. One-way ANOVA with Tukey's test was used for statistical analysis. FIG. 18I, ELISA of IFN-γ produced during 2 days of co-culture of antigen-naive OT1 T cells with BMDCs treated with IO-RNA-NPs with OVA mRNA in the presence of a magnetic field for either overnight or 30 min. For all experiments, n=3, error bars represent standard deviation from the mean, and values ​​are P values ​​calculated from two-tailed unpaired two-group t-tests or Tukey's test, as appropriate. Results in Figures 18A-18C and 18F-18I each represent at least two replicate experiments. ns=not significantly different. [Figure 18I] We show that iron oxide enhances dendritic cell transfection and activation. Figure 18A, Representative images of GFP expression in DC2.4 after 24 h incubation with RNA-NPs synthesized with various amounts of iron oxide per mg lipid. Figure 18B, Quantification of transfection efficiency from (a) using flow cytometry. For statistical analysis, we used analysis of variance with Pearson's correlation and Tukey's test. Figure 18C, Fluorescence in BMDCs after transfection with GFP-RNA-loaded liposomes with no iron oxide, iron oxide encapsulated in liposomes (IO-liposomes), or iron oxide added to the medium outside the liposomes. For statistical analysis, we used analysis of variance with Tukey's test. Figures 18D-18E, ELISA of IFN-γ produced after 2 days of co-culture of DCs loaded with OVA RNA via RNA-NPs or IO-RNA-NPs combined with naïve splenocytes (d) or antigen-experienced OVA T cells (e) from OT1 mice. FIG. 18F, Transfection efficiency in DC2.4 after 30 min incubation with IO-RNA-NPs in the presence or absence of a magnetic field. Pearson's correlation coefficient was used for statistical analysis. FIG. 18G, Viability of BMDCs 24 h after 30 min incubation with IO-RNA-NPs in the presence or absence of a magnetic field. FIG. 18H, GFP expression in BMDCs after 30 min incubation with IO-RNA-NPs (100 μg IONP:1 mg lipid) in the presence or absence of a magnetic field or overnight incubation in the absence of a magnetic field. One-way ANOVA with Tukey's test was used for statistical analysis. FIG. 18I, ELISA of IFN-γ produced during 2 days of co-culture of antigen-naive OT1 T cells with BMDCs treated with IO-RNA-NPs with OVA mRNA in the presence of a magnetic field for either overnight or 30 min. For all experiments, n=3, error bars represent standard deviation from the mean, and values ​​are P values ​​calculated from two-tailed unpaired two-group t-tests or Tukey's test, as appropriate. Results in Figures 18A-18C and 18F-18I each represent at least two replicate experiments. ns=not significantly different. [Figure 19A] We show that IO-RNA-NP enhances DC activation and migration compared to electroporation. Figure 19A, Representative flow cytometry plots (left), transfection efficiency (middle) and geometric mean fluorescence intensity (right) 24 hours after transfection of BMDCs with GFP RNA via electroporation or IO-RNA-NP (n=3). Figure 19B, Fluorescence microscopy images of DC2.4 incubated overnight with Cy3-labeled RNA-NP. Figure 19C, Heatmap comparing RNA expression in BMDCs 24 hours after treatment with IO-RNA-NP, electroporation or medium alone. Figures 19D-19E, Phenotypic markers of activation assessed by flow cytometry (Figure 19D) and IFN-α release assessed by ELISA (Figure 19E) for BMDCs 24 hours after treatment with electroporation or IO-RNA-NP. One-way ANOVA and Tukey's test were used for statistical analysis. Figure 19F, Migration of IO-RNA-NP-loaded BMDCs to the VDLN at various time points after intradermal injection. Statistical analysis was completed with Wilcoxon matched-pairs rank sum test (n>4) or Student's paired t-test (n<4). Figure 19G, Tumor growth in mice bearing subcutaneous B16F10-OVA tumors after a single vaccination with 500,000 BMDCs pulsed with OVA mRNA via electroporation or IO-RNA-NP, and 10,000,000 naive OT1 T cells (untreated: n=6, electroporated: n=6, IO-RNA-NP: n=13). Data are pooled from two independent experiments. Two-way ANOVA was used for statistical analysis. Results in Figures 19A, 19B, and 19D-19G represent at least two replicate experiments. Numbers on the graphs are P values. [Figure 19B]We show that IO-RNA-NP enhances DC activation and migration compared to electroporation. Figure 19A, Representative flow cytometry plots (left), transfection efficiency (middle) and geometric mean fluorescence intensity (right) 24 hours after transfection of BMDCs with GFP RNA via electroporation or IO-RNA-NP (n=3). Figure 19B, Fluorescence microscopy images of DC2.4 incubated overnight with Cy3-labeled RNA-NP. Figure 19C, Heatmap comparing RNA expression in BMDCs 24 hours after treatment with IO-RNA-NP, electroporation or medium alone. Figures 19D-19E, Phenotypic markers of activation assessed by flow cytometry (Figure 19D) and IFN-α release assessed by ELISA (Figure 19E) for BMDCs 24 hours after treatment with electroporation or IO-RNA-NP. One-way ANOVA and Tukey's test were used for statistical analysis. Figure 19F, Migration of IO-RNA-NP-loaded BMDCs to the VDLN at various time points after intradermal injection. Statistical analysis was completed with Wilcoxon matched-pairs rank sum test (n>4) or Student's paired t-test (n<4). Figure 19G, Tumor growth in mice bearing subcutaneous B16F10-OVA tumors after a single vaccination with 500,000 BMDCs pulsed with OVA mRNA via electroporation or IO-RNA-NP, and 10,000,000 naive OT1 T cells (untreated: n=6, electroporated: n=6, IO-RNA-NP: n=13). Data are pooled from two independent experiments. Two-way ANOVA was used for statistical analysis. Results in Figures 19A, 19B, and 19D-19G represent at least two replicate experiments. Numbers on the graphs are P values. [Figure 19C]We show that IO-RNA-NP enhances DC activation and migration compared to electroporation. Figure 19A, Representative flow cytometry plots (left), transfection efficiency (middle) and geometric mean fluorescence intensity (right) 24 hours after transfection of BMDCs with GFP RNA via electroporation or IO-RNA-NP (n=3). Figure 19B, Fluorescence microscopy images of DC2.4 incubated overnight with Cy3-labeled RNA-NP. Figure 19C, Heatmap comparing RNA expression in BMDCs 24 hours after treatment with IO-RNA-NP, electroporation or medium alone. Figures 19D-19E, Phenotypic markers of activation assessed by flow cytometry (Figure 19D) and IFN-α release assessed by ELISA (Figure 19E) for BMDCs 24 hours after treatment with electroporation or IO-RNA-NP. One-way ANOVA and Tukey's test were used for statistical analysis. Figure 19F, Migration of IO-RNA-NP-loaded BMDCs to the VDLN at various time points after intradermal injection. Statistical analysis was completed with Wilcoxon matched-pairs rank sum test (n>4) or Student's paired t-test (n<4). Figure 19G, Tumor growth in mice bearing subcutaneous B16F10-OVA tumors after a single vaccination with 500,000 BMDCs pulsed with OVA mRNA via electroporation or IO-RNA-NP, and 10,000,000 naive OT1 T cells (untreated: n=6, electroporated: n=6, IO-RNA-NP: n=13). Data are pooled from two independent experiments. Two-way ANOVA was used for statistical analysis. Results in Figures 19A, 19B, and 19D-19G represent at least two replicate experiments. Numbers on the graphs are P values. [Figure 19D]We show that IO-RNA-NP enhances DC activation and migration compared to electroporation. Figure 19A, Representative flow cytometry plots (left), transfection efficiency (middle) and geometric mean fluorescence intensity (right) 24 hours after transfection of BMDCs with GFP RNA via electroporation or IO-RNA-NP (n=3). Figure 19B, Fluorescence microscopy images of DC2.4 incubated overnight with Cy3-labeled RNA-NP. Figure 19C, Heatmap comparing RNA expression in BMDCs 24 hours after treatment with IO-RNA-NP, electroporation or medium alone. Figures 19D-19E, Phenotypic markers of activation assessed by flow cytometry (Figure 19D) and IFN-α release assessed by ELISA (Figure 19E) for BMDCs 24 hours after treatment with electroporation or IO-RNA-NP. One-way ANOVA and Tukey's test were used for statistical analysis. Figure 19F, Migration of IO-RNA-NP-loaded BMDCs to the VDLN at various time points after intradermal injection. Statistical analysis was completed with Wilcoxon matched-pairs rank sum test (n>4) or Student's paired t-test (n<4). Figure 19G, Tumor growth in mice bearing subcutaneous B16F10-OVA tumors after a single vaccination with 500,000 BMDCs pulsed with OVA mRNA via electroporation or IO-RNA-NP, and 10,000,000 naive OT1 T cells (untreated: n=6, electroporated: n=6, IO-RNA-NP: n=13). Data are pooled from two independent experiments. Two-way ANOVA was used for statistical analysis. Results in Figures 19A, 19B, and 19D-19G represent at least two replicate experiments. Numbers on the graphs are P values. [Figure 19E]We show that IO-RNA-NP enhances DC activation and migration compared to electroporation. Figure 19A, Representative flow cytometry plots (left), transfection efficiency (middle) and geometric mean fluorescence intensity (right) 24 hours after transfection of BMDCs with GFP RNA via electroporation or IO-RNA-NP (n=3). Figure 19B, Fluorescence microscopy images of DC2.4 incubated overnight with Cy3-labeled RNA-NP. Figure 19C, Heatmap comparing RNA expression in BMDCs 24 hours after treatment with IO-RNA-NP, electroporation or medium alone. Figures 19D-19E, Phenotypic markers of activation assessed by flow cytometry (Figure 19D) and IFN-α release assessed by ELISA (Figure 19E) for BMDCs 24 hours after treatment with electroporation or IO-RNA-NP. One-way ANOVA and Tukey's test were used for statistical analysis. Figure 19F, Migration of IO-RNA-NP-loaded BMDCs to the VDLN at various time points after intradermal injection. Statistical analysis was completed with Wilcoxon matched-pairs rank sum test (n>4) or Student's paired t-test (n<4). Figure 19G, Tumor growth in mice bearing subcutaneous B16F10-OVA tumors after a single vaccination with 500,000 BMDCs pulsed with OVA mRNA via electroporation or IO-RNA-NP, and 10,000,000 naive OT1 T cells (untreated: n=6, electroporated: n=6, IO-RNA-NP: n=13). Data are pooled from two independent experiments. Two-way ANOVA was used for statistical analysis. Results in Figures 19A, 19B, and 19D-19G represent at least two replicate experiments. Numbers on the graphs are P values. [Figure 19F]We show that IO-RNA-NP enhances DC activation and migration compared to electroporation. Figure 19A, Representative flow cytometry plots (left), transfection efficiency (middle) and geometric mean fluorescence intensity (right) 24 hours after transfection of BMDCs with GFP RNA via electroporation or IO-RNA-NP (n=3). Figure 19B, Fluorescence microscopy images of DC2.4 incubated overnight with Cy3-labeled RNA-NP. Figure 19C, Heatmap comparing RNA expression in BMDCs 24 hours after treatment with IO-RNA-NP, electroporation or medium alone. Figures 19D-19E, Phenotypic markers of activation assessed by flow cytometry (Figure 19D) and IFN-α release assessed by ELISA (Figure 19E) for BMDCs 24 hours after treatment with electroporation or IO-RNA-NP. One-way ANOVA and Tukey's test were used for statistical analysis. Figure 19F, Migration of IO-RNA-NP-loaded BMDCs to the VDLN at various time points after intradermal injection. Statistical analysis was completed with Wilcoxon matched-pairs rank sum test (n>4) or Student's paired t-test (n<4). Figure 19G, Tumor growth in mice bearing subcutaneous B16F10-OVA tumors after a single vaccination with 500,000 BMDCs pulsed with OVA mRNA via electroporation or IO-RNA-NP, and 10,000,000 naive OT1 T cells (untreated: n=6, electroporated: n=6, IO-RNA-NP: n=13). Data are pooled from two independent experiments. Two-way ANOVA was used for statistical analysis. Results in Figures 19A, 19B, and 19D-19G represent at least two replicate experiments. Numbers on the graphs are P values. [Figure 19G]We show that IO-RNA-NP enhances DC activation and migration compared to electroporation. Figure 19A, Representative flow cytometry plots (left), transfection efficiency (middle) and geometric mean fluorescence intensity (right) 24 hours after transfection of BMDCs with GFP RNA via electroporation or IO-RNA-NP (n=3). Figure 19B, Fluorescence microscopy images of DC2.4 incubated overnight with Cy3-labeled RNA-NP. Figure 19C, Heatmap comparing RNA expression in BMDCs 24 hours after treatment with IO-RNA-NP, electroporation or medium alone. Figures 19D-19E, Phenotypic markers of activation assessed by flow cytometry (Figure 19D) and IFN-α release assessed by ELISA (Figure 19E) for BMDCs 24 hours after treatment with electroporation or IO-RNA-NP. One-way ANOVA and Tukey's test were used for statistical analysis. Figure 19F, Migration of IO-RNA-NP-loaded BMDCs to the VDLN at various time points after intradermal injection. Statistical analysis was completed with Wilcoxon matched-pairs rank sum test (n>4) or Student's paired t-test (n<4). Figure 19G, Tumor growth in mice bearing subcutaneous B16F10-OVA tumors after a single vaccination with 500,000 BMDCs pulsed with OVA mRNA via electroporation or IO-RNA-NP, and 10,000,000 naive OT1 T cells (untreated: n=6, electroporated: n=6, IO-RNA-NP: n=13). Data are pooled from two independent experiments. Two-way ANOVA was used for statistical analysis. Results in Figures 19A, 19B, and 19D-19G represent at least two replicate experiments. Numbers on the graphs are P values. [Figure 20A]We show that IO-RNA-NPs enable quantitative cell tracking by MRI. Figure 20A, T2*-weighted MRI images 48 hours after vaccination with IO-RNA-NP-loaded DsRed+ DCs in the left groin. The yellow border indicates lymph nodes on the treated (right) and untreated (left) sides. Figure 20B, Exemplary flow cytometry plots demonstrating gating on DsRed+ cells in lymph nodes. Figure 20C, Correlation of relative lymph node size between treated and untreated lymph nodes and absolute number of DCs in the lymph nodes. Data are combined from two independent experiments. Figure 20D, Correlation of relative T2*-weighted MRI intensity and absolute number of labeled cells in treated and untreated lymph nodes. Data represent two replicate experiments. p-values ​​and r-values ​​are derived from Pearson correlation. [Figure 20B] We show that IO-RNA-NPs enable quantitative cell tracking by MRI. Figure 20A, T2*-weighted MRI images 48 hours after vaccination with IO-RNA-NP-loaded DsRed+ DCs in the left groin. The yellow border indicates lymph nodes on the treated (right) and untreated (left) sides. Figure 20B, Exemplary flow cytometry plots demonstrating gating on DsRed+ cells in lymph nodes. Figure 20C, Correlation of relative lymph node size between treated and untreated lymph nodes and absolute number of DCs in the lymph nodes. Data are combined from two independent experiments. Figure 20D, Correlation of relative T2*-weighted MRI intensity and absolute number of labeled cells in treated and untreated lymph nodes. Data represent two replicate experiments. p-values ​​and r-values ​​are derived from Pearson correlation. [Figure 20C]We show that IO-RNA-NPs enable quantitative cell tracking by MRI. Figure 20A, T2*-weighted MRI images 48 hours after vaccination with IO-RNA-NP-loaded DsRed+ DCs in the left groin. The yellow border indicates lymph nodes on the treated (right) and untreated (left) sides. Figure 20B, Exemplary flow cytometry plots demonstrating gating on DsRed+ cells in lymph nodes. Figure 20C, Correlation of relative lymph node size between treated and untreated lymph nodes and absolute number of DCs in the lymph nodes. Data are combined from two independent experiments. Figure 20D, Correlation of relative T2*-weighted MRI intensity and absolute number of labeled cells in treated and untreated lymph nodes. Data represent two replicate experiments. p-values ​​and r-values ​​are derived from Pearson correlation. [Figure 20D] We show that IO-RNA-NPs enable quantitative cell tracking by MRI. Figure 20A, T2*-weighted MRI images 48 hours after vaccination with IO-RNA-NP-loaded DsRed+ DCs in the left groin. The yellow border indicates lymph nodes on the treated (right) and untreated (left) sides. Figure 20B, Exemplary flow cytometry plots demonstrating gating on DsRed+ cells in lymph nodes. Figure 20C, Correlation of relative lymph node size between treated and untreated lymph nodes and absolute number of DCs in the lymph nodes. Data are combined from two independent experiments. Figure 20D, Correlation of relative T2*-weighted MRI intensity and absolute number of labeled cells in treated and untreated lymph nodes. Data represent two replicate experiments. p-values ​​and r-values ​​are derived from Pearson correlation. [Figure 21A]Figure 21 shows that DC migration detected by MRI predicts response to DC vaccine. Mice bearing subcutaneous B16F10-OVA tumors were treated with BMDCs loaded with IO-RNA-NPs carrying ovalbumin mRNA. Figure 21A, Tumor growth over time between treated mice (n=7) and untreated mice (n=5). Values ​​on the graph are P values ​​calculated by unpaired Student's t-test. Comparison of tumor growth over time is evaluated by two-way ANOVA. Figure 21B, Individual treated tumor growth divided into "responders" and "non-responders". Figure 21C, Correlation of relative change in MRI detected lymph node intensity (relative LN intensity) in treated compared to untreated lymph nodes with tumor size at days 2 and 27. Dotted lines indicate the 25th and 75th percentiles of lymph node relative MRI intensity. Data points from mice with significant MRI-predicted DC migration as indicated by relative VDLN intensity in the bottom 25th percentile are Xs in Figure 21E and Figure 21E, data points from mice with moderate VDLN intensity in the middle 50th percentile are dots in Figure 21D and Figure 21E, and data points from mice with high VDLN intensity in the top 75th percentile are squares in Figure 21D and Figure 21E. Figure 21D-21E, Correlation of MRI-detected DC migration on day 2 with tumor size (d) and survival rate (n=10) (e). Numbers in graphs c-e represent Pearson's correlation coefficient (r) and P value (p). Figure 21F-21H, Individual tumor growth curves (Figure 21F), summary data (Figure 21G), and tumor size at multiple time points separated by MRI intensity on day 2 post-vaccination. Numbers on the graphs are p-values ​​calculated from analysis of variance (FIG. 21G) and two-tailed unpaired t-test (FIG. 21H). [Figure 21B]Figure 21 shows that DC migration detected by MRI predicts response to DC vaccine. Mice bearing subcutaneous B16F10-OVA tumors were treated with BMDCs loaded with IO-RNA-NPs carrying ovalbumin mRNA. Figure 21A, Tumor growth over time between treated mice (n=7) and untreated mice (n=5). Values ​​on the graph are P values ​​calculated by unpaired Student's t-test. Comparison of tumor growth over time is evaluated by two-way ANOVA. Figure 21B, Individual treated tumor growth divided into "responders" and "non-responders". Figure 21C, Correlation of relative change in MRI detected lymph node intensity (relative LN intensity) in treated compared to untreated lymph nodes with tumor size at days 2 and 27. Dotted lines indicate the 25th and 75th percentiles of lymph node relative MRI intensity. Data points from mice with significant MRI-predicted DC migration as indicated by relative VDLN intensity in the bottom 25th percentile are Xs in Figure 21E and Figure 21E, data points from mice with moderate VDLN intensity in the middle 50th percentile are dots in Figure 21D and Figure 21E, and data points from mice with high VDLN intensity in the top 75th percentile are squares in Figure 21D and Figure 21E. Figure 21D-21E, Correlation of MRI-detected DC migration on day 2 with tumor size (d) and survival rate (n=10) (e). Numbers in graphs c-e represent Pearson's correlation coefficient (r) and P value (p). Figure 21F-21H, Individual tumor growth curves (Figure 21F), summary data (Figure 21G), and tumor size at multiple time points separated by MRI intensity on day 2 post-vaccination. Numbers on the graphs are p-values ​​calculated from analysis of variance (FIG. 21G) and two-tailed unpaired t-test (FIG. 21H). [Figure 21C]Figure 21 shows that DC migration detected by MRI predicts response to DC vaccine. Mice bearing subcutaneous B16F10-OVA tumors were treated with BMDCs loaded with IO-RNA-NPs carrying ovalbumin mRNA. Figure 21A, Tumor growth over time between treated mice (n=7) and untreated mice (n=5). Values ​​on the graph are P values ​​calculated by unpaired Student's t-test. Comparison of tumor growth over time is evaluated by two-way ANOVA. Figure 21B, Individual treated tumor growth divided into "responders" and "non-responders". Figure 21C, Correlation of relative change in MRI detected lymph node intensity (relative LN intensity) in treated compared to untreated lymph nodes with tumor size at days 2 and 27. Dotted lines indicate the 25th and 75th percentiles of lymph node relative MRI intensity. Data points from mice with significant MRI-predicted DC migration as indicated by relative VDLN intensity in the bottom 25th percentile are Xs in Figure 21E and Figure 21E, data points from mice with moderate VDLN intensity in the middle 50th percentile are dots in Figure 21D and Figure 21E, and data points from mice with high VDLN intensity in the top 75th percentile are squares in Figure 21D and Figure 21E. Figure 21D-21E, Correlation of MRI-detected DC migration on day 2 with tumor size (d) and survival rate (n=10) (e). Numbers in graphs c-e represent Pearson's correlation coefficient (r) and P value (p). Figure 21F-21H, Individual tumor growth curves (Figure 21F), summary data (Figure 21G), and tumor size at multiple time points separated by MRI intensity on day 2 post-vaccination. Numbers on the graphs are p-values ​​calculated from analysis of variance (FIG. 21G) and two-tailed unpaired t-test (FIG. 21H). [Figure 21D]Figure 21 shows that DC migration detected by MRI predicts response to DC vaccine. Mice bearing subcutaneous B16F10-OVA tumors were treated with BMDCs loaded with IO-RNA-NPs carrying ovalbumin mRNA. Figure 21A, Tumor growth over time between treated mice (n=7) and untreated mice (n=5). Values ​​on the graph are P values ​​calculated by unpaired Student's t-test. Comparison of tumor growth over time is evaluated by two-way ANOVA. Figure 21B, Individual treated tumor growth divided into "responders" and "non-responders". Figure 21C, Correlation of relative change in MRI detected lymph node intensity (relative LN intensity) in treated compared to untreated lymph nodes with tumor size at days 2 and 27. Dotted lines indicate the 25th and 75th percentiles of lymph node relative MRI intensity. Data points from mice with significant MRI-predicted DC migration as indicated by relative VDLN intensity in the bottom 25th percentile are Xs in Figure 21E and Figure 21E, data points from mice with moderate VDLN intensity in the middle 50th percentile are dots in Figure 21D and Figure 21E, and data points from mice with high VDLN intensity in the top 75th percentile are squares in Figure 21D and Figure 21E. Figure 21D-21E, Correlation of MRI-detected DC migration on day 2 with tumor size (d) and survival rate (n=10) (e). Numbers in graphs c-e represent Pearson's correlation coefficient (r) and P value (p). Figure 21F-21H, Individual tumor growth curves (Figure 21F), summary data (Figure 21G), and tumor size at multiple time points separated by MRI intensity on day 2 post-vaccination. Numbers on the graphs are p-values ​​calculated from analysis of variance (FIG. 21G) and two-tailed unpaired t-test (FIG. 21H). [Figure 21E]Figure 21 shows that DC migration detected by MRI predicts response to DC vaccine. Mice bearing subcutaneous B16F10-OVA tumors were treated with BMDCs loaded with IO-RNA-NPs carrying ovalbumin mRNA. Figure 21A, Tumor growth over time between treated mice (n=7) and untreated mice (n=5). Values ​​on the graph are P values ​​calculated by unpaired Student's t-test. Comparison of tumor growth over time is evaluated by two-way ANOVA. Figure 21B, Individual treated tumor growth divided into "responders" and "non-responders". Figure 21C, Correlation of relative change in MRI detected lymph node intensity (relative LN intensity) in treated compared to untreated lymph nodes with tumor size at days 2 and 27. Dotted lines indicate the 25th and 75th percentiles of lymph node relative MRI intensity. Data points from mice with significant MRI-predicted DC migration as indicated by relative VDLN intensity in the bottom 25th percentile are Xs in Figure 21E and Figure 21E, data points from mice with moderate VDLN intensity in the middle 50th percentile are dots in Figure 21D and Figure 21E, and data points from mice with high VDLN intensity in the top 75th percentile are squares in Figure 21D and Figure 21E. Figure 21D-21E, Correlation of MRI-detected DC migration on day 2 with tumor size (d) and survival rate (n=10) (e). Numbers in graphs c-e represent Pearson's correlation coefficient (r) and P value (p). Figure 21F-21H, Individual tumor growth curves (Figure 21F), summary data (Figure 21G), and tumor size at multiple time points separated by MRI intensity on day 2 post-vaccination. Numbers on the graphs are p-values ​​calculated from analysis of variance (FIG. 21G) and two-tailed unpaired t-test (FIG. 21H). [Figure 21F]Figure 21 shows that DC migration detected by MRI predicts response to DC vaccine. Mice bearing subcutaneous B16F10-OVA tumors were treated with BMDCs loaded with IO-RNA-NPs carrying ovalbumin mRNA. Figure 21A, Tumor growth over time between treated mice (n=7) and untreated mice (n=5). Values ​​on the graph are P values ​​calculated by unpaired Student's t-test. Comparison of tumor growth over time is evaluated by two-way ANOVA. Figure 21B, Individual treated tumor growth divided into "responders" and "non-responders". Figure 21C, Correlation of relative change in MRI detected lymph node intensity (relative LN intensity) in treated compared to untreated lymph nodes with tumor size at days 2 and 27. Dotted lines indicate the 25th and 75th percentiles of lymph node relative MRI intensity. Data points from mice with significant MRI-predicted DC migration as indicated by relative VDLN intensity in the bottom 25th percentile are Xs in Figure 21E and Figure 21E, data points from mice with moderate VDLN intensity in the middle 50th percentile are dots in Figure 21D and Figure 21E, and data points from mice with high VDLN intensity in the top 75th percentile are squares in Figure 21D and Figure 21E. Figure 21D-21E, Correlation of MRI-detected DC migration on day 2 with tumor size (d) and survival rate (n=10) (e). Numbers in graphs c-e represent Pearson's correlation coefficient (r) and P value (p). Figure 21F-21H, Individual tumor growth curves (Figure 21F), summary data (Figure 21G), and tumor size at multiple time points separated by MRI intensity on day 2 post-vaccination. Numbers on the graphs are p-values ​​calculated from analysis of variance (FIG. 21G) and two-tailed unpaired t-test (FIG. 21H). [Figure 21G]Figure 21 shows that DC migration detected by MRI predicts response to DC vaccine. Mice bearing subcutaneous B16F10-OVA tumors were treated with BMDCs loaded with IO-RNA-NPs carrying ovalbumin mRNA. Figure 21A, Tumor growth over time between treated mice (n=7) and untreated mice (n=5). Values ​​on the graph are P values ​​calculated by unpaired Student's t-test. Comparison of tumor growth over time is evaluated by two-way ANOVA. Figure 21B, Individual treated tumor growth divided into "responders" and "non-responders". Figure 21C, Correlation of relative change in MRI detected lymph node intensity (relative LN intensity) in treated compared to untreated lymph nodes with tumor size at days 2 and 27. Dotted lines indicate the 25th and 75th percentiles of lymph node relative MRI intensity. Data points from mice with significant MRI-predicted DC migration as indicated by relative VDLN intensity in the bottom 25th percentile are Xs in Figure 21E and Figure 21E, data points from mice with moderate VDLN intensity in the middle 50th percentile are dots in Figure 21D and Figure 21E, and data points from mice with high VDLN intensity in the top 75th percentile are squares in Figure 21D and Figure 21E. Figure 21D-21E, Correlation of MRI-detected DC migration on day 2 with tumor size (d) and survival rate (n=10) (e). Numbers in graphs c-e represent Pearson's correlation coefficient (r) and P value (p). Figure 21F-21H, Individual tumor growth curves (Figure 21F), summary data (Figure 21G), and tumor size at multiple time points separated by MRI intensity on day 2 post-vaccination. Numbers on the graphs are p-values ​​calculated from analysis of variance (FIG. 21G) and two-tailed unpaired t-test (FIG. 21H). [Fig. 21H]Figure 21 shows that DC migration detected by MRI predicts response to DC vaccine. Mice bearing subcutaneous B16F10-OVA tumors were treated with BMDCs loaded with IO-RNA-NPs carrying ovalbumin mRNA. Figure 21A, Tumor growth over time between treated mice (n=7) and untreated mice (n=5). Values ​​on the graph are P values ​​calculated by unpaired Student's t-test. Comparison of tumor growth over time is evaluated by two-way ANOVA. Figure 21B, Individual treated tumor growth divided into "responders" and "non-responders". Figure 21C, Correlation of relative change in MRI detected lymph node intensity (relative LN intensity) in treated compared to untreated lymph nodes with tumor size at days 2 and 27. Dotted lines indicate the 25th and 75th percentiles of lymph node relative MRI intensity. Data points from mice with significant MRI-predicted DC migration as indicated by relative VDLN intensity in the bottom 25th percentile are Xs in Figure 21E and Figure 21E, data points from mice with moderate VDLN intensity in the middle 50th percentile are dots in Figure 21D and Figure 21E, and data points from mice with high VDLN intensity in the top 75th percentile are squares in Figure 21D and Figure 21E. Figure 21D-21E, Correlation of MRI-detected DC migration on day 2 with tumor size (d) and survival rate (n=10) (e). Numbers in graphs c-e represent Pearson's correlation coefficient (r) and P value (p). Figure 21F-21H, Individual tumor growth curves (Figure 21F), summary data (Figure 21G), and tumor size at multiple time points separated by MRI intensity on day 2 post-vaccination. Numbers on the graphs are p-values ​​calculated from analysis of variance (FIG. 21G) and two-tailed unpaired t-test (FIG. 21H). [Figure 22A]We show that MRI-detected DC migration on day 2 post-vaccination predicts the antitumor efficacy of therapeutic DC vaccines. Figure 22A, Schematic of treatment schedule. Mice received subcutaneous injections of 1,000,000 B16F10-OVA cells in the lateral flank. On day 5, mice received intradermal (id) injections of 500,000 BMDCs loaded with 10-RNA-NPs with OVA RNA and intravenous (iv) injections of 10,000,000 OT1 T cells. Mice were imaged by MRI 2 days later to track tumor growth and survival. Figure 22B, Individual tumor growth curves (left) and summary data (right) for all treated mice (n=9) before death. Figures 22C-22D, Correlation of T2*-weighted MRI intensity on day 2 with tumor size on days 14 (c) and 17 (Figure 22D). Dotted lines indicate the 25th and 75th percentiles of lymph node relative MRI intensity. Figure 22E, Individual tumor growth curves (left) and summary data (right) throughout the death of all treated mice. Numbers on the graphs are p-values ​​calculated using two-way ANOVA for significance. Figure 22F, Correlation between T2*-weighted MRI intensity on day 2 and survival. Figure 22G, Survival curves of all treated mice. Numbers on the graphs are p-values ​​calculated using log-rank test. P-values ​​and r-values ​​in Figures 22C, 22D, and 22F are derived from Pearson correlation. [Figure 22B]We show that MRI-detected DC migration on day 2 post-vaccination predicts the antitumor efficacy of therapeutic DC vaccines. Figure 22A, Schematic of treatment schedule. Mice received subcutaneous injections of 1,000,000 B16F10-OVA cells in the lateral flank. On day 5, mice received intradermal (id) injections of 500,000 BMDCs loaded with 10-RNA-NPs with OVA RNA and intravenous (iv) injections of 10,000,000 OT1 T cells. Mice were imaged by MRI 2 days later to track tumor growth and survival. Figure 22B, Individual tumor growth curves (left) and summary data (right) for all treated mice (n=9) before death. Figures 22C-22D, Correlation of T2*-weighted MRI intensity on day 2 with tumor size on days 14 (c) and 17 (Figure 22D). Dotted lines indicate the 25th and 75th percentiles of lymph node relative MRI intensity. Figure 22E, Individual tumor growth curves (left) and summary data (right) throughout the death of all treated mice. Numbers on the graphs are p-values ​​calculated using two-way ANOVA for significance. Figure 22F, Correlation between T2*-weighted MRI intensity on day 2 and survival. Figure 22G, Survival curves of all treated mice. Numbers on the graphs are p-values ​​calculated using log-rank test. P-values ​​and r-values ​​in Figures 22C, 22D, and 22F are derived from Pearson correlation. [Figure 22C]We show that MRI-detected DC migration on day 2 post-vaccination predicts the antitumor efficacy of therapeutic DC vaccines. Figure 22A, Schematic of treatment schedule. Mice received subcutaneous injections of 1,000,000 B16F10-OVA cells in the lateral flank. On day 5, mice received intradermal (id) injections of 500,000 BMDCs loaded with 10-RNA-NPs with OVA RNA and intravenous (iv) injections of 10,000,000 OT1 T cells. Mice were imaged by MRI 2 days later to track tumor growth and survival. Figure 22B, Individual tumor growth curves (left) and summary data (right) for all treated mice (n=9) before death. Figures 22C-22D, Correlation of T2*-weighted MRI intensity on day 2 with tumor size on days 14 (c) and 17 (Figure 22D). Dotted lines indicate the 25th and 75th percentiles of lymph node relative MRI intensity. Figure 22E, Individual tumor growth curves (left) and summary data (right) throughout the death of all treated mice. Numbers on the graphs are p-values ​​calculated using two-way ANOVA for significance. Figure 22F, Correlation between T2*-weighted MRI intensity on day 2 and survival. Figure 22G, Survival curves of all treated mice. Numbers on the graphs are p-values ​​calculated using log-rank test. P-values ​​and r-values ​​in Figures 22C, 22D, and 22F are derived from Pearson correlation. [Figure 22D]We show that MRI-detected DC migration on day 2 post-vaccination predicts the antitumor efficacy of therapeutic DC vaccines. Figure 22A, Schematic of treatment schedule. Mice received subcutaneous injections of 1,000,000 B16F10-OVA cells in the lateral flank. On day 5, mice received intradermal (id) injections of 500,000 BMDCs loaded with 10-RNA-NPs with OVA RNA and intravenous (iv) injections of 10,000,000 OT1 T cells. Mice were imaged by MRI 2 days later to track tumor growth and survival. Figure 22B, Individual tumor growth curves (left) and summary data (right) for all treated mice (n=9) before death. Figures 22C-22D, Correlation of T2*-weighted MRI intensity on day 2 with tumor size on days 14 (c) and 17 (Figure 22D). Dotted lines indicate the 25th and 75th percentiles of lymph node relative MRI intensity. Figure 22E, Individual tumor growth curves (left) and summary data (right) throughout the death of all treated mice. Numbers on the graphs are p-values ​​calculated using two-way ANOVA for significance. Figure 22F, Correlation between T2*-weighted MRI intensity on day 2 and survival. Figure 22G, Survival curves of all treated mice. Numbers on the graphs are p-values ​​calculated using log-rank test. P-values ​​and r-values ​​in Figures 22C, 22D, and 22F are derived from Pearson correlation. [Figure 22E]We show that MRI-detected DC migration on day 2 post-vaccination predicts the antitumor efficacy of therapeutic DC vaccines. Figure 22A, Schematic of treatment schedule. Mice received subcutaneous injections of 1,000,000 B16F10-OVA cells in the lateral flank. On day 5, mice received intradermal (id) injections of 500,000 BMDCs loaded with 10-RNA-NPs with OVA RNA and intravenous (iv) injections of 10,000,000 OT1 T cells. Mice were imaged by MRI 2 days later to track tumor growth and survival. Figure 22B, Individual tumor growth curves (left) and summary data (right) for all treated mice (n=9) before death. Figures 22C-22D, Correlation of T2*-weighted MRI intensity on day 2 with tumor size on days 14 (c) and 17 (Figure 22D). Dotted lines indicate the 25th and 75th percentiles of lymph node relative MRI intensity. Figure 22E, Individual tumor growth curves (left) and summary data (right) throughout the death of all treated mice. Numbers on the graphs are p-values ​​calculated using two-way ANOVA for significance. Figure 22F, Correlation between T2*-weighted MRI intensity on day 2 and survival. Figure 22G, Survival curves of all treated mice. Numbers on the graphs are p-values ​​calculated using log-rank test. P-values ​​and r-values ​​in Figures 22C, 22D, and 22F are derived from Pearson correlation. [Figure 22F]We show that MRI-detected DC migration on day 2 post-vaccination predicts the antitumor efficacy of therapeutic DC vaccines. Figure 22A, Schematic of treatment schedule. Mice received subcutaneous injections of 1,000,000 B16F10-OVA cells in the lateral flank. On day 5, mice received intradermal (id) injections of 500,000 BMDCs loaded with 10-RNA-NPs with OVA RNA and intravenous (iv) injections of 10,000,000 OT1 T cells. Mice were imaged by MRI 2 days later to track tumor growth and survival. Figure 22B, Individual tumor growth curves (left) and summary data (right) for all treated mice (n=9) before death. Figures 22C-22D, Correlation of T2*-weighted MRI intensity on day 2 with tumor size on days 14 (c) and 17 (Figure 22D). Dotted lines indicate the 25th and 75th percentiles of lymph node relative MRI intensity. Figure 22E, Individual tumor growth curves (left) and summary data (right) throughout the death of all treated mice. Numbers on the graphs are p-values ​​calculated using two-way ANOVA for significance. Figure 22F, Correlation between T2*-weighted MRI intensity on day 2 and survival. Figure 22G, Survival curves of all treated mice. Numbers on the graphs are p-values ​​calculated using log-rank test. P-values ​​and r-values ​​in Figures 22C, 22D, and 22F are derived from Pearson correlation. [Figure 22G]We show that MRI-detected DC migration on day 2 post-vaccination predicts the antitumor efficacy of therapeutic DC vaccines. Figure 22A, Schematic of treatment schedule. Mice received subcutaneous injections of 1,000,000 B16F10-OVA cells in the lateral flank. On day 5, mice received intradermal (id) injections of 500,000 BMDCs loaded with 10-RNA-NPs with OVA RNA and intravenous (iv) injections of 10,000,000 OT1 T cells. Mice were imaged by MRI 2 days later to track tumor growth and survival. Figure 22B, Individual tumor growth curves (left) and summary data (right) for all treated mice (n=9) before death. Figures 22C-22D, Correlation of T2*-weighted MRI intensity on day 2 with tumor size on days 14 (c) and 17 (Figure 22D). Dotted lines indicate the 25th and 75th percentiles of lymph node relative MRI intensity. Figure 22E, Individual tumor growth curves (left) and summary data (right) throughout the death of all treated mice. Numbers on the graphs are p-values ​​calculated using two-way ANOVA for significance. Figure 22F, Correlation between T2*-weighted MRI intensity on day 2 and survival. Figure 22G, Survival curves of all treated mice. Numbers on the graphs are p-values ​​calculated using log-rank test. P-values ​​and r-values ​​in Figures 22C, 22D, and 22F are derived from Pearson correlation. [Diagram 23] A series of graphs showing Cy5+ cells (left column) or CD45+MHC class II+Cy5+ cells (right column) detected in the lungs (top row), spleen (middle row), or liver (bottom row) of untreated mice or mice treated with Chol-RNA-NP, RNA-NP, or Cy5-labeled RNA only. [Figure 24] Paired graphs of % GFP (left) or % PDL1 (right) for untreated mice or mice treated with Chol-RNA-NPs or Chol-siRNA-NPs. [Figure 25A]We show that translatable nanoparticles transfect and activate DCs. Fig. 25A, GFP expression in BMDCs after 24 h of incubation with particles loaded with each RNA. Fig. 25B, Co-expression of CD40, CD80, and CD86 in BMDCs after 24 h of incubation with each particle construct. Fig. 25C, Viability of BMDCs after 24 h of incubation with each construct. Fig. 25D, BMDCs were loaded with IO-RNA-NPs carrying OVA RNA and incubated with OVA-specific OT1 T cells. T cell activation is shown as IFN-γ assessed by ELISA. Fig. 25E, Relative activation score calculated as the product of the mean values ​​of viability, transfection efficiency, activation, and T cell stimulation for each formulation normalized to the score of DOTAP. [Figure 25B] We show that translatable nanoparticles transfect and activate DCs. Fig. 25A, GFP expression in BMDCs after 24 h of incubation with particles loaded with each RNA. Fig. 25B, Co-expression of CD40, CD80, and CD86 in BMDCs after 24 h of incubation with each particle construct. Fig. 25C, Viability of BMDCs after 24 h of incubation with each construct. Fig. 25D, BMDCs were loaded with IO-RNA-NPs carrying OVA RNA and incubated with OVA-specific OT1 T cells. T cell activation is shown as IFN-γ assessed by ELISA. Fig. 25E, Relative activation score calculated as the product of the mean values ​​of viability, transfection efficiency, activation, and T cell stimulation for each formulation normalized to the score of DOTAP. [Figure 25C]We show that translatable nanoparticles transfect and activate DCs. Fig. 25A, GFP expression in BMDCs after 24 h of incubation with particles loaded with each RNA. Fig. 25B, Co-expression of CD40, CD80, and CD86 in BMDCs after 24 h of incubation with each particle construct. Fig. 25C, Viability of BMDCs after 24 h of incubation with each construct. Fig. 25D, BMDCs were loaded with IO-RNA-NPs carrying OVA RNA and incubated with OVA-specific OT1 T cells. T cell activation is shown as IFN-γ assessed by ELISA. Fig. 25E, Relative activation score calculated as the product of the mean values ​​of viability, transfection efficiency, activation, and T cell stimulation for each formulation normalized to the score of DOTAP. [Figure 25D] We show that translatable nanoparticles transfect and activate DCs. Fig. 25A, GFP expression in BMDCs after 24 h of incubation with particles loaded with each RNA. Fig. 25B, Co-expression of CD40, CD80, and CD86 in BMDCs after 24 h of incubation with each particle construct. Fig. 25C, Viability of BMDCs after 24 h of incubation with each construct. Fig. 25D, BMDCs were loaded with IO-RNA-NPs carrying OVA RNA and incubated with OVA-specific OT1 T cells. T cell activation is shown as IFN-γ assessed by ELISA. Fig. 25E, Relative activation score calculated as the product of the mean values ​​of viability, transfection efficiency, activation, and T cell stimulation for each formulation normalized to the score of DOTAP. [Figure 25E]We show that translatable nanoparticles transfect and activate DCs. Fig. 25A, GFP expression in BMDCs after 24 h of incubation with particles loaded with each RNA. Fig. 25B, Co-expression of CD40, CD80, and CD86 in BMDCs after 24 h of incubation with each particle construct. Fig. 25C, Viability of BMDCs after 24 h of incubation with each construct. Fig. 25D, BMDCs were loaded with IO-RNA-NPs carrying OVA RNA and incubated with OVA-specific OT1 T cells. T cell activation is shown as IFN-γ assessed by ELISA. Fig. 25E, Relative activation score calculated as the product of the mean values ​​of viability, transfection efficiency, activation, and T cell stimulation for each formulation normalized to the score of DOTAP. [Figure 26A] IO-RNA-NPs induce antigen-specific DC activation. Figure 26A, Gating strategy. Positive populations were selected using fluorescence minus one (FMO) control. Figure 26B, Expression of CD86 and co-expression of CD80 and CD86 in BMDCs after 24 h incubation with RNA-NPs or IO-RNA-NPs. Data are plotted as geometric mean fluorescence intensity and percentage. One-way ANOVA and Tukey's test were used for statistical comparison. Numbers on graphs are P values. Figure 26C, BMDCs were loaded with IO-RNA-NPs with either OVA RNA or GFP RNA and incubated with OVA-specific OT1 T cells. T cell activation is shown as IFN-γ assessed by ELISA. [Figure 26B]IO-RNA-NPs induce antigen-specific DC activation. Figure 26A, Gating strategy. Positive populations were selected using fluorescence minus one (FMO) control. Figure 26B, Expression of CD86 and co-expression of CD80 and CD86 in BMDCs after 24 h incubation with RNA-NPs or IO-RNA-NPs. Data are plotted as geometric mean fluorescence intensity and percentage. One-way ANOVA and Tukey's test were used for statistical comparison. Numbers on graphs are P values. Figure 26C, BMDCs were loaded with IO-RNA-NPs with either OVA RNA or GFP RNA and incubated with OVA-specific OT1 T cells. T cell activation is shown as IFN-γ assessed by ELISA. [Figure 26C] IO-RNA-NPs induce antigen-specific DC activation. Figure 26A, Gating strategy. Positive populations were selected using fluorescence minus one (FMO) control. Figure 26B, Expression of CD86 and co-expression of CD80 and CD86 in BMDCs after 24 h incubation with RNA-NPs or IO-RNA-NPs. Data are plotted as geometric mean fluorescence intensity and percentage. One-way ANOVA and Tukey's test were used for statistical comparison. Numbers on graphs are P values. Figure 26C, BMDCs were loaded with IO-RNA-NPs with either OVA RNA or GFP RNA and incubated with OVA-specific OT1 T cells. T cell activation is shown as IFN-γ assessed by ELISA. [Figure 27-1] Figure 1 shows that IO-RNA-NPs induce the expression of antiviral gene sets. Gene set enrichment plot of eight gene sets related to RNA uptake and processing in primary BMDCs 24 h after treatment with GFP mRNA via either IO-RNA-NPs or electroporation. [Figure 27-2]Figure 1 shows that IO-RNA-NPs induce the expression of antiviral gene sets. Gene set enrichment plot of eight gene sets related to RNA uptake and processing in primary BMDCs 24 h after treatment with GFP mRNA via either IO-RNA-NPs or electroporation. [Figure 27-3] Figure 1 shows that IO-RNA-NPs induce the expression of antiviral gene sets. Gene set enrichment plot of eight gene sets related to RNA uptake and processing in primary BMDCs 24 h after treatment with GFP mRNA via either IO-RNA-NPs or electroporation. [Figure 27-4] Figure 1 shows that IO-RNA-NPs induce the expression of antiviral gene sets. Gene set enrichment plot of eight gene sets related to RNA uptake and processing in primary BMDCs 24 h after treatment with GFP mRNA via either IO-RNA-NPs or electroporation. [Figure 28A] Figure 28 shows that IO-RNA-NP enhances the activation of BMDCs. Figure 28A, Phenotypic markers of activation in BMDCs assessed by flow cytometry 24 hours after electroporation or treatment with IO-RNA-NP. Data are presented as geometric mean fluorescence intensity. One-way ANOVA and Tukey's test were used for statistical analysis. Figure 28B, BMDC viability assessed by automated cell counter 24 hours after electroporation or incubation with RNA-NP or IO-RNA-NP. [Figure 28B]Figure 28 shows that IO-RNA-NP enhances the activation of BMDCs. Figure 28A, Phenotypic markers of activation in BMDCs assessed by flow cytometry 24 hours after electroporation or treatment with IO-RNA-NP. Data are presented as geometric mean fluorescence intensity. One-way ANOVA and Tukey's test were used for statistical analysis. Figure 28B, BMDC viability assessed by automated cell counter 24 hours after electroporation or incubation with RNA-NP or IO-RNA-NP. [Figure 29A] 1 is a table showing summary data of lipid libraries. Unless otherwise stated, liposomes were formed from the listed components in a 1:1 ratio. For each particle construct, summary data obtained after 24 hours of incubation with BMDCs carrying GFP mRNA or after 48 hours of incubation of BMDCs transfected with OVA with OVA-specific OT1 T cells is shown. Activation scores are calculated as the product of transfected cells (GFP (%)), activated cells (CD40+CD80+CD86+ (%)), viability (%), and T cell stimulation capacity (IFN-γ (pg / mL)). Relative activation scores are calculated as (activation score sample) / (activation score DOTAP). DOTAP = 1,2-dioleoyl-3-trimethylammonium-propane, Chol = cholesterol, DOPE = 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, DMPC = 1,2-dimyristoyl-sn-glycero-3-phosphocholine, DPPC = 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, DOTMA = 1,2-di-O-octadecenyl-3-trimethylammonium propane. *Liposomal MPL is a mixture of lipids with a cholesterol:DMPG:DPPC:MLA ratio of 5.2:1.1:8.7:0.15 and the adjuvant monophosphoryl lipid A (MLA). [Figure 29B]1 is a table showing the characterization of iron oxide loaded RNA nanoparticles. Zeta potential and size (measured with Nanosight) are displayed as the mean + / - standard deviation. Results are representative summary data of three replicate experiments for each zeta potential, and four replicates for each size. Size measurements were completed with RNA bound to liposomes. Zeta potential was measured on liposomes without RNA. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] Herein, for the first time, data are presented that lead to the development of bifunctional RNA-loaded nanoparticles (RNA-NPs) that enhance DC migration to lymph nodes and track migration in vivo using widely available MRI-based imaging modalities. As described herein, cationic liposomes with an iron oxide nanoparticle core were incubated with mRNA and then transfected with RNA-NPs. The resulting iron oxide-loaded RNA-NPs (IO-RNA-NPs) were used to transduce DsRed ex vivo in the presence of a magnetic field. + DCs were transfected. The IO-RNA-NP-loaded DCs were then injected intradermally into C57Bl6 mice and T2 * The lymph nodes were noninvasively tracked with weighted 11T MRI. MRI intensity was correlated with Prussian blue staining for iron oxide content and with flow cytometry for absolute number of DsRed+ cells in each lymph node. The presence of iron oxide in the RNA-NPs did not significantly alter particle properties including size, charge, RNA binding capacity, and transfection of DCs. Furthermore, the inclusion of iron oxide within the RNA-NPs allowed for magnetically enhanced RNA delivery and transfection efficiency through the application of an external magnetic field. Compared to RNA electroporation, IO-RNA-NP loading enhanced antiviral cytokine (IFN-α) production and DC migration to lymph nodes. IO-RNA-NPs also enhanced T2 * It also resulted in a decrease in enhanced MRI intensity and an increase in lymph node size detected by MRI, which directly correlated with the number of iron oxide-laden cells in the treated lymph nodes. T2 measured 2 days after vaccination* Enhanced MRI intensity correlated with inhibition of tumor growth in mouse tumor models. These data suggest that IO-RNA-NPs enhance DC activation and enable non-invasive cell tracking by MRI. Without being bound to a particular theory, these data support the use of IO-RNA-NPs to predict anti-tumor immune responses and use MRI-detected DC migration as a biomarker of vaccine efficacy.

[0016] Liposomes, cells, and compositions The present disclosure provides a liposome comprising a ribonucleic acid (RNA) molecule and a lipid mixture comprising DOTAP and cholesterol. In various embodiments, the liposome comprises an RNA molecule, a lipid mixture comprising DOTAP and cholesterol, and iron oxide nanoparticles (IONPs), optionally with the DOTAP and cholesterol present in the lipid mixture at a DOTAP:cholesterol mass ratio of about 3:1. In various embodiments, the liposome of the present disclosure comprises an RNA molecule and a lipid mixture comprising DOTAP and cholesterol, optionally with the DOTAP and cholesterol present in the lipid mixture at a DOTAP:cholesterol mass ratio of about 3:1. As used herein, the term "DOTAP" refers to N-(2,3-dioleoyloxy-1-propyl)trimethylammonium methylsulfate.

[0017] In an exemplary embodiment, the liposome has a diameter of about 80 nm to about 500 nm, e.g., about 80 nm to about 450 nm, about 80 nm to about 400 nm, about 80 nm to about 350 nm, about 80 nm to about 300 nm, about 80 nm to about 250 nm, about 80 nm to about 200 nm, about 90 nm to about 500 nm, about 100 nm to about 500 nm, about 150 nm to about 500 nm, about 200 nm to about 500 nm, about 250 nm to about 500 nm, about 300 nm to about 500 nm, about 350 nm to about 500 nm, or about 400 nm to about 500 nm. In exemplary embodiments, the liposomes have a diameter of about 90 nm to about 300 nm, e.g., about 100 nm to about 250 nm, about 110 nm±5 nm, about 115 nm±5 nm, about 120 nm±5 nm, about 125 nm±5 nm, about 130 nm±5 nm, about 135 nm±5 nm, about 140 nm±5 nm, about 145 nm±5 nm, about 150 nm±5 nm, about 155 nm±5 nm, about 160 nm±5 nm, about 170 nm±5 nm, about 180 nm±5 nm, about 190 nm±5 nm, about 200 nm±5 nm, about 210 nm±5 nm, about 220 nm±5 nm, about 230 nm±5 nm, about 240 nm±5 nm, about 250 nm±5 nm, about 260 nm±5 nm, about 270 nm±5 nm, about 280 nm±5 nm, about 290 nm±5 nm, about 300 nm±5 nm, about 310 nm±5 nm, about 320 nm±5 nm, about 330 nm±5 nm, about 340 nm±5 nm, about 350 nm±5 nm, about 360 nm±5 nm, about 370 nm±5 nm, about 380 nm±5 nm, about 390 nm±5 nm, about 395 nm±5 nm, about 395 nm±5 nm, about 400 nm±5 nm, about 400 nm±5 nm, about 410 nm±5 nm, about 420 nm±5 nm, about 430 nm±5 nm, about 440 nm±5 nm, about 450 nm±5 nm, about 460 nm±5 nm, about 470 nm±5 nm, about 480 nm±5 nm, about 495 nm± 65 nm±5 nm, about 170 nm±5 nm, about 175 nm±5 nm, about 180 nm±5 nm, about 190 nm±5 nm, about 200 nm±5 nm, about 210 nm±5 nm, about 220 nm±5 nm, about 230 nm±5 nm, about 240 nm±5 nm, about 250 nm±5 nm, about 260 nm±5 nm, about 270 nm±5 nm, about 280 nm±5 nm, about 290 nm±5 nm, about 300 nm±5 nm. In exemplary embodiments, the liposomes have an overall surface net charge of about 20 mV to about 50 mV (e.g., about 20 mV to about 45 mV, about 20 mV to about 40 mV, about 20 mV to about 35 mV, about 20 mV to about 30 mV, about 20 mV to about 25 mV, about 25 mV to about 50 mV, about 30 mV to about 50 mV, about 35 mV to about 50 mV, about 40 mV to about 50 mV, or about 45 mV to about 50 mV. Typically, the liposomes have an overall net surface charge of about 40 mV to about 50 mV.

[0018] In an exemplary embodiment, the mass of cholesterol is greater than 12% and less than 37% of the total lipid mass of the lipid mixture of the liposomes of the present disclosure. For example, the mass of cholesterol is greater than 15% and less than 35% of the total lipid mass. In an exemplary embodiment, the mass of cholesterol is about 15% to about 30% of the total lipid mass of the lipid mixture. In an exemplary embodiment, the mass of cholesterol is about 20% to about 30% of the total lipid mass of the lipid mixture. In an exemplary embodiment, the mass of cholesterol is about 25% ± 3% of the total lipid mass of the lipid mixture. In an exemplary embodiment, the mass of DOTAP is at least 50% of the total lipid mass of the lipid mixture. For example, the mass of DOTAP is about 63% to about 88% of the total lipid mass of the lipid mixture. In an exemplary example, the mass of DOTAP is about 75% ± 5% of the total lipid mass of the lipid mixture. In some embodiments, when the lipid mixture comprises a third lipid different from DOTAP and cholesterol, the mass of the third lipid is less than about 10% of the total lipid mass of the lipid mixture, optionally less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% of the total lipid mass of the lipid mixture. In certain embodiments, the lipid mixture consists essentially of DOTAP and cholesterol.

[0019] In exemplary embodiments, the liposomes contain RNA molecules (or "RNA") that can be single-stranded or double-stranded, synthetic or derived from natural sources (e.g., isolated and / or purified), can contain natural, non-natural or modified nucleotides, and can contain natural, non-natural or modified internucleotide linkages. In exemplary embodiments, the nucleic acid molecule can contain one or more modified nucleotides, such as 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl)uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, β-D-galactosyl eosin, inosine, N 6-Isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N-substituted adenines, 7-methylguanine, 5-methylammomethyluracil, 5-methoxyaminomethyl-2-thiouracil, β-D-mannosylkenosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N 6 -isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxocine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methyl ester, 3-(3-amino-3-N-2-carboxypropyl)uracil, and 2,6-diaminopurine, etc. In exemplary embodiments, the RNA contains one or more non-natural or modified internucleotide bonds, such as phosphoramidate or phosphorothioate bonds, instead of the phosphodiester bonds found between nucleotides of naturally occurring DNA or RNA molecules. In exemplary embodiments, the RNA does not contain insertions, deletions, inversions, and / or substitutions. However, as discussed herein, in some cases, it may be preferable for the RNA to contain one or more insertions, deletions, inversions, and / or substitutions. In some aspects, the RNA molecule is a mature or processed mRNA lacking introns. In exemplary aspects, the RNA molecule comprises a 5' cap, a poly(A) tail, or a combination of both. In various aspects, the 5' cap comprises 7-methylguanylate and is attached to the 5' end of the RNA molecule via a 5'-to-5' triphosphate bond. In various aspects, the 5' cap is added to the RNA molecule via a chemical addition reaction. In exemplary embodiments, the RNA molecule is constructed based on chemical synthesis and / or enzymatic ligation reactions using procedures known in the art. For example, see Sambrook et al. See, e.g., Ausubel et al. (supra). In various embodiments, the RNA molecules are produced extracellularly via in vitro transcription techniques. In certain embodiments, the RNA molecule is a synthetic RNA molecule produced by in vitro transcription.

[0020] In an exemplary embodiment, the liposome comprises less than or about 10 μg of RNA molecules per 150 μg of lipid mixture. In an exemplary embodiment, the liposome is made by incubating about 10 μg of RNA with about 150 μg of liposome. In another embodiment, the liposome comprises more RNA molecules per mass of lipid mixture. For example, the liposome may comprise more than 10 μg of RNA molecules per 150 μg of liposome. In some cases, the liposome comprises more than 15 μg of RNA molecules per 150 μg of liposome or lipid mixture. In some embodiments, the RNA molecule encodes a protein or is an antisense molecule. In some embodiments, the protein is selected from the group consisting of tumor antigens, costimulatory molecules, cytokines, growth factors, lymphokines, (e.g., cytokines and growth factors effective in inhibiting tumor metastasis, cytokines or growth factors shown to have antiproliferative effects on at least one cell population). Such cytokines, lymphokines, growth factors, or other hematopoietic factors include, but are not limited to: M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IFN, TNFα, TNF1, TNF2, G-CSF, Meg-CSF, GM-CSF, thrombopoietin, stem cell factor, and erythropoietin.Additional growth factors for use herein include angiogenin, bone morphogenetic protein-1, bone morphogenetic protein-2, bone morphogenetic protein-3, bone morphogenetic protein-4, bone morphogenetic protein-5, bone morphogenetic protein-6, bone morphogenetic protein-7, bone morphogenetic protein-8, bone morphogenetic protein-9, bone morphogenetic protein-10, bone morphogenetic protein-11, bone morphogenetic protein-12, bone morphogenetic protein-13, bone morphogenetic protein-14, bone morphogenetic protein-15, bone morphogenetic protein-16, bone morphogenetic protein-17, bone morphogenetic protein-18, bone morphogenetic protein-19, bone morphogenetic protein-20, bone morphogenetic protein-21, bone morphogenetic protein-22, bone morphogenetic protein-23, bone morphogenetic protein-24, bone morphogenetic protein-25, bone morphogenetic protein-26, bone morphogenetic protein-27, bone morphogenetic protein-28, bone morphogenetic protein-29, bone morphogenetic protein-30, bone morphogenetic protein-31, bone morphogenetic protein-32, bone morphogenetic protein-33, bone morphogenetic protein-34, bone morphogenetic protein-35, bone morphogenetic protein-36, bone morphogenetic protein-37, bone morphogenetic protein-38, bone morphogenetic protein-39, bone morphogenetic protein-40, bone morphogenetic protein-41, bone morphogenetic protein-42, bone morphogenetic protein-43, bone morphogenetic protein-44, bone morphogenetic protein-45, bone morphogenetic protein-46, bone morphogenetic protein-47, bone morphogenetic protein-48, bone morphogenetic protein-49, bone morphogenetic protein-50, bone morphogenetic protein-5 Protein receptor IA, bone morphogenetic protein receptor IB, brain-derived neurotrophic factor, ciliary neurotrophic factor, ciliary neurotrophic factor receptor α subunit, cytokine-induced neutrophil chemotactic factor 1, cytokine-induced neutrophil, chemotactic factor 2α, cytokine-induced neutrophil chemotactic factor 2β, β-endothelial cell growth factor, endothelin 1, epithelial-derived neutrophil attractant, glial cell line-derived neurotrophic factor receptor α1, glial cell line-derived neurotrophic factor receptor α2, growth-associated protein, growth-associated protein α, growth-associated protein β, growth-associated protein γ, heparin binding Epidermal growth factor, hepatocyte growth factor, hepatocyte growth factor receptor, insulin-like growth factor I, insulin-like growth factor receptor, insulin-like growth factor II, insulin-like growth factor binding protein, keratinocyte growth factor, leukemia inhibitory factor, leukemia inhibitory factor receptor alpha, nerve growth factor nerve growth factor receptor, neurotrophin-3, neurotrophin-4, pre-B cell growth stimulatory factor, stem cell factor, stem cell factor receptor, transforming growth factor alpha, transforming growth factor beta, transforming growth factor beta 1, transforming growth factor beta 1.2, transforming growth factor beta 2, transforming growth factor beta 3, transforming growth factor beta 5, latent transforming growth factor beta 1, transforming growth factor beta binding protein I, transforming growth factor beta binding protein II, transforming growth factor beta binding protein III, tumor necrosis factor receptor type I, tumor necrosis factor receptor II, urokinase-type plasminogen activator receptor, and chimeric proteins and biologically or immunologically active fragments thereof.In exemplary embodiments, the tumor antigen is an antigen derived from a viral protein, an antigen derived from a point mutation, or an antigen encoded by a cancer-germline gene. In exemplary embodiments, the tumor antigen is pp65, p53, KRAS, NRAS, MAGEA, MAGEB, MAGEC, BAGE, GAGE, LAGE / NY-ESO1, SSX, tyrosinase, gp100 / pmel17, Melan-A / MART-1, gp75 / TRP1, TRP2, CEA, RAGE-1, HER2 / NEU, WT1. In exemplary embodiments, the costimulatory molecule is selected from the group consisting of CD80 and CD86.

[0021] In certain examples, the RNA molecule codes for or is an antisense molecule, and is optionally an siRNA, shRNA or miRNA.The antisense molecule can mediate RNA interference (RNAi).As known to those skilled in the art, RNAi is a ubiquitous mechanism of gene regulation in plants and animals, in which target mRNA is degraded in a sequence-specific manner (Sharp, Genes Dev., 15, 485-490 (2001); Hutvagner et al., Curr. Opin. Genet. Dev., 12, 225-232 (2002); Fire et al., Nature, 391, 806-811 (1998); Zamore et al., Cell, 101, 25-33 (2000)). The natural RNA degradation process is initiated by the dsRNA-specific endonuclease Dicer, which promotes the cleavage of long dsRNA precursors into 21-25 nucleotide long double-stranded fragments called small interfering RNAs (siRNAs; also known as short interfering RNAs) (Zamore, et al., Cell. 101, 25-33 (2000); Elbashir et al., Genes Dev., 15, 188-200 (2001); Hammond et al., Nature, 404, 293-296 (2000); Bernstein et al., Nature, 409, 363-366 (2001). siRNAs are incorporated into large protein complexes that recognize and cleave target mRNAs (Nykanen et al. al., Cell, 107, 309-321 (2001). It has been reported that the introduction of dsRNA into mammalian cells does not lead to efficient Dicer-mediated siRNA generation, and therefore does not induce RNAi (Caplen et al., Gene 252, 95-105 (2000); Ui-Tei et al., FEBS Lett, 479, 79-82 (2000)). By introducing synthetic 21-nucleotide siRNA duplexes that inhibit the expression of transfected and endogenous genes in various mammalian cells, the need for Dicer in cellular siRNA maturation can be circumvented (Elbashir et al., Nature, 411: 494-498 (2001)).

[0022] In this regard, the RNA molecule in some embodiments is an siRNA molecule that is specific for mediating RNAi and, in some embodiments, inhibiting expression of a protein. As used herein, the term "siRNA" refers to an RNA (or RNA analog) that comprises about 10 to about 50 nucleotides (or nucleotide analogs) that can induce or mediate RNAi. In exemplary embodiments, the siRNA molecule comprises about 15 to about 30 nucleotides (or nucleotide analogs) or about 20 to about 25 nucleotides (or nucleotide analogs), e.g., 21 to 23 nucleotides (or nucleotide analogs). The siRNA can be double-stranded or single-stranded, preferably double-stranded.

[0023] In an alternative embodiment, the RNA molecule is alternatively a short hairpin RNA (shRNA) molecule specific for inhibiting expression of a protein. As used herein, the term "shRNA" refers to a molecule of about 20 or more base pairs in which the single stranded RNA contains a partially palindromic base sequence and forms a double stranded structure (i.e., a hairpin structure). The shRNA can be an siRNA (or siRNA analog) folded into a hairpin structure. The shRNA typically comprises about 45 to about 60 nucleotides, including about 21 nucleotide antisense and sense portions of the hairpin, an optional overhang on the non-loop side of about 2 to about 6 nucleotides in length, and a loop portion that can be, for example, about 3 to 10 nucleotides in length. The shRNA can be chemically synthesized. Alternatively, the shRNA can be produced by ligating the sense and antisense strands of a DNA sequence in reverse orientation and synthesizing the RNA in vitro with T7 RNA polymerase using the DNA as a template.

[0024] Without wishing to be bound by any theory or mechanism, it is believed that shRNA induces After being introduced, the shRNA is degraded to about 20 bases or more (for example, typically 21, 22, or 23 bases), which induces RNAi and brings about an inhibitory effect. Therefore, the shRNA can be used as an effective component of the present disclosure to induce RNAi. The shRNA may preferably have a 3'-overhanging end. The length of the double-stranded portion is not particularly limited, but is preferably 10 nucleotides or more, more preferably 20 nucleotides or more. Here, the 3'-overhanging end is preferably DNA, more preferably DNA having a length of at least 2 nucleotides, and even more preferably DNA having a length of 2 to 4 nucleotides.

[0025] In an exemplary embodiment, the antisense molecule is a microRNA (miRNA). As used herein, the term "microRNA" refers to a small (e.g., 15-22 nucleotide) non-coding RNA molecule that base pairs with mRNA molecules to silence gene expression via translational repression or targeted degradation. MicroRNAs and their therapeutic potential have been reported in the art. See, for example, Mulligan, MicroRNA: Expression, Detection, and Therapeutic Strategies, Nova Science Publishers, Inc., Hauppauge, NY, 2011; Bader and Lammers, "The Therapeutic Potential of microRNAs" Innovations in Pharmaceutical Technology, pages 52-55 (March 2011).

[0026] In certain examples, the RNA molecule is an antisense molecule, optionally an siRNA, shRNA or miRNA, which targets and reduces expression of a protein in an immune checkpoint pathway. In various embodiments, the protein in the immune checkpoint pathway is CTLA-4, PD-1, PD-L1, PD-L2, B7-H3, B7-H4, TIGIT, LAG3, CD112, TIM3, BTLA, or a co-stimulatory receptor: ICOS, OX40, 41BB, or GITR. In certain examples, the protein in the immune checkpoint pathway is CTLA4, PD-1, PD-L1, B7-H3, B7H4, or TIM3. Immune checkpoint signaling pathways are reviewed in Pardoll, Nature Rev Cancer 12(4):252-264(2012).

[0027] In an exemplary embodiment, the liposome comprises a mixture of RNA molecules, e.g., RNA isolated from cells derived from a human. In some embodiments, the human has a tumor, and the mixture of RNA is RNA isolated from the human tumor. In an exemplary embodiment, the human has a cancer, optionally any cancer described herein. Optionally, the tumor from which the RNA is isolated is selected from the group consisting of glioma, (including but not limited to glioblastoma), medulloblastoma, diffuse intrinsic pontine glioma, or peripheral tumors with metastatic invasion into the central nervous system (e.g., melanoma or breast cancer). In an exemplary embodiment, the tumor from which the RNA is isolated is a cancer tumor, e.g., any of these cancers described herein.

[0028] In exemplary embodiments of the present disclosure, the liposome further comprises iron oxide nanoparticles (IONPs). Optionally, the IONPs are present in the core of the liposome. In exemplary embodiments, the liposomes comprising IONPs are magnetic due to the inclusion of IONPs. Thus, in some embodiments, the liposomes comprising IONPs are referred to as "magnetic liposomes" or "magnetoliposomes." In certain examples, the IONPs are about 1% to about 20% of the total liposome mass, e.g., about 5% to about 20%, about 10% to about 20%, about 15% to about 20%, about 1% to about 15%, about 1% to about 10%, about 1% to about 5%. The IONPs in some embodiments are about 5% to about 15% of the total liposome mass. In some examples, the IONPs are about 12%±3% of the total mass of the liposome. Each IONP in the core has a diameter of about 10 nm to about 200 nm in exemplary embodiments. In some examples, each IONP is about 20 nm, about 30 nm, about 40 nm, or about 50 nm. m, about 50 nm, about 150 nm, about 160 nm, about 170 nm, about 180 nm, about 190 nm, about 200 nm, or about 60 nm to about 140 nm (e.g., about 65 nm, about 70 nm, about 80 nm, about 90 nm, about 100 nm, about 110 nm, about 120 nm, about 130 nm, or about 140 nm). In an exemplary embodiment, each IONP has a diameter of about 130 nm ± 5 nm.

[0029] Further provided herein is a cell comprising (e.g., transfected with) the liposome of the present disclosure. In an exemplary embodiment, the cell is any type of cell that can contain the liposome of the present disclosure. In some embodiments, the cell is a eukaryotic cell, such as a plant, an animal, a fungus, or an algae. In an alternative embodiment, the cell is a prokaryotic cell, such as a bacterium or a protozoan. In an exemplary embodiment, the cell is a cultured cell. In an alternative embodiment, the cell is a primary cell, i.e., a primary cell that is directly isolated from an organism (e.g., a human). The cell may be an adherent cell or a suspension cell, i.e., a cell that grows in suspension. In an exemplary embodiment, the cell is a mammalian cell. Most preferably, the cell is a human cell. The cell may be any cell type, may be derived from any type of tissue, and may be at any developmental stage. In an exemplary embodiment, the cell comprising the liposome is an antigen-presenting cell (APC). As used herein, "antigen-presenting cell" or "APC" refers to an immune cell that mediates cellular immune responses by processing and presenting antigens for recognition by specific T cells. In an exemplary embodiment, the APC is a dendritic cell, a macrophage, a Langerhans cell, or a B cell. In an exemplary embodiment, the APC is a dendritic cell (DC). In an exemplary embodiment, when the cells are administered to a subject, e.g., a human, the cells are autologous to the subject. In an exemplary example, the immune cell is a tumor-associated macrophage (TAM).

[0030] Also provided by the present disclosure are populations of cells in which at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of the population are cells that contain (e.g., are transfected with) liposomes of the present disclosure. The population of cells in some embodiments is a heterogeneous cell population, or in some embodiments, a substantially homogeneous population, the population primarily comprising cells that contain liposomes of the present disclosure.

[0031] Provided herein is a composition comprising a liposome of the present disclosure, a cell comprising a liposome of the present disclosure, a population of cells of the present disclosure, or any combination thereof, and a pharma- ceutically acceptable carrier, excipient, or diluent. In an exemplary embodiment, the composition is a pharmaceutical composition intended for administration to humans. In an exemplary embodiment, the composition is a sterile composition. In an exemplary example, the composition comprises a plurality of liposomes of the present disclosure. Optionally, at least 50% of the plurality of liposomes have a diameter of about 100 nm to about 250 nm, and optionally have a core comprising IONPs.

[0032] In exemplary aspects, the compositions of the present disclosure may include additional components other than liposomes, cells containing liposomes, or populations of cells. The compositions may, in various aspects, include, for example, acidifiers, additives, adsorbents, aerosol propellants, air displacing agents, alkalizing agents, anti-caking agents, anticoagulants, antimicrobial preservatives, antioxidants, preservatives, bases, binders, buffers, chelating agents, coating agents, colorants, drying agents, detergents, diluents, disinfectants, disintegrants, dispersants, solubility enhancers, dyes, softeners, emulsifiers, emulsion stabilizers, fillers, film formers, flavor enhancers, flavorings, glidants, and the like. The composition may include any pharma- ceutically acceptable ingredient, including, for example, a gelling agent, a granulating agent, a moisturizing agent, a lubricant, a mucoadhesive agent, an ointment base, an ointment, an oily vehicle, an organic base, a pastille base, a pigment, a plasticizer, an abrasive, a preservative, a sequestering agent, a skin-penetrating agent, a solubilizing agent, a solvent, a stabilizing agent, a suppository base, a surfactant, a surface active agent, a suspending agent, a sweetening agent, a therapeutic agent, a thickening agent, a tonicifying agent, a toxicological agent, a thickening agent, a water-absorbing agent, a water-miscible cosolvent, a water softener, or a humectant. See, for example, the Handbook of Pharmaceutical Excipients, Third Edition, 1999, pp. 111-115, 1999. d Edition, A. H. Kibbe (Pharmaceutical Press, London, UK, 2000), which is incorporated by reference in its entirety. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), which is incorporated by reference in its entirety.

[0033] The composition of the present disclosure may be suitable for administration by any acceptable route, including parenteral and subcutaneous.Other routes include, for example, intravenous, intradermal, intramuscular, intraperitoneal, intranodal and intrasplenic.In an exemplary embodiment, if the composition comprises liposomes (not cells that contain liposomes), the composition is suitable for systemic (e.g., intravenous) administration.In an exemplary embodiment, if the composition comprises cells that contain liposomes (not extracellular liposomes), the composition is suitable for intradermal administration.

[0034] When the composition is in a form intended for administration to a subject, it can be isotonic with the intended administration site. For example, when the solution is in a form intended for parenteral administration, it can be isotonic with blood. The composition is typically sterile. In certain embodiments, this can be achieved by filtration through a sterile filtration membrane. In certain embodiments, parenteral compositions are generally placed in a container with a sterile access port, for example, an intravenous solution bag, or a vial with a stopper that can be pierced by a hypodermic injection needle, or a pre-filled syringe. In certain embodiments, the composition can be stored either in a prepared form or in a form that is reconstituted or diluted before administration (e.g., lyophilized).

[0035] Manufacturing method The present disclosure provides a method of making liposomes. In an exemplary embodiment, the method includes: (A) mixing DOTAP and cholesterol in a DOTAP:cholesterol mass ratio of about 3:1 to form a lipid mixture; (B) drying the lipid mixture; (C) rehydrating the lipid mixture with a rehydration solution to form a rehydrated lipid mixture; and (D) incubating the rehydrated lipid mixture at a temperature greater than about 40° C. and intermittently vortexing the rehydrated lipid mixture to form liposomes. In an exemplary embodiment, the method further includes incubating the liposomes for 12 hours or more after step (D), and optionally further includes sonicating the liposomes. In an exemplary embodiment, the method further includes incubating the liposomes for 12 hours or more after step (D) at about 20° C. to about 30° C. or about 2° C. to about 4° C. In a typical example, the method further comprises filtering the liposomes through at least a 150 nm filter, and optionally, the liposomes are filtered through a 200 nm filter and / or a 450 nm filter. In some embodiments, the liposomes are filtered through a 450 nm filter and a 200 nm filter, and optionally, the liposomes are sequentially filtered through a 450 nm filter followed by a 200 nm filter. In an exemplary example, the method further comprises incubating the liposomes with an RNA molecule. In some embodiments, the method comprises mixing about 7.5 μg±0.75 μg of DOTAP and about 2.5 μg±0.25 μg of cholesterol to form a lipid mixture. In some embodiments, the DOTAP and cholesterol are dissolved in chloroform to form a lipid mixture. In some embodiments, nitrogen gas is used to dry the lipid mixture. The rehydration solution in an exemplary embodiment is a buffer, optionally phosphate buffered saline (PBS). In an illustrative example, the rehydrated lipid mixture is incubated in a water bath at a temperature of about 50° C. and vortexed about every 10 minutes to form liposomes. In an illustrative embodiment, the lipid mixture or rehydration solution further comprises iron oxide nanoparticles (IONPs).Optionally, the rehydration solution includes a solution of carboxylated iron oxide nanoparticles, each carboxylated iron oxide nanoparticle having a diameter of about 50 nm to about 150 nm. In an illustrative example, the method further includes adding IONPs to the lipid mixture or the rehydration solution. In some embodiments, each IONP has a diameter of about 10 nm to about 200 nm. The IONPs have a diameter of about 60 nm to about 140 nm or about 10 nm to about 30 nm. In some embodiments, the lipid mixture or rehydration solution comprises at least about 1 μg IONPs per 10 mg lipid mixture, at least about 100 μg IONPs per 10 mg lipid mixture, at least about 1 mg IONPs per 10 mg lipid mixture, or at least about 1.5 mg IONPs per 10 mg lipid mixture, and optionally, the lipid mixture or rehydration solution comprises about 5 mg or less IONPs per 10 mg lipid mixture. In some examples, the method includes incubating the liposomes with an RNA molecule. The RNA molecule in some embodiments is any of those described herein, e.g., an RNA molecule encoding a tumor antigen, a cytokine, an antisense molecule. In some examples, the RNA molecule is isolated for tumor cells obtained from the subject. In some embodiments, about 5 μg of the RNA molecule is incubated for every about 75 μg lipid of the liposome. In some embodiments, the method includes incubating the liposome with the RNA molecule at a mass ratio of about 1:15 RNA molecule:DOTAP. In an illustrative example, when the liposome contains IONP, about 10 μg of RNA molecule is incubated for every about 150 μg of liposome.

[0036] The present disclosure provides liposomes made by any of the methods for making liposomes described herein. The liposomes may be used to transfect cells. Thus, the present disclosure provides cells that contain (e.g., transfected) liposomes made by any of the methods for making liposomes described herein. In an exemplary example, the cells are any of the cells described herein, including but not limited to antigen-presenting cells (APCs). In an exemplary example, the cells are dendritic cells (DCs). In an exemplary embodiment, the cells are part of a cell population. Thus, a population of cells is provided that includes (transfected) cells that contain liposomes made by any of the methods for making liposomes described herein. In some aspects, at least 50% of the cell population are (e.g., transfected) cells that contain liposomes.

[0037] Also provided herein is a composition comprising a liposome produced by any of the methods for producing liposomes described herein, a cell comprising a liposome, a population of cells comprising a cell comprising a liposome, or any combination thereof, and a pharma- ceutically acceptable carrier, excipient, or diluent. In an exemplary embodiment, the composition may be according to the composition described above. In some embodiments, the composition comprises a plurality of liposomes, and at least 50% of the liposomes have a diameter of about 100 nm to about 250 nm.

[0038] How to use As shown herein, compared to RNA electroporation, the magnetic liposomes of the present disclosure containing IONPs and RNA enhanced the production of antiviral cytokines (IFN-α) and induced DC migration to lymph nodes. Such liposomes also inhibited T2 *This resulted in a reduction in the enhanced MRI intensity and an increase in MRI-detected lymph node size that directly correlated with the number of iron oxide-loaded cells in the treated lymph node. These data suggest that the magnetic liposomes of the present disclosure that contain IONPs and RNA enhance DC activation and enable non-invasive cell tracking by MRI. Without being bound to a particular theory, these data support the use of the magnetic liposomes of the present disclosure that contain IONPs and RNA to predict anti-tumor immune responses and use MRI-detected DC migration as a biomarker of vaccine efficacy.

[0039] Provided herein is a method of delivering RNA to cells in a tumor, e.g., a brain tumor, comprising intravenously administering a composition of the present disclosure, the composition comprising a liposome. Also provided herein is a method of delivering RNA to cells in the tumor, and optionally, the microenvironment of a brain tumor. In an exemplary embodiment, the method comprises administering a composition of the present disclosure intravenously, the composition comprising a liposome. In some aspects, the liposome comprises an siRNA targeting a protein of an immune checkpoint pathway, optionally PDL1. In various aspects, the cell in the microenvironment is an antigen-presenting cell (APC), optionally a tumor-associated macrophage. The present disclosure also provides a method of activating an antigen-presenting cell in a brain tumor microenvironment. In an exemplary embodiment, the method comprises administering a composition of the present disclosure intravenously, the composition comprising a liposome.

[0040] The present disclosure provides a method for delivering RNA molecules to cells. In an exemplary embodiment, the method includes incubating cells with liposomes comprising ribonucleic acid (RNA) molecules and a lipid mixture comprising DOTAP and cholesterol, the DOTAP and cholesterol being present in the lipid mixture at a DOTAP:cholesterol mass ratio of about 3:1. In an exemplary embodiment, the liposomes comprise IONPs as described herein. In an exemplary example, the cells are incubated with the liposomes in the presence of a magnetic field. In an exemplary embodiment, the magnetic field is a static magnetic field. In an exemplary embodiment, the magnetic field is an oscillating magnetic field. In an exemplary embodiment, the magnetic field is a magnetic field having a strength of about 100 mT. In an exemplary example, the cells are incubated with the liposomes in the presence of a magnetic field for a time period of less than about 2 hours or less than about 1 hour, and optionally, the cells are incubated with the liposomes in the presence of a magnetic field for about 30 minutes ± 10 minutes. In an exemplary example, the cells are antigen-presenting cells (APCs), optionally dendritic cells (DCs). In various examples, the APC (e.g., DC) is obtained from a subject. In certain embodiments, the RNA molecule is isolated from a tumor cell obtained from a subject, e.g., a human. In certain embodiments, the RNA molecule is an antisense molecule, which targets and reduces the expression of a protein of interest. In an exemplary embodiment, the RNA molecule is an siRNA molecule, which targets a protein of an immune checkpoint pathway. Suitable proteins of an immune checkpoint pathway are known in the art and described herein. In various examples, the siRNA targets PDL1.

[0041] Once the RNA is delivered to the cells, the cells can be administered to a subject for the treatment of the disease. Thus, the present disclosure provides a method of treating a subject with a disease. In an exemplary embodiment, the method includes delivering the RNA molecule to a cell of a subject according to the above-described method of delivering the RNA molecule to a cell. In some aspects, the RNA molecule is delivered to the cell ex vivo, and the cell is administered to the subject. Alternatively, the method includes directly administering the liposome to the subject. In an exemplary embodiment, the method of treating a subject with a disease includes administering a composition of the present disclosure in an amount effective to treat the disease in the subject. In an exemplary aspect, the disease is cancer, and in some aspects, the cancer is located across the blood-brain barrier and / or the subject has a tumor located in the brain. In some aspects, the tumor is a glioma, a low-grade glioma, or a high-grade glioma, specifically a grade III astrocytoma or a glioblastoma. Alternatively, the tumor can be a medulloblastoma or a diffuse intrinsic pontine glioma. In another example, the tumor may be a metastatic infiltration from a non-CNS tumor, e.g., breast cancer, melanoma, or lung cancer. In an exemplary embodiment, the composition comprises liposomes, and optionally, the composition comprising liposomes is administered intravenously to the subject. In an alternative embodiment, the composition comprises cells transfected with liposomes. Optionally, the cells of the composition are APCs, and optionally, DCs. In an exemplary embodiment, the composition comprising cells comprising liposomes is administered intradermally to the subject, and optionally, the composition is administered intradermally to the groin of the subject. In an exemplary example, the DCs are isolated from white blood cells (WBCs) obtained from the subject, and optionally, the WBCs are obtained via leukapheresis. In some embodiments, the RNA molecule encodes a tumor antigen. In some embodiments, the RNA molecule is isolated from tumor cells, e.g., the tumor cells are cells of a tumor of the subject. In an exemplary embodiment, the liposomes comprise IONPs, and the method further comprises tracking the migration of the cells comprising the liposomes in the subject. In an exemplary embodiment, tracking includes magnetic resonance imaging (MRI). For example, tracking can include imaging of one or more of the subject's Optionally, MRI is performed on the lymph node before and after administration of the composition or cells. In an exemplary embodiment, the method of treatment includes T2 * Weighted MRI intensity was compared with T2 * The method optionally includes measuring the lymph node size of the subject via MRI. Also, optionally, the method includes comparing the lymph node size of the lymph node containing the DCs transfected with liposomes containing IONPs with the lymph node size of the control untreated lymph node.

[0042] The terms "treat", "treating" and "treatment" refer to partially or completely, temporarily or permanently eliminating, reducing, inhibiting or ameliorating any of the clinical symptoms, signs or progression of an event, disease or condition associated with an inflammatory disorder as described herein. As recognized in the relevant art, a drug used as a therapeutic agent may reduce the severity of a given pathology, but need not eliminate all signs of the disease to be considered a useful therapeutic agent. Similarly, a treatment administered prophylactically need not be completely effective in preventing the onset of symptoms to constitute a viable prophylactic agent. It is sufficient to merely reduce the impact of the disease (e.g., by reducing the number or severity of symptoms, enhancing the effectiveness of another treatment, or producing another beneficial effect) or reduce the likelihood of the disease developing or worsening in a subject. One embodiment of the present invention relates to a method for determining the effectiveness of a treatment, comprising administering a therapeutic agent to a patient in an amount and for a time sufficient to induce a sustained improvement over baseline in an indicator reflecting the severity of a particular disorder.

[0043] As used herein, the term "treat" as well as related words do not necessarily mean 100% or complete treatment. Rather, there are various degrees of treatment, which one skilled in the art will recognize as having potential benefits or therapeutic effects. In this regard, the method of treating cancer of the present disclosure can provide any amount or level of treatment. Furthermore, the treatment provided by the method can include treatment of one or more conditions or symptoms or signs of the disease being treated. For example, the treatment method of the present disclosure can suppress one or more symptoms of the disease. The treatment provided by the method of the present disclosure can also include delaying the progression of the disease. The term "treat" also encompasses prophylactic treatment of the disease. Thus, the treatment provided by the method of the present disclosure can delay the onset or recurrence of the disease being prophylactically treated. In exemplary embodiments, the method delays the onset of the disease by 1 day, 2 days, 4 days, 6 days, 8 days, 10 days, 15 days, 30 days, 2 months, 4 months, 6 months, 1 year, 2 years, 4 years, or more. Prophylactic treatment encompasses reducing the risk of the disease being treated. In exemplary embodiments, the method reduces the risk of disease by 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, or more.

[0044] With respect to the aforementioned methods, the liposome or a composition comprising the same is, in some embodiments, administered systemically to the subject. Optionally, the method includes administering the liposome or composition by parenteral administration. In various examples, the liposome or composition is administered intravenously to the subject.

[0045] In various embodiments, the liposome or composition is administered according to any regimen, including, for example, daily (once a day, twice a day, three times a day, four times a day, five times a day, six times a day), three times a week, twice a week, every second day, every third day, every fourth day, every fifth day, every sixth day, every week, every other week, every three weeks, every month, or every other month. In various embodiments, the liposome or composition is administered to the subject once a week.

[0046] The term "therapeutically effective amount" refers to an amount of a therapeutic agent effective to ameliorate or alleviate a symptom or sign of a disease associated with a disease or disorder.

[0047] In an exemplary aspect, the treatment of a disease is achieved by enhancing an immune response to the disease in a subject. Thus, the present disclosure provides a method of enhancing an immune response to a disease, e.g., tumor or cancer, in a subject. In an exemplary embodiment, the method comprises administering to a subject a liposome of the present disclosure in an amount effective to enhance the subject's immune response to the disease, e.g., tumor or cancer. In an exemplary aspect, the enhanced immune response is evidenced by increased activation of dendritic cells, as demonstrated, for example, by enhanced expression of genes associated with DC activation, enhanced expression of costimulatory molecules on the surface of DCs, increased production of antiviral cytokines (e.g., IFNα), increased T cell stimulation (e.g., as shown by increased IFN-γ production by T cells upon contact with activated DCs), increased migration to lymph nodes, and enhanced inhibition of tumor growth. Thus, the present disclosure further provides a method of increasing activation of DCs or activating DCs. In an exemplary embodiment, the method comprises administering to a subject a liposome of the present disclosure in an amount effective to increase activation of DCs or in an amount effective to activate DCs. Thus, the present disclosure also provides a method of increasing the production of antiviral cytokines (e.g., IFNα). In an exemplary embodiment, the method comprises administering to a subject a liposome of the present disclosure in an amount effective to increase the production of antiviral cytokines in the subject. Further, a method of increasing T cell stimulation in a subject is provided. In an exemplary embodiment, the method comprises administering to a subject a liposome of the present disclosure in an amount effective to increase T cell stimulation in the subject. In various aspects, the increased T cell stimulation is evident from an increased T cell production of IFN-γ. The present disclosure further provides a method of increasing T cell production of IFN-γ. In an exemplary embodiment, the method comprises contacting a T cell with a dendritic cell (DC) of the present disclosure, optionally, the liposome comprises IONPs, and the DC is transfected with the liposome in the presence of a magnetic field. Further, a method of increasing dendritic cell (DC) migration to lymph nodes in a subject is provided. In an exemplary embodiment, the method comprises administering to a subject a composition of the present disclosure in an amount effective to increase DC migration to lymph nodes.As used herein, the term "increase" and words derived therefrom may not be a 100% or complete increase. Rather, there are various degrees of increase or enhancement that those skilled in the art will recognize as having potential benefits or therapeutic effects. In exemplary embodiments, the increase or enhancement provided by the method of the present disclosure is at least or about 10% increase or enhancement (e.g., at least or about 20% increase or enhancement, at least or about 30% increase or enhancement, at least or about 40% increase or enhancement, at least or about 50% increase or enhancement, at least or about 60% increase or enhancement, at least or about 70% increase or enhancement, at least or about 80% increase or enhancement, at least or about 90% increase or enhancement, at least or about 95% increase or enhancement, at least or about 98% increase or enhancement).

[0048] The present disclosure further provides a method of increasing dendritic cell (DC) migration to lymph nodes of a subject. In an exemplary embodiment, the method comprises administering to a subject a composition of the present disclosure in an amount effective to increase DC migration to lymph nodes. The present disclosure further provides a method of activating dendritic cells (DC) in a subject. In an exemplary embodiment, the method comprises administering to a subject a composition of the present disclosure in an amount effective to activate DC in the subject. In various examples, the DC results in superior inhibition of tumor growth. Thus, the present disclosure provides a method of inhibiting tumor growth in a subject. In an exemplary embodiment, the method comprises administering to a subject a liposome of the present disclosure in an amount effective to inhibit tumor growth in the subject. In various aspects, the method comprises administering to a subject a composition of the present disclosure in an amount effective to activate DC in the subject. In various aspects of these methods, the method comprises incubating DC obtained from a subject with liposomes of the present disclosure and administering to the subject DCs containing the liposomes. In various examples, the method comprises using MRI to track migration of DCs containing the liposomes to lymph nodes in the subject. In various embodiments, tracking of DCs can be used to predict a subject's response to therapy with DCs containing liposomes. As used herein, the term "inhibit" and words derived therefrom may not be 100% or complete inhibition. Rather, there are various degrees of inhibition that those skilled in the art recognize as having potential benefits or therapeutic effects. In exemplary embodiments, the inhibition provided by the method of the present disclosure is at least or about 10% inhibition (e.g., at least or about 20% inhibition, at least or about 30% inhibition, at least or about 40% inhibition, at least or about 50% inhibition, at least or about 60% inhibition, at least or about 70% inhibition, at least or about 80% inhibition, at least or about 90% inhibition, at least or about 95% inhibition, at least or about 98% inhibition).

[0049] The present disclosure provides a method for tracking the migration of dendritic cells (DCs) to lymph nodes of a subject. In an exemplary embodiment, the method includes (i) treating a subject having a disease according to the disclosed method of treating the subject, wherein the cells are DCs and the liposomes comprise IONPs, and (ii) performing magnetic resonance imaging (MRI) of one or more lymph nodes of the subject. In an exemplary embodiment, the method includes measuring the T2 * Emphasis (T2 * weighted) MRI intensity of control untreated lymph nodes. * Compared with the weighted MRI intensity, T2 * Lymph nodes that show a decrease in enhanced MRI intensity represent lymph nodes to which DCs have migrated. In certain embodiments, one or more lymph nodes are inguinal lymph nodes of the subject, and optionally, the composition is administered intradermally to the subject's groin. In an illustrative example, MRI is performed on the lymph node before and after administration of the composition or cells, and optionally, MRI is performed before administration and about 48 hours after administration, and optionally, MRI is performed about 72 hours after administration. In some embodiments, the method includes measuring the T2 of lymph nodes containing DCs transfected with liposomes containing IONPs. * Weighted MRI intensity was compared with T2 *In an exemplary embodiment, the method includes measuring the lymph node size of the subject through MRI, and optionally further includes comparing the lymph node size of the lymph node that contains the DCs transfected with liposomes that contain IONPs with the lymph node size of the control untreated lymph node.

[0050] The present disclosure also provides a method for determining a subject's therapeutic response to a dendritic cell (DC) vaccination therapy in the subject. In an exemplary embodiment, the method includes (i) treating the subject according to the treatment method of the present disclosure, where the cells are DCs and the liposomes contain IONPs, and (ii) tracking DC migration to lymph nodes according to any of the methods of tracking DC migration of the present disclosure. In some aspects, the T2 * If the enhanced MRI intensity is decreased, it is determined that the DC vaccination therapy brings about a positive therapeutic response in the subject.In an illustrative example, the positive therapeutic response comprises the subject's progression-free period and overall survival period prolonged for at least 4 weeks after administration of the therapy.In some embodiments, the positive therapeutic response comprises the subject's progression-free period and overall survival period prolonged for at least 8-12 weeks after administration of the therapy.

[0051] The present disclosure also provides a method of monitoring a therapeutic response to a dendritic cell (DC) vaccination therapy in a subject. In an exemplary embodiment, the method comprises tracking DC migration to lymph nodes at a first time point and at a second time point according to any one of the tracking methods of the present disclosure, and determining the T2 * Weighted MRI intensity was T2 of treated lymph nodes at the first time point * A reduction compared to the enhanced MRI intensity indicates an effective therapeutic response to the DC vaccination therapy.

[0052] Also provided is a method of increasing T cell production of IFN-γ, comprising contacting T cells with dendritic cells (DCs) of the present disclosure comprising or transfected with a liposome of the present disclosure, optionally wherein the liposome comprises IONPs and the DCs are transfected with the liposome in the presence of a magnetic field.

[0053] cancer The cancer treatable by the methods disclosed herein can be any cancer, for example, any malignant growth or tumor caused by abnormal and uncontrolled cell division that can spread to other parts of the body through the lymphatic system or bloodstream. In some embodiments, the cancer is a cancer in which integrins and G protein α subunits are expressed on the surface of cells.

[0054] In some embodiments, the cancer is acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, anal cancer, anal canal cancer, or anorectal cancer, eye cancer, intrahepatic bile duct cancer, cancer of the joints, cancer of the neck, cancer of the gallbladder, or cancer of the pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the oral cavity, cancer of the vulva, chronic lymphocytic leukemia, chronic bone marrow cancer, colon cancer, esophageal cancer, cervical cancer, gastrointestinal carcinoid tumor, hominid cancer, rhabdomyosarcoma ... The cancer is selected from the group consisting of Hodgkin's lymphoma, hypopharyngeal cancer, renal cancer, laryngeal cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharyngeal cancer, non-Hodgkin's lymphoma, ovarian cancer, pancreatic cancer, peritoneal, omental, and mesenteric cancer, pharyngeal cancer, prostate cancer, rectal cancer, kidney cancer (e.g., renal cell carcinoma (RCC)), small intestine cancer, soft tissue cancer, gastric cancer, testicular cancer, thyroid cancer, ureteral cancer, and bladder cancer. In a particular embodiment, the cancer is selected from the group consisting of head and neck cancer, ovarian cancer, cervical cancer, bladder and esophageal cancer, pancreatic cancer, gastrointestinal cancer, gastric cancer, breast cancer, endometrial and colorectal cancer, hepatocellular carcinoma, glioblastoma, bladder cancer, lung cancer, such as non-small cell lung cancer (NSCLC), bronchioloalveolar carcinoma.

[0055] subject In representative embodiments, subjects of the disclosed methods include, but are not limited to, mammals of the order Rodentia, such as mice and hamsters, and mammals of the order Logomorpha, such as rabbits, mammals of the order Felidae, including Felidae (cats) and Canidae (dogs), mammals of the order Artiodactyla, including Bovidae (cows) and Suidae (pigs), or mammals of the order Perissodactyla, including Equidae (horses). In some aspects, the mammal belongs to the order Primates, Ceboids, or Simoids (monkeys), or belongs to the suborder Anthropoids (humans and apes). In representative aspects, the mammal is a human. In some aspects, the human is an adult aged 18 years or older. In some aspects, the human is a child aged 17 years or younger.

[0056] The invention thus generally described will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the invention. EXAMPLES

[0057] Example 1 This example demonstrates an exemplary method of making cholesterol-containing liposomes of the present disclosure and their use for RNA delivery to dendritic cells (DCs).

[0058] A series of experiments were performed to generate cholesterol-containing liposomes that were highly efficient for RNA delivery to DCs. Control liposomes without cholesterol were generated essentially as described in Sayour et al., Oncoimmunology 6(1):e1256527 (2017).

[0059] Liposomes were made with various amounts of cholesterol using various thin film rehydration techniques. Each formulation contained 10 mg total lipid. The compositions made are outlined in the table below.

[0060] [Table 1]

[0061] Briefly, for each composition, DOTAP and cholesterol (or DOTAP alone) were dissolved in chloroform and added to a borosilicate glass tube. The chloroform was evaporated with nitrogen gas (N2) and then evaporated without nitrogen before rehydration with PBS. The particles were then rehydrated with 2 mL of PBS and incubated in a 50°C water bath, vortexing every 10 min, for 1 h to allow liposomes to form. The liposomes were then left overnight at room temperature. The next day, the liposomes were sonicated for 5 min at room temperature and filtered through a 450 nm filter followed by a 200 nm filter.

[0062] The transfection efficiency of liposomes containing cholesterol was compared to that of liposomes lacking cholesterol using an immortalized cell line of dendritic cells called DC2.4 by flow cytometry. RNA encoding green fluorescent protein (GFP) (GFP RNA) was loaded into each type of liposome by incubating approximately 75 μg of liposomes with approximately 5 μg of RNA in buffer. The mixture was kept at room temperature for 15-20 min to allow the formation of RNA-loaded DOTAP liposomes. For cell transfection, approximately 27 μg of RNA-loaded DOTAP liposomes were incubated overnight with approximately 200,000 DC2.4 cells. GFP-positive (GFP RNA) + The percentage of transfected cells was assessed via flow cytometry. Briefly, transfected cells were washed with PBS followed by the addition of approximately 300 μL of 0.05% trypsin. After 5 min, trypsin was neutralized using serum-containing medium and cells were transferred to fluorescence-activated cell sorting (FACS) tubes. The cells were washed with PBS and resuspended in FACS buffer for flow cytometric analysis of GFP expression on a FACS Calibur.

[0063] As shown in Figure 1A, the addition of cholesterol to DOTAP liposomes significantly enhanced the levels of cellular transduction. Liposomes containing 12–37% cholesterol significantly increased the levels of GFP-+ At least a three-fold increase in cells was obtained. The highest level of cell transfection was obtained with liposomes formulated with 25% cholesterol content, but the level of cell transfection using liposomes formulated with 37% cholesterol content was also significantly greater than liposomes lacking cholesterol. Liposomes containing 25% cholesterol content were used in subsequent studies.

[0064] In a separate experiment, GFP RNA was labeled with Cy5 via the ArcturusTurbo labeling kit and incorporated into DOTAP liposomes with 0% or 25% cholesterol, made essentially as described above. Liposomes were incubated overnight with DC2.4 dendritic cells and analyzed via flow cytometry. Liposomes containing cholesterol (Chol-RNA-NP) delivered RNA to a significantly higher percentage of cells than standard RNA-liposomes without a decrease in viability (Figures 1B and 1C).

[0065] Primary bone marrow-derived DCs (BMDCs) loaded with RNA isolated from mouse glioma cell lines The transfection efficiency of liposomes containing cholesterol was compared to that of liposomes lacking cholesterol using RNeasy. Briefly, total tumor-derived RNA (KR158b-luciferase) from tumor cells was isolated using the commercially available RNeasy mini kit (Qiagen) according to the manufacturer's instructions. Liposomes containing either 0% or 25% cholesterol, made essentially as described above, were loaded with RNA from KR158B-luciferase tumor cells. These cells were then incubated with KR158b-luciferase-specific T cells from other vaccinated animals for 2 days. After 48 hours, supernatants were collected to assess IFN-γ production as a feature of T cell activation. IFN-γ production was determined via IFN-γ ELISA (Invitrogen, BMS606) according to the manufacturer's instructions.

[0066] As shown in Figure 1D, cholesterol-containing liposomes induced more IFN-γ production from T cells, indicating that cholesterol-loaded liposomes increased a key DC function in activating T cell responses.

[0067] These results indicate that cholesterol-containing liposomes deliver RNA to cells with higher efficiency compared to cholesterol-free liposomes. The data show that a mass ratio of DOTAP and cholesterol of 3:1 results in excellent transfection efficiency of the liposomes, which can transfect DCs very efficiently, and the transfected DCs then activate T cells to produce IFNγ. The results presented here suggest the clinical utility of cholesterol-containing liposomes as part of a DC vaccination strategy to activate T cells.

[0068] Example 2 This example shows that cholesterol-containing liposomes can target immune cells in brain tumors.

[0069] Liposomes with 0% cholesterol or 25% cholesterol (made with DOTAP at a DOTAP:cholesterol ratio of 3:1) were made as described in Example 1. Liposomes were loaded with Cy3- or Cy5-labeled RNA (OVA RNA) encoding ovalbumin and injected intravenously into mice bearing KR158b-luciferase tumors. KR158b-luciferase is a temozolomide- and radiation-resistant mouse glioma line that recapitulates the characteristic findings of human glioblastoma, including infiltration into surrounding brain tissue. After 24 hours, brains were extracted from three mice and stored for immunofluorescence imaging. Figure 2A represents an immunofluorescence image of the cortex, and Figure 2B represents an immunofluorescence image of the tumor. Tumors were extracted from a separate set of mice, and the number of Cy5-labeled cells in each tumor was analyzed via flow cytometry. Untreated mice and mice treated with Cy5-labeled RNA only served as negative controls. As shown in FIG. 2C, the number of Cy5+ cells in the brain tumor was highest with liposomes containing cholesterol.

[0070] Different brain tumor models were tested. RNA-liposomes (made with DOTAP at a DOTAP:cholesterol ratio of 3:1) with or without 25% cholesterol were loaded with Cy5-labeled RNA and injected intravenously into mice bearing GL261 tumors. GL261 is a murine gliosarcoma commonly used as a therapeutic model representing human glioblastoma. After 24 hours, tumors were harvested to assess the number of Cy5-labeled cells by flow cytometry. As in the case of mice bearing KR158b-luciferase tumors, only liposomes with cholesterol delivered Cy3- or Cy5-labeled mRNA to cells in GL261 tumors (Figure 2D). These results were important because they suggest that it is possible to manipulate these standard immunosuppressive cells in the area immediately surrounding the brain tumor, thereby providing an unprecedented advantage to a vaccination strategy using these liposomes.

[0071] DOTAP liposomes containing various amounts of cholesterol (0%, 12.5%, 25%, or 37%) were prepared as described above and loaded with Cy3-labeled OVA RNA. The RNA-loaded liposomes were then intravenously injected into C57Bl6 mice bearing KR158b-luciferase tumors. Tumors from the mice were harvested 24 hours later and evaluated by flow cytometry. As shown in Figure 3, there was a clear dependence on the amount of cholesterol in the liposomes. Liposomes loaded with 25% cholesterol showed the highest amount of Cy3+ cells in the tumor.

[0072] Further studies were performed to determine the propensity of liposomes to deliver RNA to specific cell types. Brain tumor slices from mice in Figure 2C were stained with immunofluorescent antibodies against the endothelial cell marker CD31. Images were then taken with a fluorescent microscope to assess the relationship between the delivered RNA and endothelial blood vessels. As shown in Figure 4, RNA-loaded liposomes containing cholesterol did not precisely colocalize with cells expressing CD31. These results suggest that RNA is delivered to cells surrounding blood vessels, but not to the endothelial cells themselves.

[0073] Further experiments were performed to characterize the cells targeted by the liposomes upon injection. C57Bl6 mice received an intracranial injection of 10,000 KR158b-luciferase cells. Three weeks later, the mice received an intravenous injection of liposomes composed of 25% cholesterol and 75% DOTAP and loaded with Cy5-labeled RNA. The following day, tumors were excised, dissociated with papain, strained into single cell suspensions, and stained for flow cytometry with Live / Dead Dye (LIVE / DEAD Fixable Near-IR Dead Cell Stain Kit, Invitrogen L10119) and antibodies for CD45 (PerCP-Cy5.5, BioLegend) and MHCII (FITC, ThermoFisher) in FACS buffer. Cells were then fixed with 4% paraformaldehyde (PFA) and evaluated on a BD LSRII flow cytometer. As shown in Figure 5A-5C, RNA-loaded liposomes containing cholesterol were found almost exclusively in CD45+ cells in brain tumors. Furthermore, about half of these cells were MHC class II positive. This experiment was repeated in GL61 tumors with nearly identical results. Because CD45 is a universal marker for myeloid-derived cells and MHCII is an integral part of the antigen-presenting machinery found only in antigen-presenting cells, this evidence indicates that RNA liposomes with cholesterol efficiently deliver RNA to immune cells in brain tumors, about half of which are MHCII+ antigen-presenting cells. Since the CD45 compartment is known to be recruited to support tumor growth inhibiting antitumor immune responses, RNA delivery to either CD45+ population is interesting from a therapeutic perspective. MHCII+ antigen-presenting cells in tumors are thought to induce antigen-specific immune tolerance, whereas MHCII- cells contain myeloid-derived suppressor cells, known to produce cytokines and express co-regulatory molecules that further inhibit antitumor immune responses.

[0074] To assess whether this enhanced RNA delivery was specific to brain tumors, a study was performed to determine whether cholesterol-containing RNA-loaded liposomes also enhanced RNA delivery to peripheral organs. C57Bl6 mice received an intravenous injection of Cy5-labeled RNA liposomes with 25% cholesterol by mass. Spleen, liver, and lungs were excised at 24 hours, strained into single-cell suspensions, lysed, and stained with CD45 (PerCP-Cy5.5) and MHCII (FITC) for flow cytometry. As shown in Figures 6A-6C, cholesterol-containing RNA-loaded liposomes were found to be more abundant in CD45+ cells in the liver than RNA-loaded liposomes containing 0% cholesterol. In the lungs and spleen, cholesterol-containing RNA-loaded liposomes were found to be nearly as abundant as RNA-loaded liposomes containing 0% cholesterol. These peripheral organs RNA uptake in each of the 100 and 1000 RNA-containing tumors was plotted against uptake in the brain tumors (6D-F). In this analysis, a direct relationship between uptake in one organ and uptake in the brain tumor would suggest a similar or related mechanism for uptake at both sites. In no case was there a significant relationship between uptake in that organ and uptake in the brain tumor. These data suggest that uptake of cholesterol-containing RNA-liposomes in brain tumors occurs through a mechanism that is distinct from the mechanism by which cholesterol-containing RNA-liposomes are uptaken in the lung, spleen, or liver. These data also suggest that cholesterol-containing RNA-liposomes are attractive candidates as vaccines for treating lung and liver tumors.

[0075] Example 3 This example demonstrates the process of making magnetic liposomes of the present disclosure.

[0076] We designed and performed several experiments aimed at making iron oxide (IO)-loaded DOTAP liposomes useful for RNA delivery to dendritic cells (DCs) and as contrast agents for magnetic resonance imaging (MRI).

[0077] The protocol for making control liposomes described in Example 1 was modified to include iron oxide. In the first set of experiments, the starting material in chloroform was sonicated, rehydrated with rehydrating material, and then sonicated. Table 1 details the various materials and conditions tested to make IO-loaded DOTAP liposomes. IOs were made in-house and coated with oleic acid. For experiments #1-5, DOTAP was present at a concentration of at least 350 μg, and the starting material included one or more IOs in chloroform, polyethylene glycol (PEG), N-methyl-2-pyrrolidone (NMP), and oleic acid. For experiments #6-7, 45 μg of DOTAP and 10 μL of a 30 mg / mL IO solution were the starting materials. In experiments #8 and 9, DOTAP was the only starting material, and in experiment 10, no DOTAP was included at all. For experiments #1-7, iron oxide was the starting material. In experiments #8-10, iron oxide was used as the rehydration agent.

[0078] [Table 2]

[0079] The resulting particles were analyzed by transmission electron microscopy (TEM). For experiments #1-5, TEM images showed that the iron oxide was contained within the oleic acid, but not the liposomes. For experiment #6, the iron oxide was present on the outside of the liposomes. For experiment #7, many of the liposomes had little or no IO. For experiments #8-10, the IO-containing liposomes were not detected. No liposomes were produced that could be used.

[0080] In the second series of experiments, DOTAP and IO made from different sources were used. In some experiments, oleic acid was the starting material. Table 2 details the various materials tested to make IO-loaded DOTAP liposomes. The conditions for each of these experiments were the same as in experiment #2. The resulting particles were analyzed via TEM.

[0081] [Table 3]

[0082] In each of Experiments #11-15, liposomes were not detected by TEM, and in the case of Experiment #16, liposomes and iron oxide particles were detected as separate entities.

[0083] In the third series of experiments, the starting material was sonicated, rehydrated with purified distilled water, and incubated at 50°C for 1 h with sonication every 10 min. The particles were then left overnight before being sonicated for 5 min and subsequently filtered through a 450 nm Whatman filter and a 200 nm PALL filter. IO was added as starting material, as rehydrated material, or after filtration. Table 3 details the different materials tested to generate IO-loaded DOTAP liposomes. The resulting particles were analyzed by transmission electron microscopy (TEM).

[0084] [Table 4]

[0085] For experiments #17-20, 5 μg of RNA was added to 75 μg samples of each liposome composition. These RNA-loaded liposomes were then loaded onto an electrophoresis gel and run at a voltage of 80 mV to assess the amount of unbound RNA. These RNA-loaded liposomes were then evaluated by cryo-TEM to determine if iron oxide was bound within the liposomes. Unbound RNA was identified in liposomes from experiment #20. For experiments #17-19, each particle construct was bound with RNA, but no IO was detected in the liposomes.

[0086] In the fourth series of experiments, various amounts of PEGylated iron oxide nanoparticles (10 nm diameter, 200 μg, 400 μg, 1 mg, or 1.5 mg) or 400 μg of ferraheme (FH) were added to the lipid cake. FH is a contrast agent consisting of 30 nm dextran-coated IO nanoparticles. Table 4 details the materials used.

[0087] [Table 5]

[0088] In the case of experiments #25-26, liposomes showed efficient RNA binding ability and transfection efficiency. However, IO nanoparticles were not detected within the liposomes. In the case of experiments #27-28, liposomes demonstrated low transfection efficiency.

[0089] In the fifth series of experiments, liposomes were mixed with iron oxide in chloroform (experiments 30–31) and rehydrated with 4 mL of room temperature PBS or left without iron oxide in the chloroform phase and rehydrated with 2.5 mg of commercial IO nanoparticles in 100 μL of PBS. All samples were sonicated for 1 h at a starting temperature of 55 °C and then left overnight at room temperature before being analyzed by 450 nm NMR. Filtered through a Whatman filter and a 200 nm PALL filter. Table 5 details the materials used.

[0090] [Table 6]

[0091] In experiment #29, iron oxide was detected outside the liposomes. In experiments #30-31, large aggregates of iron oxide were detected.

[0092] In the sixth set of experiments, lipid cakes containing 7.5 mg of DOTAP and 2.5 mg of cholesterol were rehydrated with a solution containing IO nanoparticles. In one experiment, 2 mg of carboxylated IO nanoparticles (10 nm diameter) were used. In three experiments, various amounts of 130 nm carboxylated iron oxide nanoparticles (NanoMag) were used to create liposomes containing various amounts of iron oxide within the liposome core. Liposomes formed by rehydrating the lipid cake with 2 mg of carboxylated 10 nm iron oxide nanoparticles or 10 μg, 100 μg, or 1 mg of NanoMag were tested for RNA binding and transfection efficiency following the protocol described in Sayour et al., Oncoimmunology 6(1):e1256527(2015). All four sets of liposomes were able to bind RNA and transfect cells. Liposomes with 1 mg of IONPs showed the highest level of transfection efficiency. These liposomes were shown to have IO within the liposomes by cryo-TEM, and advantageously, these liposomes stimulated anti-tumor immunity in tumor models.

[0093] Example 4 This example demonstrates an exemplary method for making magnetic liposomes and their characterization.

[0094] Cationic liposomes were generated using a variation of the thin film rehydration technique described in Example 1. Figure 7A shows a schematic of the basic steps. In one variation of the technique, iron oxide nanoparticles (IONPs) are added in step 3. Briefly, 7.5 mg of DOTAP and 2.5 mg of cholesterol were dissolved in chloroform and added to a borosilicate glass tube (step 1). The chloroform was evaporated with N2 (step 2) and dried for 1 h before rehydration with a dense iron oxide solution (5 mg of NanoMag® at 200 μL / mL) (step 3). The particles were then incubated in a 50°C water bath and vortexed every 10 min to allow liposome formation for 1 h. The liposomes were then left at room temperature overnight. The next day, the liposomes were sonicated for 5 min at room temperature and filtered through 450 nm and 200 nm filters (step 4).

[0095] In the second variation of the technique, IO was added to step 1. 2.5 mg of DOTAP and 2.5 mg of cholesterol were dissolved in chloroform along with oleic acid-coated iron oxide and added to a borosilicate glass tube (step 1). The chloroform was evaporated with N2 (step 2), dried for 1 h, and then rehydrated with PBS (step 3). The particles were then incubated in a 50°C water bath and vortexed every 10 min for 1 h to allow liposome formation. The liposomes were then left at room temperature overnight. The next day, the liposomes were sonicated for 5 min at room temperature and filtered through 450 nm and 200 nm filters (step 4).

[0096] The most effective nanoparticles were found to be produced by a method involving the addition of carboxylated iron oxide nanoparticles during the rehydration step (step 3), where a solution of high density (≥1 mg / mL) iron oxide nanoparticles (instead of PBS) was used as the rehydration agent. The process involving the addition of carboxylated iron oxide nanoparticles in step 1 also produced effective nanoparticles, although to a lesser extent, compared to the addition of IO in step 3.

[0097] Magnetic liposomes produced by the above method were loaded with GFP RNA at a ratio of 5 μg RNA:75 ug lipid. Liposomes were analyzed on a Nanosight NS300 instrument. These magnetic liposomes were shown to have IO within the liposomes by cryo-TEM (Figure 7B), which appeared to be mainly in the range of 100 nm to 300 nm, with another bump at 370 possibly indicating aggregation of multiple particles (Figure 7C). Thus, the magnetic liposomes were confirmed to be indeed nanoparticles (NPs). Throughout this disclosure, iron oxide-RNA nanoparticles (IO-RNA-NPs) are synonymous with magnetic liposomes.

[0098] IO-RNA-NPs produced by the method described above using a 1 mg / mL or higher solution of IONPs as the rehydrating agent, or by the method described in Example 3, were loaded with GFP RNA at a ratio of 5 μg RNA:75 μg lipid. Each liposome was added to a well of a 1% agarose gel. As shown in Figure 7D, the absence of bands in each condition indicates that all methods yielded liposomes with 100% binding of the RNA loaded in these conditions.

[0099] We transfected DC2.4 with GFP RNA using RNA-NPs with or without iron oxide, and IO-RNA-NPs showed significant transfection efficiency, higher than that of standard RNA-NPs without iron oxide (Figure 7E).

[0100] DC2.4 were transfected using RNA-NPs loaded with IO and cholesterol (Chol-IO-RNA-NPs) and compared to standard IO-loaded RNA-NPs (0% cholesterol). GFP+ cells were measured by flow cytometry. As shown in Figure 7F, the presence of cholesterol increased the transfection efficiency by more than two-fold compared to NPs loaded with IO without cholesterol. This result indicates that a 3:1 ratio of DOTAP and cholesterol provides optimal transfection efficiency for iron oxide-loaded liposomes. Bright field images of transfected DCs were taken (Figure 7G). Fluorescence imaging of transfected DCs was performed (Figure 7H), demonstrating the presence of Cy3-labeled RNA in the perinuclear region of DCs. Localization to this region appeared to occur regardless of iron oxide or cholesterol content.

[0101] IO-loaded liposomes were prepared as described above, except for varying amounts of carboxylated IO (130 nm diameter). Lipids (10 mg, 7.5 mg DOTAP and 2.5 mg cholesterol) were rehydrated into a coloroform with varying amounts of carboxylated iron oxide (200 μg, 400 μg, 1 mg, or 1.5 mg) to yield particles with final iron oxide content of 0.5 μg / uL, 1 μg / uL, 2.5 μg / uL, or 3.75 μg / uL. These particles were loaded with Cy5-labeled GFP RNA and used to transfect DC2.4. Flow cytometry at 24 hours showed that increasing iron oxide content increased transfection efficiency (Figure 7I). This enhancement has not been reported before for any cell type, and this observation may support the novel use of iron oxide-loaded liposomes to enhance transfection of cells, e.g., DCs.

[0102] Example 5 This example illustrates the effect of a magnetic field on magnetic liposomes.

[0103] The effect of a 101 mT magnetic field on the ability of magnetic liposomes to deliver RNA to cells was tested. As described in Example 1, magnetic liposomes with either 0% or 25% cholesterol were loaded with GFP RNA. The magnetic liposomes loaded with GFP RNA were incubated with DC2.4 dendritic cells for 30 minutes in the presence or absence of a magnetic field. In one set of cells, RNA-loaded magnetic liposomes were incubated with DC2.4 dendritic cells overnight in the absence of a magnetic field generated by a MagneFect-Nano II 24-well magnet array. After 30 minutes, the medium containing the particles was removed and replaced with fresh medium. Gene delivery was evaluated as the expression of GFP by flow cytometry at 24 hours. As shown in Figure 8A, GFP RNA was not expressed in the magnetic liposomes. + The number of DCs was greater in the presence of a magnetic field compared to its absence. These data support that a magnetic field can be used to enhance RNA delivery to DCs.

[0104] Cholesterol-loaded magnetic liposomes synthesized with various amounts of iron oxide (0 μg, 10 μg, 100 μg, 1000 μg) per 10 mg of lipid were loaded with Cy5-labeled GFP RNA. The RNA-loaded magnetic liposomes were then used to transfect DC2.4 dendritic cells for 30 minutes in the presence of a static magnetic field. As shown in Figure 8B, the presence of iron oxide within the liposomes increased the % GFP in a dose-dependent manner. + The smallest amount of IO increased %GFP + The highest amount of IO resulted in a 5-fold increase in % transfected cells, while the highest amount of IO resulted in a 2-fold difference in DCs. These data support that iron oxide content enhances the responsiveness to magnetic fields and subsequent transfection of dendritic cells.

[0105] Magnetic liposomes (1 mg IO per 10 mg lipid) were loaded with Cy3-labeled RNA and subsequently incubated with DC2.4 dendritic cells for 30 min in the presence or absence of a magnetic field or overnight in the absence of a magnetic field. +Flow cytometry was performed 24 hours after magnetic exposure to determine the % of cells that were GFP. As shown in Figure 8C, + The transfection efficiency was highest in cells exposed overnight (18 h) to IO-free liposomes in the absence of a magnetic field. However, the same level of transfection was only obtained for a small fraction of the time (30 min) when the liposomes contained IO and were exposed to a magnetic field during the incubation period of the RNA and cells. These results suggest that the transfection efficiency of magnetic liposomes was six times higher in the presence of a magnetic field. The significant reduction in time (30 min vs. 18 h) is significant, since overnight incubation with cationic liposomes is associated with cytotoxicity. Thus, a reduction in the incubation time of the RNA and cells by more than 95% would increase the number of transfected cells produced per patient.

[0106] The presence of iron oxide within cells provides an additional opportunity to manipulate cells with magnetic fields. One application of this technique is to distinguish cells that have taken up iron oxide nanoparticles from those that have not. To test this application, BMDCs were incubated overnight with RNA-loaded magnetoliposomes as described above. After 18 hours, DCs were transferred to an Eppendorf tube and placed in a magnetic separator for 30 minutes at 37°C. As can be seen in Figure 8D, visible clumps of BMDCs were attracted to the side of the Eppendorf tube where the magnetic field strength was greatest.

[0107] Primary bone marrow-derived dendritic cells (BMDCs) are more representative than patient-derived dendritic cells used in clinical studies. In one study, the effect of a magnetic field on cell transfection efficiency using magnetic liposomes was tested using primary BMDCs. Liposomes containing DOTAP and cholesterol at a 3:1 DOTAP:cholesterol ratio, with or without 1 mg of IO (10% by mass), were loaded with Cy5-labeled GFP RNA. The RNA-loaded liposomes were then incubated with primary BMDCs for 30 min in the presence or absence of a magnetic field, or overnight in the absence of a magnetic field. As shown in Figure 8E, the percentage of labeled BMDCs was higher when cells were incubated with RNA in the presence of a magnetic field. GFP expression assessed by flow cytometry, and as shown in Figure 8F, primary BMDC cells transfected with liposomes containing IO in the presence of a static magnet resulted in a nearly two-fold increase in %GFP+ cells compared to cells transfected with liposomes lacking IO or liposomes containing IO but incubated in the absence of a magnet. These results show that a 30 min incubation of iron oxide-loaded nanoparticles in the presence of a magnetic field was sufficient to achieve a 100% increase in transfection efficiency compared to overnight incubation in the absence of the magnetic field.

[0108] Example 6 This example shows that RNA-loaded magnetic liposomes stimulate DC activation and migration to lymph nodes.

[0109] Dendritic cells are key components of the antiviral immune response. One of the main roles of these cells is to produce type I interferons (IFN-α or IFN-β) in response to exposure to foreign nucleic acids, which is characteristic of viral infection. These antigen-experienced DCs are classified as CD8 + They present viral antigens to T cells. T cells that bind antigens on DCs in the presence of costimulatory molecules are stimulated to release IFN-γ. Figure 9A shows a diagram of these pathways.

[0110] Considering these cytokine stimulation pathways, we measured the release of IFN-α by DCs incubated with GFP RNA-loaded liposomes (GFP mRNA+NP), electroporated with GFP RNA (electroporated), incubated with non-RNA-loaded liposomes, and untreated DCs in a ratio of 1.33 μg RNA:25 μg liposomes:200,000 cells in 24-well plates. Supernatants were collected 20 h after the start of incubation and analyzed for IFN-α production by ELISA. As shown in Figure 9B, the levels of IFN-α were highest when DCs were incubated with GFP-RNA-loaded liposomes. This increase in IFN-α production obtained with magnetic liposomes is clinically relevant, as it has been shown to be essential for antitumor immune responses in a similar vaccination model.

[0111] To test the T cell stimulating ability of RNA-NP-loaded DCs, ovalbumin-specific OT1 transgenic T cells were incubated with BMDCs loaded with magnetic liposomes carrying ovalbumin RNA. After 48 hours, the supernatant was removed and ELISA was performed to evaluate the release of IFN-γ from these cells. As shown in Figure 9C, BMDCs loaded with magnetic liposomes induced the activation of T cells.

[0112] Previous studies in humans with glioblastoma have shown that migration of RNA-pulsed dendritic cells to lymph nodes directly correlates with successful immunization (Mitchell et al., Nature 519:366-369 (2015)). Therefore, we sought to evaluate the effect of magnetic liposomes on the migration capacity of dendritic cells compared to the current gold standard DC transfection technique (electroporation). Naive OT1 ( C57Bl6 mice (at 18 h) or C57Bl6 mice (at 48 and 72 h) received intradermal injections of DsRedDCs loaded with OVA RNA (at 18 h) or Cy3-labeled GFP RNA (at 48 and 72 h) via electroporation or magnetic liposomes (on the opposite side). Lymph nodes on both sides were harvested at 18, 48, or 72 h and dissociated with collagenase. Flow cytometry was then performed to quantify the number of cells that migrated to each lymph node in each animal. As shown in Figure 9D, magnetic liposome-loaded dendritic cells enhanced migration to lymph nodes (LNs) by more than 80% on day 2 and more than 25% on day 3, compared to DC migration to LNs when DCs were electroporated with RNA. This enhanced migration ability suggests that magnetoliposome-loaded DCs are fundamentally different from electroporated DCs and may provide unique advantages for antitumor immune responses.

[0113] This example demonstrated that magnetic liposomes can enhance DC activation.

[0114] Example 7 This example demonstrates that magnetic liposomes enable MRI-based cell tracking.

[0115] Magnetoliposomes were loaded with OVA RNA and incubated with BMDCs. These DCs were then injected intradermally into the left groin of C57Bl6 mice. After 48 hours, the mice were imaged with 11T MRI using various MRI imaging sequences. These sequences included T2 * The following image sequences were included: T2 RARE weighted sequences with repetition time (TR) / echo time (TE) ratios of 90 / 3 with and without fat saturation, 3500 / 12 with fat saturation, 207 / 17 with fat saturation, and 90 / 5 with fat, and T2 RARE weighted sequences with TR / TE of 500 / 14 with and without fat saturation. Regions were drawn around the lymph nodes in all slices of these image sequences.* The intensity changes between treated and untreated lymph nodes in T2_RARE weighted images and T2_RARE weighted images for each set of imaging parameters are shown in representative images in Figure 10A and quantified in Figure 10B. Images and data show the T2_RARE weighted images in treated lymph nodes. * The weighted images show a decrease in signal intensity, which is the expected effect of iron oxide.

[0116] After imaging, lymph nodes were harvested and stained for DsRed. + The cells were analyzed by flow cytometry. The number of cells in each lymph node was then counted as T2 with fat saturation. * The relative change in intensity in the weighted images (Figure 10C) and the average relative change in lymph node size compared to untreated lymph nodes across the different imaging sequences above (Figure 10D) were plotted against each other. When determining the average increase in lymph node size, the volume of each inguinal lymph node (treated and untreated) was found by drawing a region of interest around each lymph node in each MRI slice. ImageJ was then used to calculate the area of ​​each of these slices. These areas were multiplied by the width of each slice to determine the volume of that slice. These volumes were then summed for all slices in that image set that contained lymph nodes to generate the volume of the MRI detected lymph nodes for each imaging sequence. The relative change in lymph node size for each sequence was then found by dividing the volume of the treated lymph node by the volume of the contralateral untreated lymph node for each sequence. The overall average change in lymph node size was then determined by taking the average of all of the relative changes in lymph node volume calculated across the seven imaging sequences above.

[0117] As shown in Figures 10C and 10D, the number of iron oxide-loaded dendritic cells in each lymph node and the T2 * There was a clear quantitative relationship between the intensity of the weighted MRI images (10C) and the size of the lymph nodes (10D). The correlation appeared to be surprisingly reliable. Previous attempts to quantify cell migration have required relatively complex calculations of signal-to-noise ratios or comparison of intensity within a "void volume" (de Chickera S, et al., Int Immunol. 2012;24(1):29-41. doi:10.1093 / intimm / dxr095. PubMed PMID:22190576 and Zhang et al., Radiology 274(1):192-200 doi:10.1148 / radiol.14132172).

[0118] T2 * The finding that both enhanced MRI intensity and lymph node size are directly correlated with the number of magnetoliposome-loaded dendritic cells at the vaccination site, the draining lymph node, is a significant advancement since a relatively untrained observer can now assess the success of a vaccination strategy using a very simple analytical technique. Furthermore, while others have shown a relationship between dendritic cell migration and MRI output, none have utilized multifunctional particles that can deliver antigen to DCs, activate those DCs, and enable MRI-based tracking of these cells. Thus, the magnetic liposomes described herein are the first multifunctional particles with the ability to (1) deliver RNA to DCs with high efficiency, (2) activate DCs to release IFNα, (3) enable enhanced transfection efficiency with application of an external magnetic field, and (4) generate sufficient changes in MRI signal to semiquantitatively assess dendritic cell migration to lymph nodes. Linear regression was used to generate a line of best fit, and Pearson's correlation was used to calculate the goodness of fit. It is displayed here as a p-value that evaluates the relationship between counted cells and MRI intensity.

[0119] Example 8 This example shows that DC migration detected by MRI predicts inhibition of tumor growth.

[0120] C57Bl6 mice were challenged with B16F10-OVA tumors via subcutaneous administration of 1,000,000 cells on day 0. On the same day, mice received intradermal injections of 500,000 bone marrow-derived dendritic cells with RNA encoding ovalbumin (OVA) at a ratio of 150 μg magnetic liposomes to 10 ug RNA for every 2,000,000 cells, and intravenous injections of 10,000,000 OT1 T cells. Two days later, mice were imaged with 11T MRI using a unique set of six MRI sequences as described in Example 7.

[0121] In the first experiment, tumor-bearing C57Bl6 mice were treated as above or left untreated. Tumor growth was measured over 20 days, and the results are shown in Figure 11A. As shown in this figure, tumor size was significantly smaller in mice treated with BMDCs loaded with magnetic liposomes containing OVA RNA compared to untreated mice.

[0122] In the second experiment, tumor-bearing C57Bl6 mice were treated as above and tumor growth was measured for 30 days (Figure 11B). The subset of mice whose tumors grew rapidly were designated "non-responders" and the subset whose tumors did not grow were designated "responders." As shown in Figure 11C, responders and non-responders showed significantly different tumor volumes at day 27. Figure 11D shows the analysis of MRI sequences of these mice on day 2. As shown in Figure 11D, the MRI sequences showed a significant difference in T2 * This shows that there is a significant difference in the intensity of the fat-suppressed images. * The fat suppression sequence is unique. Six other theoretically similar sequences were evaluated, but none provided a quantitative relationship between day 2 MRI intensity and tumor growth. See, for example, FIG. 11E. Plotting day 27 tumor volume against day 2 MRI intensity showed a significant linear relationship, as shown in FIG. 11F.

[0123] These data suggest that magnetic liposomes enhance MRI-based detection of dendritic cell migration two days after treatment. These results suggest that the multifunctional particles allow for the detection of tumor growth and accurately predict which mice will respond to treatment 4 weeks after treatment. This is the first demonstration of a correlation between tumor growth inhibition by multifunctional particles and MRI intensity. The predictive effect of MRI has only been shown by one other group (Zhang Z, Li W, Procissi D, Li K, Sheu AY, Gordon AC, Guo Y, Khazaie K, Huan Y, Han G, Larson AC. Antigen-loaded dendritic cell migration: MR imaging in a pancreatic carcinoma model. Radiology. 2015;274(1):192-200. doi:10.1148 / radiol.14132172. PubMed PMID:25222066; PMCID:PMC4314117). However, this group used a less direct approach that relied on the signal-to-noise ratio of before and after images. This group also did not use multifunctional particles. The simplified method described here uses simple but specific MRI sequences to allow quantification and comparison to unvaccinated lymph nodes of the same animals.

[0124] Example 9 This example demonstrates how to treat a human patient with a DC vaccine comprising magnetic liposomes of the present disclosure and how to predict response to treatment.

[0125] The magnetic liposomes loaded with iron oxide are made essentially as described in Example 7B. A tumor is excised from a cancer patient and RNA is isolated from the tumor cells. The RNA is then amplified via reverse transcription into a cDNA library, amplification into the cDNA library using PCR, and in vitro transcription, and loaded into magnetic liposomes essentially as described in Example 8. In another embodiment, RNA encoding a specific tumor-associated antigen is generated and loaded into magnetic liposomes essentially as described in Example 8. White blood cells are isolated from the same cancer patient via leukapheresis. The WBCs are treated with IL-4 and GM-CSF to generate dendritic cells. The DCs are loaded with magnetic liposomes prepared with RNA essentially as described in Example 8. Approximately 2x10 6 cells containing magnetic liposomes with RNA are then loaded into magnetic liposomes. 7 Dendritic cells are injected intradermally into the patient's groin. * Various MRI images, including weighted images, will be taken immediately prior to vaccination and 24, 48, and 72 hours after vaccination.

[0126] MRIs obtained before and after treatment were used to assess each patient's lymph node size and T2 * Determine the change in enhanced lymph node intensity. Regions of interest are then drawn around each inguinal lymph node for processing in ImageJ as described in Example 8. Briefly, the mean lymph node volume across seven imaging sequences and the T2 intensity at days 1, 2, and 3 post-treatment are calculated. * The mean intensity within lymph nodes on the weighted images is plotted against progression-free and overall survival for patients with malignant gliomas. The strong correlation between lymph node size or hypointensity and progression-free or overall survival is then used to predict patient response to treatment within days of vaccination.

[0127] Example 10 This example demonstrates how to deliver immune modulatory nucleic acids to immune cells in the periphery and within malignant brain tumors.

[0128] Patients with malignant brain tumors undergo surgical resection or biopsy of the primary tumor site. RNA from the tumor is isolated and amplified as described in Example 9. The amplified mRNA encoding the tumor antigen is bound to liposomes composed of approximately 75% DOTAP and 25% cholesterol at a ratio of 25ug RNA:375ug liposome. In another embodiment, the mRNA comprises mRNA specific for a tumor associated antigen, optionally linked to a site-specific mRNA. The RNA comprises the megalovirus antigen pp65. In another embodiment, the RNA comprises mRNA encoding an immunomodulatory protein, for example, a costimulatory molecule such as CD86, a chemotactic factor such as CCL3, or an activating cytokine such as granulocyte-monocyte colony-stimulating factor (GM-CSF). In another embodiment, the RNA comprises siRNA or shRNA designed to modulate immune function of the transfected cells. An example of an immune-modulating target for siRNA or shRNA delivery is programmed cell death ligand 1 (PD-L1). In another embodiment, the RNA comprises other nucleic acids useful for activating or inhibiting immune function. In another embodiment, the RNA comprises two or more of the RNA constructs listed above in combination therapy. For example, tumor-derived mRNA is combined with pp65 mRNA with or without siRNA for PDL1. In another embodiment, the liposomes contain 1 mg of iron oxide per 10 mg of lipid. These liposomes are then injected intravenously into the patient on a regular basis. In one embodiment, the intervals are twice weekly for six injections, twice monthly for six additional injections, or until disease progression. In another embodiment, patients receive different RNA constructs in successive vaccinations, for example, patients receive liposomes loaded with tumor-derived mRNA for three weeks, followed by six bimonthly injections of tumor-derived mRNA and PDL1 siRNA.

[0129] In patients vaccinated with liposomes containing iron oxide, T2 *Weighted MRI sequences will be acquired, and the change in MRI intensity before and after vaccination will be plotted against time to progression and overall survival to assess whether MRI-detected particle localization in brain tumors correlates with patient response to treatment.

[0130] Example 11 This example demonstrates the effect of lipid composition on particle localization and characterization of RNA-loaded cells.

[0131] We previously reported that cationic liposomes loaded with mRNA encoding tumor antigens (RNA-NPs) induced potent immune activation in peripheral organs sufficient to eliminate subcutaneous and intracranial tumors in preclinical models of melanoma. 9,10 However, these particles accumulate primarily in the lungs due to their positive charge (Figure 24). 9 To avoid this pulmonary uptake, the lipid composition was modified to contain cholesterol in an attempt to reduce the enrichment of positive charges on the liposome surface. This modification failed to alter particle localization to the lungs and spleen, but did increase RNA-NP localization to the liver (Figure 23). We then tested particle localization in mice using intracranial KR158b-luciferase, a radiotherapy-, chemotherapy-, and checkpoint inhibitor-resistant mouse glioma line. Surprisingly, immunofluorescence microscopy 24 hours after injection of the liposomes revealed that these modified liposomes accumulated in the brain tumor but not in the surrounding normal cortex (Figure 12A). However, cholesterol-free liposomes did not accumulate in either region.

[0132] Intrigued by this result, we repeated this observation in a larger cohort of animals and quantified particle uptake in KR158b-luciferase and GL261 using flow cytometry. We found that the presence of cholesterol enhanced liposome uptake in both tumors (Figure 12B-C), with this effect being most pronounced at a cholesterol concentration of 25% by weight (Figure 12D). Taken together, this evidence indicates that cholesterol-bearing liposomes may be a simple tool to deliver immune-modulating nucleic acids to brain tumors.

[0133] We next sought to characterize the RNA-loaded cells in brain tumors. Because liposomes accumulate only in tumors and not in normal brain, we hypothesized that they may have infiltrated tumor-associated vascular endothelium. RNA-loaded cells were localized near the endothelium of brain tumors. Although we observed a large increase in the number of cells in the brain tumor, both immunofluorescence microscopy and flow cytometry showed that these cells lacked CD31 (Figure 2A). However, in contrast to the bulk tumor, which was approximately 50% CD45+, RNA-labeled cells in both GL261 and KR158b were nearly 100% CD45+ (Figure 13B,C). Furthermore, RNA-labeled CD45+ cells in KR158b and GL261 were disproportionately F4 / 80+, MHCII+, CD11b+, and Ly6G / 6C+ (Figure 13D-G). This intriguing result suggests that Chol-RNA-NPs are directly delivering nucleic acids to antigen-presenting cells in the brain tumor microenvironment, which are composed of tumor-associated macrophages (TAMs).

[0134] Example 12 This example demonstrates the effect of Chol-RNA-NPs on cells loaded with RNA.

[0135] TAMs are known to suppress antitumor immune responses, but can be reprogrammed into an antitumor phenotype characterized by increased expression of MHCII, CD80, and CD86 ( 6,11). Since we previously showed that RNA-NPs activate innate immune cells in peripheral organs, we next evaluated whether these liposomes could also activate TAMs in the brain tumor microenvironment. We again loaded liposomes with fluorescently labeled mRNA and injected them systemically into mice. We found that after 24 hours, F4 / 80+ cells that had taken up Chol-RNA-NPs significantly upregulated the expression of MHCII (Figure 14A). Furthermore, we found that these Cy5-labeled MHCII+ cells also expressed high levels of CD80 and CD86 (Figure 14B, C). Interestingly, we also found an increase in CD80 on TAMs in the bulk population that did not contain RNA.

[0136] Example 13 This example shows the delivery of PDL1 siRNA by Chol-RNA-NPs.

[0137] To test this hypothesis, we sought to combine Chol-RNA-NPs with cell-specific checkpoint blockers. First, we generated a library of anti-PDL1 siRNAs from published literature and screened them for their ability to suppress the expression of PDL1 in DCs 2, 3, and 4 days after transfection without compromising transfection efficiency. Through this screening, we identified an siRNA species (siPDL1) that significantly reduced the expression of PDL1 without reducing GFP expression (Figure 24).

[0138] We then tested whether Chol-RNA-NPs could deliver this siRNA to intracranial brain tumors. Supporting our results of delivering mRNA, we found that Chol-RNA-NPs significantly increased the delivery of Cy3-labeled siRNA to CD45+MHCII+ cells in intracranial tumors (Figure 15A-C). Similar to the mRNA-loaded cells, many of these cells expressed the APC markers MHCII, F4 / 80, and CD11b (Figure 15D-F).

[0139] We then tested whether the siRNA delivered by Chol-RNA-NPs was functionally active by staining for PDL1 expression in these cells. In these experiments, we utilized a non-coding siRNA (siCTRL) as a control. We found that a single injection of Chol-RNA-NPs with siPDL1 reduced PDL1 expression in siRNA-loaded antigen-presenting cells compared to cells in untreated tumors and in the bulk of treated tumors (Figure 15G-I). We then demonstrated that this effect could be expanded with additional administrations. We found that administration of siPDL1 via Chol-RNA-NPs three times a day dramatically reduced PDL1 expression in transfected MDSCs compared to untreated cells (untreated: 60.06 + / - 22.24, Cy5+siPDL1: 16.7 + / - 19.23, p = 0.0255), bulk cells in the tumor (bulk: 45.82 + / - 17.04, Cy5+siPDL1: 16.7 + / - 19.23, p = 0.047), and cells treated with control siRNA (CTRL: 77.14 + / - 28, Cy5+siPDL1: 16.7 + / - 19.23, p = 0.0081) (Figure 15J). Taken together, this evidence indicates that Chol-RNA-NPs can be used to activate intratumoral immune cells and modify cellular behavior with immune-modulatory nucleic acids ( Figure 15K ).

[0140] Example 14 This example describes the materials and methods used in the experiments of Examples 11-13.

[0141] RNA preparation and labeling: GFP and OVA mRNA were generated via in vitro transcription as previously described. 12 PDL1 and CTRL siRNAs were purchased from Santa Cruz Biotechnology. Nucleic acid labeling was completed using Arcturus Turbo Labeling Kits according to the manufacturer's instructions (ThermoFisher Scientific).

[0142] Cell culture: DC2.4 and KR158b-luciferase were kindly provided by John Sampson, Duke University. 13 GL261 was purchased from EMD Millipore. DC2.4 and KR158b-luciferase were cultured in high glucose DMEM with pyruvate supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1% penicillin / streptomycin (LifeTechnologies) at 5% CO2 and 37°C. GL261 was cultured in DMEM / F-12 with Glutamax, 10% FBS, and 1% penicillin / streptomycin (LifeTechnologies).

[0143] Synthesis of RNA-NPs: (1) Synthesis of liposomes: Liposomes were prepared as previously described 12 Briefly, dehydrated DOTAP and cholesterol 700000P (Avanti Polar Lipids) were suspended in chloroform and mixed at DOTAP:cholesterol ratios of 4:0, 3.5:0.5, 3:1, or 2.5:1.5. The chloroform was then evaporated under nitrogen. The lipid cake was then brought to a concentration of 2.5 mg / mL in phosphate-buffered saline (PBS), heated at 50°C for 1 h with vortexing every 10 min, and left at room temperature overnight. The lipid was then sonicated for 5 min and filtered through 450 and 200 nm filters (Whatman and PALL, respectively). (2) Formation of RNA-NP complexes: Chol-RNA-NPs were prepared as previously described for RNA-NPs. 12 Briefly, 375ug of lipid was combined with 25ug of mRNA or siRNA per mouse and incubated for 15 minutes prior to injection.

[0144] In vitro transfection: DC2.4 were plated in 24-well plates at 100,000 cells per well. After 24 hours, RNA-NP was added to the wells at 1.667ug of mRNA per well. Transfection was assessed by flow cytometry at 24, 48, 72, and 96 hours.

[0145] C57Bl / 6 mice were purchased from Jackson Laboratories. Animal procedures were approved by the University of Florida Animal Care and Use Committee (UFIACUC201607966).

[0146] Flow cytometry analysis: Flow cytometry was performed using BD Biosciences Analysis was performed using a FACS Canto-II from BD Biosciences, using antibodies from Biolegend, Bioregend, and Invitrogen. For in vitro experiments, DCs were harvested, washed with PBS, and stained for 20 min. Samples were then washed twice with PBS and suspended in FACS buffer. Cell counts and viability were assessed with a Vi-Cell XR Cell Viability Analyzer (Beckman Coulter). For in vivo experiments, lymph nodes were harvested in cold PBS, diced with a razor blade, digested with papain for 20 min at 37°C, then filtered through a 70 μm cell strainer, washed with PBS, and stained with the appropriate antibodies for 20 min. Counting beads were added to each tube immediately before flow analysis.

[0147] Immunofluorescence: Mice bearing intracranial brain tumors were sacrificed and perfused with PBS and 4% formalin 24 hours after injection of fluorescently labeled RNA-NPs. Brains were then harvested, fixed in 4% formalin, transferred to 4% sucrose solution overnight, and stored in PBS. Slices were completed with a Leica RM2235 microtome. Images were captured with an Olympus IX70 inverted fluorescence microscope.

[0148] Statistical analysis: Data are expressed as mean ± standard deviation. Student's t-test was used for statistical analysis. Paired t-test was used for paired data. Analysis was performed using GraphPad Prism version 8. References: The following references are cited throughout Examples 11-14. (1) Hilf, N., et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240-245 (2019); (2) Schumacher, TN & Schreiber, RD Neoantigens in cancer immunotherapy.Science 348,69-74(2015);(3)Grobner,S.N.,et al.The landscape of genomic alterations across childhood cancers.Nature 555,321-327(2018);(4)Charles,N.A.,Holland,E.C.,Gilbertson,R.,Glass,R.& Kettenmann,H.The brain tumor microenvironment.Glia 59,1169-1180(2011);(5)Lewis,C.E.& Pollard,J.W.Distinct role of macrophages in different tumor microenvironments.Cancer Res 66,605-612(2006);(6)Poon,C.C.,Sarkar,S.,Yong,V.W.& Kelly,J.J.P.Glioblastoma-associated microglia and macrophages:targets for therapies to improve prognosis.Brain 140,1548-1560(2017);(7)Morantz,R.A.,Wood,G.W.,Foster,M.,Clark,M.& Gollahon,K.Macrophages in experimental and human brain tumors.Part 2:studies of the macrophage content of human brain tumors.J Neurosurg 50,305-311(1979);(8)Abbott,N.J.,Ronnback,L.& Hansson,E.Astrocyte-endothelial interactions at the blood-brain barrier.Nat Rev Neurosci 7,41-53(2006);(9)Sayour,EJ,et al.Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.Oncoimmunology 6,e1256527(2017);(10)Sayour,EJ ,et al.Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy.Nano Lett(2018);(11)Mosser,DM& Edwards,JPExploring the full spectrum of macrophage activation.Nat Rev Immunol 8,958-969(2008);(12)Sayour,EJ,et al.Systemic activation of antigen presenting cells via RNA-loaded nanoparticles.OncoImmunology,00-00(2016);(13)Shen,Z.,Reznikoff,G.,Dranoff,G.& Rock,KLCloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.J Immunol 158,2723-2730(1997).

[0149] Example 15 This example shows that magnetic nanoparticles that activate dendritic cells (DCs) enable early prediction of anti-tumor responses by MRI.

[0150] Abstract: Cancer vaccines elicit antitumor responses in a subset of patients, but the lack of clinically meaningful biomarkers to predict therapeutic response has limited their development. Here, we design multifunctional RNA-loaded magnetic liposomes that initiate potent antitumor immunity and serve as early MRI-based imaging biomarkers of therapeutic response. These particles activate DCs more effectively than electroporation, resulting in superior inhibition of tumor growth in therapeutic models. Inclusion of iron oxide enhances DC transfection and allows tracking of DC migration by MRI. We demonstrate enhanced T2 * We show that hypointensity on weighted MRI strongly correlates with DC trafficking and is an early predictor of anti-tumor responses. In preclinical tumor models, MRI-predicted "responders" identified 2 days after vaccination had significantly smaller tumors 2-5 weeks after treatment and survived 100% longer than MRI-predicted "non-responders." Thus, these studies provide a simple and scalable nanoparticle formulation to generate potent anti-tumor immune responses and predict individual treatment outcomes by MRI.

[0151] Cancer immunotherapy produces impressive tumor regressions in settings where conventional treatments offer no benefit 1 However, even the most effective immunotherapy strategies extend survival in only a subset of patients. 2~6 Although several pretreatment biomarkers have been suggested to be sensitive to immunotherapy, there are currently no robust markers that predict clinical response. 7~9 Future development of promising cancer immunotherapies will require dynamic biomarkers to distinguish responders from non-responders before tumor progression. 9 .

[0152] The inventors have previously reported that indium 111 We demonstrated that DC migration to the draining lymph nodes (VDLN) of the vaccine site, assessed by SPECT / CT imaging of labeled DCs, may provide an early biomarker of overall survival in GBM patients treated with RNA-pulsed DC vaccines10 However, radioactive cell labeling for PET and SPECT is cumbersome and not widely available in clinical practice. 11 Clinical evaluation of this biomarker will require a widely available method to sensitively track DC migration without additional cell processing. MRI is a widely available imaging technique that has been used to qualitatively track large numbers of cells in humans, but MRI-based quantification of cell migration to lymph nodes remains challenging. 12~18 .

[0153] In addition, electroporation has been widely used to deliver RNA to DCs in clinical trials. 10,19~23 , immunostimulatory replacement of electroporation may further enhance therapeutic efficacy. Nanomaterials are attractive for non-viral mRNA delivery, 24 However, few nanoparticles have been widely adopted in clinics due to the complexity of large-scale clinical-grade manufacturing. 7,25,26 Here, we overcome this limitation with scalable multifunctional nanoliposomes based on previously translated material that efficiently transfect DCs with RNA, stimulate significant DC activation, and establish MRI-detected DC migration as a biomarker of antitumor responses to DC vaccines (Figure 16).

[0154] In this study, we first screen a library of lipid particles with a proven safety profile in humans to develop lipid nanoparticle formulations optimized for DC activation in vitro. We then combine the T2MRI contrast enhancing effects of iron oxide nanoparticles (IONPs) with these immunostimulatory RNA-loaded cationic nanoliposomes (RNA-NPs). The resulting iron oxide-loaded RNA-NPs (IO-RNA-NPs) deliver RNA to DCs, activate them, and allow for the prediction of tumor regression by MRI. We find that IO-RNA-NPs dramatically alter gene expression profiles in DCs, leading to increased expression of costimulatory markers, production of inflammatory cytokines (e.g., IFN-α), and enhanced migration to lymph nodes compared to electroporation. Importantly, we also demonstrate that DCs loaded with RNA encoding tumor antigens via IO-RNA-NPs inhibit tumor growth in a therapeutic model in which RNA-electroporated DCs do not provide benefit. In contrast to previous studies demonstrating qualitative MRI changes with IONP-loaded DCs 13,27~29 Here, we demonstrate that MRI-detected DC trafficking predicts long-term inhibition of tumor growth and survival in a mouse tumor model. * A significant decrease in enhanced MRI intensity strongly correlated with a reduction in tumor size 2-5 weeks after vaccination and predicted a 100% increase in median survival compared to treated mice without this change. Collectively, our findings indicate that these DC-activating IO-RNA-NPs stimulate a potent inhibition of tumor growth and allow early prediction of antitumor responses to DC vaccines with widely available imaging techniques.

[0155] Design of liposomes loaded with immunostimulatory iron oxide: We first sought to develop a simple, translatable method to deliver mRNA to DCs and track their movement with MRI. IONPs are attractive MRI contrast agents because of their proven clinical utility, but current methods to optimize IONPs for RNA delivery in preclinical settings utilize polymers (e.g., polyethyleneimine) that lack a robust safety record in humans. Cationic liposomes are attractive agents for mRNA delivery in clinical settings due to their simple, scalable synthesis and favorable safety profile in animals and humans. 30~32 Current lipid nanoparticle compositions in clinical evaluation are optimized for targeted mRNA delivery in vivo but not for DC activation. 30,32~34 Moreover, previous attempts to develop cationic liposomes for DC activation in vitro were limited to evaluating the expression of activation markers instead of functional outcomes (e.g., the ability of transfected DCs to activate antigen-specific T cells). 35 Here, we created a library of lipid nanoparticles using commercially available materials with established safety profiles in clinical trials. 7 We assessed their ability to transfect and activate bone marrow-derived DCs (BMDCs) in vitro using both basic (i.e., transfection efficiency, viability) and functional tests (Figure 29A). To do this, we developed a scoring system based on BMDC transfection, viability, expression of costimulatory markers (CD80, CD86, CD40), and the ability to stimulate antigen-specific T cells in vitro. We developed a system to transfect and activate mouse DCs using 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP) liposomes (Figures 25A-25E). We found that inclusion of cholesterol in 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP) liposomes produced particles that were most effective for transfection and activation of mouse DCs, with activation scores 18-fold higher than cholesterol-free DOTAP liposomes (Figures 25A-25E).

[0156] We then developed a method to incorporate commercially available IONPs into these DC-activated cationic liposomes to enable MRI tracking without significantly increasing the complexity of the synthesis. We reasoned that because cationic liposomes have a positively charged interior, adding negatively charged IONPs during particle formation could generate liposomes with a solid iron oxide core. Thus, we rehydrated cationic lipids with various concentrations of carboxylated IONPs (0, 1, 10, 100, or 150ug of IONPs per mg of lipid) and incubated the resulting liposomes with mRNA to generate RNA lipoplexes without IONPs (RNA-NP) or with IONPs (IO-RNA-NP). Inclusion of IONPs resulted in the formation of 100-300nm liposomes with a well-defined lipid bilayer and a solid core of IONPs by cryo-TEM (Figure 17a). Consistent with IONP encapsulation within liposomes, particle size (0ug: 207.9±67.2nm, 100ug: 208.7±92.3nm) and charge (0ug: 44.1±4.5meV, 100ug: 40.2±7.58meV) remained consistent regardless of IONP content (Figure 17b, Figure 29B). However, particles containing iron oxide exhibited substantial magnetic properties (saturation magnetization=233938A / m) (Figure 17c).

[0157] We next tested whether the inclusion of IONPs would prevent RNA binding and delivery. Under the experimental conditions, all particles bound 100% of the available RNA (15:1 lipid:RNA ratio) (Figure 17d), whereas in conditions of excess RNA, particles showed slightly higher RNA binding capacity with increasing IONP content (0ug: 0.36μg RNA / μg lipid, 100μg: 0.54μg RNA / μg lipid, p=0.0010) (Figure 17e). Importantly, the particles were not able to bind to the DCs. 36Overnight incubation with DC2.4, an immortalized human cell line, demonstrated that the inclusion of even higher amounts of IONPs did not increase toxicity (Figure 17f) or decrease RNA delivery (Figure 17g). Collectively, this evidence suggests that rehydration of cationic lipids in the presence of negatively charged IONPs produces IO-RNA-NPs with the magnetic properties of IONPs and the RNA-binding capacity of cationic liposomes.

[0158] IONPs increase DC transfection and activation: We next sought to confirm that IONPs do not inhibit transfection efficiency and DC activation. Interestingly, fluorescence images and flow cytometry revealed a dose-dependent increase in transfection efficiency of particles with increasing iron oxide content in DC2.4, an immortalized cell line of DCs (0ug: 10.6%, 150ug: 33.0%, p=0.0009; Pearson r=0.8696, p=0.054) (Figure 18a-b), and primary BMDCs (0ug: 7.0%, 100ug: 9.9%, p=0.001) (Figure 18c). However, the addition of unbound IONPs that were not previously complexed with cationic liposomes did not provide any benefit (RNA-NPs: 7.0% ± 0.96, RNA-NPs+IONPs: 5.8% ± 0.05, p=0.244) (Figure 18c). These results suggest that IONPs enhance transfection efficiency, but only when incorporated into liposomes.

[0159] We then assessed whether this increased transfection was accompanied by enhanced DC activation and function. RNA-NPs significantly increased the expression of the costimulatory molecules CD80 and CD86 beyond that obtained with the proinflammatory cytokines IL-4 and GM-CSF. While IONPs only slightly increased the expression of CD86 and co-expression of both molecules, IO-RNA-NPs further enhanced the expression of CD86 and co-expression of both molecules (Figures 26A-26C). Given this suggestion that IONPs contribute to a more activated DC phenotype, we evaluated the effect of IONPs on DC function. Bone marrow-derived dendritic cells (BMDCs) were treated with RNA-NPs or IO-RNA-NPs carrying mRNA encoding ovalbumin (OVA) and increased the expression of naive OVA-specific OT1. IO-RNA-NP DCs were incubated with BMDCs or antigen-experienced OVA T cells. While both particle constructs induced significant T cell activation as measured by IFN-γ production at 48 h, the inclusion of IONPs within the RNA-NPs significantly enhanced the activation of antigen-experienced T cells (RNA-NP DCs: 2611.8 ± 67.06 pg / mL, IO-RNA-NP DCs: 3653.5 ± 216.8 pg / mL, p = 0.0014) (Figure 18d) and the priming of naive T cells (RNA-NP DCs: 319.0 ± 41.29 pg / mL, IO-RNA-NP DCs: 874.6 ± 23.9 pg / mL, p < 0.0001) (Figure 18e) in an antigen-specific manner (Figures 26A-26C). These unexpected results indicate that the inclusion of IONPs in liposomes enhances the activation of BMDCs and the priming of antitumor T cell responses. We next evaluated whether IONP-mediated DC transfection could be further enhanced with the application of an external magnetic field. 37,38Application of a magnetic field enhanced the transfection efficiency of DCs in a manner dependent on the concentration of IONPs in the liposomes (Figure 18f), doubling the transfection efficiency at the highest tested concentration of IONPs (-magnet: 5.8 ± 0.7%, +magnet: 10.3 ± 0.9%, p = 0.0014) without compromising viability (Figure 18g-h). Importantly, under the influence of a magnetic field, a 30 min incubation with IO-RNA-NPs resulted in a two-fold increase in transfection efficiency compared to an overnight incubation with primary BMDCs (overnight: 5.5 ± 0.97%, 30 min + magnet: 10.3 ± 0.85%, p = 0.0010) (Figure 18h) and led to a comparable T cell priming capacity (overnight: 3653.5 ± 216.8 pg / mL, 30 min + magnet: 3070.4 ± 536.1 pg / mL, p = 0.16) (Figure 18i). Thus, using a magnetic field, transfection times can be significantly reduced while maintaining a high level of transfection efficiency.

[0160] IO-RNA-NPs activate DCs more effectively than electroporation. Although liposome-mediated RNA delivery results in potent DC activation in vivo, 7,30,31 Electroporation remains the preferred technique for delivering RNA to DCs ex vivo in clinical settings due to its high transfection efficiency (60–80% of BMDCs) compared with other non-viral transfection methods. 10,19~23,39,40 Indeed, electroporation transfected a higher percentage of BMDCs than IO-RNA-NP (electroporation: 81.1%, IO-RNA-NP: 17.733%, p<0.0001) (Figure 19a). However, electroporation bypasses the natural antigen processing in endosomes and phagolysosomes, thereby bypassing pattern recognition receptors that contribute to DC activation. 41~43A clear difference between these transfection methods is evident in the fluorescence microscopy of DCs after delivery of Cy3-labeled RNA (Figure 19b). RNA delivered by IO-RNA-NPs is clustered in bright intracellular compartments consistent with endosomes and phagolysosomes, whereas RNA delivered by electroporation is diluted throughout the cytosol (Figure 19b). We hypothesized that this natural antigen uptake allows IO-RNA-NPs to activate DCs more effectively than electroporation. To test this hypothesis, we evaluated the effects of electroporation and IO-RNA-NP-mediated transfection on DC activation, including gene expression, upregulation of costimulatory molecules, secretion of inflammatory cytokines, cell migration to lymph nodes, and antitumor immune responses.

[0161] We first evaluated the effect of each transfection method on gene expression. IO-RNA-NP-treated BMDCs showed significant changes in RNA expression profile after 24 h compared to untreated or electroporated (Figure 19c), including enhanced expression of gene sets related to antiviral defense, production of type I interferon, toll-like receptor (TLR) signaling, and antigen processing and presentation (Figure 27). Flow cytometry revealed that both treatments increased the expression of costimulatory molecules, but IO-RNA-NPs induced higher co-expression of these markers (Figure 19d, Figures 28A-28B). We next assessed whether this activated phenotype was accompanied by increased IFN-α secretion. We and others have previously shown that IFN-α is required to mount a systemic antitumor immune response to RNA-NPs. 30,31From our RNA-seq data, we found that IO-RNA-NP increased the production of IFN-α (IO-RNA-NP DC: 13.1 ± 3.4 pg; untreated DC: 7.6 ± 1.3 pg, p = 0.0369) (Figure 19e). In contrast, electroporation did not significantly decrease IFN-α production compared to controls (electroporated DC: 4.45 ± 1.1 pg; untreated DC 7.6 ± 1.0 pg, p = 0.2879) (Figure 19e). This result suggests that IO-RNA-NP stimulates an IFN-α-dependent antitumor immune response that is not present in electroporated cells.

[0162] We previously reported in a blinded, randomized pilot clinical trial that enhanced migration of RNA-loaded DC vaccines to the VDLN correlated with improved survival in patients with GBM. 10 Therefore, we compared the migratory capacity of DCs loaded with IO-RNA-NPs or electroporation in a mouse model of our clinical protocol, in which DCs are prepared in the condition of GM-CSF and IL-4. 10 In this experiment, each mouse received a contralateral intradermal injection of DsRed+DCs treated with RNA electroporation or IO-RNA-NPs. When assessed at different time points in three separate experiments, IO-RNA-NP-loaded DCs migrated to lymph nodes more efficiently than electroporation-treated DCs (18 h: p = 0.003, n = 3; 24 h: p = 0.0313, n = 6; and 72 h: p = 0.16, n = 2) (Figure 19f).

[0163] We then evaluated the effect of IO-RNA-NP and electroporation on the inhibition of tumor growth in established tumor models. We found that a single vaccination with DCs loaded with OVA mRNA via IO-RNA-NP 5 days after tumor inoculation significantly inhibited the growth of subcutaneous B16F10-OVA tumors (IO-RNA-NP vs. untreated: p=0.0057, IO-RNA-NP vs. electroporation: p=0.0044) (Figure 19g). In contrast, DCs treated with electroporation of OVA RNA did not provide a therapeutic effect (electroporation vs. untreated: p=0.8) (Figure 19g).

[0164] In summary, we demonstrated that IO-RNA-NPs induce potent DC activation characterized by immune-related gene signatures, expression of costimulatory molecules, secretion of inflammatory cytokines (IFN-α), and enhanced migration to lymph nodes. This DC activation is sufficient to inhibit tumor growth in therapeutic models where electroporation of RNA does not provide benefit. These results suggest that IO-RNA-NPs are a promising alternative to electroporation for DC vaccines.

[0165] Cell Tracking by MRI: We next sought to evaluate the utility of IO-RNA-NPs for DC tracking by MRI. DsRed+BMDCs were treated with IO-RNA-NPs and injected intradermally into the groin of naive mice. Two days later, MRI images revealed a visible increase in the volume of treated lymph nodes across multiple imaging parameters (Figure 20a). Flow cytometry (Figure 20b) showed a significant increase in the volume of treated lymph nodes compared to the contralateral untreated lymph nodes. We found that the relative increase in VDLN size correlated strongly with the absolute number of DsRed+ cells in treated lymph nodes (r=0.9134, p<0.0001) (Figure 20c). *Weighted MRI sequences detected a decrease in intensity in the VDLN compared to the contralateral untreated lymph node consistent with a high concentration of iron oxide (VDLN Relative Intensity). These decreases in MRI intensity were strongly correlated with the absolute cell counts in the treated lymph node (r=-0.6842, p=0.0613) (Figure 20d). This result demonstrates the ability of MRI to distinguish lymph nodes with high and low concentrations of IONP-loaded DCs.

[0166] As an early biomarker of antitumor response in conditions of minimal residual disease and established tumor models, MRI showed that IO-RNA-NP stimulated strong DC activation and resulted in consistent changes in MRI intensity in lymph nodes, so we evaluated the usefulness of DC migration detected by MRI as a biomarker for predicting antitumor immune response. We first developed a model of minimal residual disease (MRD) in which vaccination resulted in various antitumor responses. On the same day of tumor implantation, intradermal injection of DC loaded with IO-RNA-NP carrying OVA mRNA significantly inhibited the growth of subcutaneous B16F10-OVA tumors compared to untreated controls (day 19: p=0.0376, day 23: p=0.0351, day 25: p=0.0328) (Figure 21a). However, treated mice showed heterogeneous tumor growth inhibition (Figure 21b). These differences became evident at day 27, when a subset of mice had visible tumors and others were tumor-free (Figure 21b). Comparison of MRI images on day 2 showed that "responders" had significantly higher T2 * A significant decrease in the enhanced MRI intensity was found, coinciding with an increase in the concentration of iron oxide-laden DCs in the treated lymph nodes (r=0.9324, p=0.0209) (Figure 21c). The predictive value of this biomarker was confirmed in subsequent experiments, with T2 * It was demonstrated that the reduction in enhanced MRI intensity directly correlated with both tumor size at day 27 (r=0.6577, p=0.0542) (FIG. 21d) and overall survival (r=-0.6957, p=0.0374) (FIG. 21e).

[0167] We next assessed whether MRI intensity of treated lymph nodes could be used to separate treated mice into meaningful groups to predict treatment outcome. We found that mice with high DC migration, as indicated by MRI-intensity in the bottom 25th percentile, had significantly smaller tumors than mice with intensity in the top 75th percentile throughout the analysis (P=0.0131) (Figure 21f-g), as well as on individual days including days 17 (p=0.0086), 22 (p=0.0256), and 26 (p=0.0118) (Figure 21h). These results provide strong evidence that DC migration detected by MRI 2 days after treatment is an early dynamic biomarker of antitumor immune responses.

[0168] After establishing its utility in MRD models, we investigated the predictive ability of MRI-detected DC migration in the context of established tumors. In this experiment, all mice had palpable subcutaneous tumors before treatment with DCs loaded with IO-RNA-NPs (Figure 22a). Here, a much faster tumor growth was observed, but heterogeneous efficacy was still recorded in the cohorts responding to DC vaccination (Figure 22b). Correlation of MRI taken 2 days after vaccination with tumor growth curves again revealed that an early decrease in intensity in treated lymph nodes strongly correlated with a future inhibition of tumor growth (tumor size at day 14: r=0.7235, p=0.0276; tumor size at day 17: r=0.7323, p=0.0248) (Figure 22c, Figure 22d). T2 * Mice with high-intensity enhanced MRI had substantial tumors, whereas mice with low-intensity were tumor-free. This evidence suggests that MRI imaging just 2 days after vaccination is sensitive enough to predict the subsequent antitumor immune response to DC vaccines.

[0169] We then continued to observe these animals to determine whether MRI-detected DC migration would predict survival, a more clinically relevant outcome. Notably, MRI intensity on day 2 in treated lymph nodes correlated strongly with long-term inhibition of tumor growth (median 50% vs. bottom 25th percentile: p=0.0023, top 75th vs. bottom 25th percentile: p=0.0001) and survival (r=-0.8557, p=0.0033) (Figures 22e, 22f). Mice with significant DC migration to lymph nodes as revealed by relative MRI intensity below the 25th percentile on day 2 survived significantly longer than mice with moderate DC migration as revealed by MRI intensity in the median 50th percentile (p=0.0338, log-rank analysis) and survived twice as long as mice lacking DC migration as revealed by relative MRI intensity in the top 75th percentile (p=0.0896, log-rank analysis) (top 25th percentile: 25±7.0 days, median 50%: 34±2.049 days, bottom 25th percentile: 52.5±3.5 days) (Figure 22g). These results indicate that MRI imaging of DC tracking can be used as a highly correlated biomarker to identify long-term antitumor responses to IO-RNA-NP-loaded DC vaccines as early as 2 days after vaccination.

[0170] Example 16 This example demonstrates the materials and methods used in Example 15.

[0171] Particle characterization: Size: IO-RNA-NPs were diluted 2000-fold in cold PBS and measured with a NanoSight NS300 (Malvern). Particle size was calculated from over 1400 frames using 5 acquisitions per sample, 60 seconds per acquisition. Data was processed using NTA3.3 Dev Build 3.3.104 (camera type: sCMOS). Selected plots and data represent 4 independent batches of each particle construct. Charge: Zeta potential was assessed with a Nicomp ZLSZ3000. Measurements reported are the average of 5 cycles for each particle representing 3 independent batches. Magnetism: Magnetic measurements were performed using a Quantum Design MPMS-3 superconducting quantum interference device (SQUID) magnetometer. Particles were prepared and analyzed in PBS at 2.5 mg / mL. Magnetization curves were obtained by applying a magnetic field of 10 Oe (0.8 kA / m) at various temperatures from 4 K to 345 K. RNA binding: Liposomes were loaded with RNA at liposome:RNA ratios of 15:1, 10:1, 5:1, 1:1, or 0:1 and incubated for 15 min to allow liposome formation, followed by staining with RNA loading buffer. 20 uL of IO-RNA-NPs were then loaded into each well of a 1% agarose gel and electrophoresed at 80 V for 20 min. Free RNA was assessed using a ChemiDoc imaging system (Bio-Rad) and Image Lab software (Bio-Rad). The relative RNA binding capacity of each particle was calculated as follows: RNA bound (%) * Total RNA (ug), where "bound RNA" is 1-(sample バンド強度 / RNA only バンド強度) was calculated. Cryo-electron microscopy: Sample preparation for cryo-transmission electron microscopy (cryo-TEM) was performed at the Electron Microscopy Core of the Interdisciplinary Center for Biotechnology Research at the University of Florida. Three microliter aliquots of suspended liposomes were applied to C-flat holey carbon grids (Protochips Inc.) and vitrified using a Vitrobot™ Mark IV (FEI Co.) operating at 4°C with approximately 90% humidity in a control chamber. The vitrified samples were stored under liquid nitrogen and transferred to a Gatan cryoholder (model 626 / 70) for imaging. The samples were examined with a Tecnai (FEI Co.) G2F20-TWIN transmission electron microscope operating at a voltage of 200 kV using low-dose conditions (approximately 20e / Å2) and a 4kx4k CCD camera (Gatan Inc.).

[0172] Preparation of RNA and labeling of green fluorescent protein (GFP) and OVA RNA was performed as previously described. Generated 31 The isolated RNA was labeled with Cy3 and Cy5 dyes using a commercially available Arcturus Turbo Labeling kit (ThermoFisher Scientific) according to the manufacturer's instructions.

[0173] Cell culture DC2.4 is an immortalized dendritic cell line, kindly provided by John Sampson of Duke University. 36 B16F10-OVA is a mouse melanoma cell line expressing the chicken ovalbumin gene (OVA) and was a kind gift from Dr. Richard G. Vile at Mayo Clinic. Both cell types were cultured at 37°C and 5% CO2 in high glucose DMEM with pyruvate supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1% penicillin / streptomycin (LifeTechnologies).

[0174] Synthesis of IO-RNA-NPs Liposome synthesis: Liposomes were prepared as previously described. 31 Briefly, cationic liposomal DOTAP was obtained in dehydrated form from Avanti, Polar Lipids Inc. (Alabaster, AL, USA). 25–100 mg of dehydrated liposomes were mixed with cholesterol 700000P (Avanti Polar Lipids) in a 3:1 ratio of DOTAP:cholesterol in chloroform. The chloroform was evaporated in a nitrogen gas chamber to obtain a thin layer of lipid. The lipid was then rehydrated to 2.5 mg / mL in PBS. In the case of IO-RNA-NPs, the lipid cake was instead rehydrated with a high-density solution of carboxylated IONPs (NanoMag) at 10 mg / mL, followed by 2.5 mg lipid / mL in DPBS. The rehydrated liposomes were then placed in a 50°C water bath and vortexed every 10 min for 1 h. The liposomes were then stored overnight at room temperature before being vortexed, placed in a bath sonicator for 5 min, and filtered through a 0.45 μm syringe filter (Whatman Puradisc) and then a 0.20 μm syringe filter (PALL Acrodisc syringe filter with Supor membrane). Formation of IO-RNA-NP complexes: IO-RNA-NPs were prepared as previously described for RNA-NPs. 31 10 μg of mRNA was added to 150 μg of IO-RNA-NPs (per 2 million cells) in PBS buffer. The mixture was incubated at room temperature for 15 minutes to ensure complex formation and then added to DCs.

[0175] IO-RNA-NP transfection of DCs Overnight transfection: IO-RNA-NP was added to DCs in culture at 160ug IO-RNA-NP:2,000,000 DCs. 30 minute transfection: DCs were pulled down to the bottom of a 24-well plate by centrifugation at 100rcf for 1 minute before adding IO-RNA-NP. The particles were made of neodymium iron boron (NdFe 14B) They were left in the medium for 30 min in the presence or absence of a magnetic field generated by a permanent magnetic disk. After 30 min, the plates were centrifuged again at 100 rcf for 1 min, after which the IO-RNA-NPs were removed and replaced with fresh medium.

[0176] Mice C57Bl / 6, OT1 transgenic (C57Bl / 6-Tg(TcraTcrb)1100Mjb / J) and DsRed (B6.Cg-Tg(CAG-DsRed * MST)1Nagy / J) mice were purchased from Jackson Laboratories. Animal procedures were approved by the University of Florida Animal Care and Use Committee (UFIACUC201607966).

[0177] Generation of dendritic cells DCs were isolated from mouse bone marrow based on previously established methods. 50 Briefly, tibias and femurs were harvested from C57Bl / 6 or DsRed mice, and the bone marrow was flushed out using a 25-gauge syringe with serum-containing medium. After lysing red blood cells with 10 mL of Pharmlyse (BD Bioscience), mononuclear cells were isolated from the entire The cells were then suspended in DC medium (RPMI-1640, 5% FBS, 1 M HEPES [LifeTechnologies], 55 mM b-mercaptoethanol [LifeTechnologies], 100 mM sodium pyruvate [LifeTechnologies], 10 mM non-essential amino acids [LifeTechnologies], 200 mM L-glutamine [LifeTechnologies], 10 mg GM-CSF [R&D Systems], 10 mg IL4 [R&D Systems], 1% penicillin / streptomycin [LifeTechnologies]). The cells were then plated at 8 × 10 ng / well in a total volume of 3 mL / well. 5 The cells were cultured in 6-well plates at a concentration of 10 cells / mL. Non-adherent cells were discarded and the medium was changed on day 3. On day 7, non-adherent cells were harvested and cultured in 10 6The cells were replated in 100 mm culture dishes at a density of 100 cells / mL. After 24 h, nonadherent cells were collected and transfected with mRNA via electroporation, RNA only, RNA-NP, or IO-RNA-NP, and left overnight.

[0178] Generation of T cells. Naive OVA-specific T cells: T cells specific for OVA peptide epitope 257-264 were generated from the spleens of OT1 transgenic mice (C57Bl / 6-Tg(TcraTcrb)1100Mjb / J). OT1 splenocytes were isolated by lysis of RBCs and suspended in PBS for immediate use in coculture or treatment. Antigen-experienced T cells: Antigen-experienced T cells were prepared as previously described. 4 Briefly, C57Bl6 mice were vaccinated intradermally with OVA-pulsed DCs. One week after vaccination, splenocytes from these mice were isolated and cultured with OVA-pulsed BMDCs at a splenocyte:DC ratio of 4,000,000:400,000 in T cell medium containing IL-2 for 5 days. Activated T cells were allowed to reach confluence and then split into new wells.

[0179] Co-culture assay DCs were transfected with OVA or GFP mRNA via electroporation, co-culture (RNA-only), RNA-NP, or IO-RNA-NP. After 24 h, treated DCs were co-cultured with naive OT1 splenocytes or antigen-experienced OVA T cells at a T cell:DC ratio of 400,000:40,000 in 96-well plates. Supernatants were collected after 48 h and interferon-γ (ebioscience) was assessed by ELISA.

[0180] Flow cytometry analysis: Flow cytometry was performed using a FACS Canto-II from BD Biosciences, using antibodies from BD Biosciences, Biolegend, and Invitrogen. For in vitro experiments, DCs were harvested, washed with PBS, and stained for 20 min. Samples were then washed twice with PBS and suspended in FACS buffer. Cell counts and viability were assessed with a Vi-Cell XR Cell Viability Analyzer (Beckman Coulter). For in vivo experiments, lymph nodes were harvested in cold PBS, diced with a razor blade, digested with papain for 20 min at 37°C, then filtered through a 70 μm cell strainer, washed with PBS, and stained with the appropriate antibodies for 20 min. Counting beads were added to each tube immediately before flow analysis.

[0181] MRI imaging and analysis Image acquisition: MRI imaging was performed 18-72 h after intradermal injection of IO-RNA-NP-loaded DCs in the groin at the UFAMRIS facility in an 11T MRI magnet (Magnex Scientific, 11.1T / 40 cm bore) equipped with a Bruker AV3HD console and Paravision6.01 software, using a custom-built 30 mm ID orthogonal birdcage transmit-receive volume coil. Mice were imaged under isoflurane anesthesia and monitored via continuous measurements of body temperature and respiration, according to UFIACUC201607966. To maintain body temperature, temperature Circulating hot water from a controlled hot water heater was used. Six slice 2D MRI sequences were acquired using respiratory gating for various imaging parameters with an image size of 192x192, a field of view of 25.08mmx25.921mm, and a slice thickness of 1.0mm. * Weighted images were acquired using the following parameters to evaluate IONP-dependent changes in lymph node hypointensity: repetition time (TR) = 90 ms, echo time (TE) = 5 ms, flip angle = 10° (with fat saturation). A series of five other imaging sequences were acquired to evaluate lymph node size. Sequence 1 (T2 *): TR = 90 ms, TE = 3 ms, flip angle = 10°. Sequence 2 (T2 * Sequence 1 (T2_407 / 17): TR = 407.204 ms, TE = 17 ms, echo interval = 4.25, RARE factor = 4, with fat saturation. Sequence 2 (T2_407 / 17): TR = 407.204 ms, TE = 17 ms, echo interval = 4.25, RARE factor = 4, with fat saturation. Sequence 3 (T2, fat saturation): TR = 500 ms, TE = 14 ms, echo interval = 7 ms, RARE factor = 4. Sequence 4 (T2, fat saturation): TR = 500 ms, TE = 14 ms, echo interval = 7 ms, RARE factor = 4. Sequence 5 (T2): TR = 3000 ms, TE = 28 ms, echo interval = 3 ms, RARE factor = 8, with fat saturation.

[0182] Image analysis: Image analysis was completed using ImageJ (NIH). An investigator blinded to treatment groups manually created regions of interest around each lymph node for each slice in which the node appeared. MRI intensity of each lymph node was measured using a T2 * Lymph node volume was calculated as the average of lymph node intensity across all slices in which lymph nodes appeared on the weighted MRI sequence. Lymph node volume was calculated as the product of slice thickness (1 mm) and the total area of ​​each lymph node in each slice (e.g., V = slice thickness). * (area スライス1 +Area スライス2 +Area スライス3 …+area スライスn Relative size was calculated for each imaging sequence by dividing the volume of the treated lymph node by the volume of the contralateral untreated lymph node. Relative volume was calculated for all six imaging sequences and reported as the average relative volume across the imaging sequences. Relative intensity was calculated for T2 * For the weighted MRI images, the MRI intensity was calculated by dividing the MRI intensity of the treated lymph nodes by the MRI intensity of the untreated lymph nodes.

[0183] Therapeutic Model Tumor Implantation: B16F10-OVA cells were harvested using 0.05% trypsin (Gibco), washed once with serum-containing medium and once with Dulbecco's phosphate-buffered saline (DPBS). The cell pellet was cultured at 10 7The cells were resuspended in DPBS at a concentration of 100,000,000 cells / mL. 1,000,000 B16F10-OVA cells were injected subcutaneously with a 25-gauge syringe into the left flank of C57Bl / 6 mice anesthetized with isoflurane. Subcutaneous tumors were measured every 2-4 days using a WESTWARD Digital Caliper. Animals with subcutaneous tumors that reached a humane endpoint were euthanized. Adoptive cell therapy: Naïve or antigen-experienced T cells were generated as above, suspended in PBS at 100,000,000 / mL, and injected into cancer-bearing mice at 100uL per mouse. DC vaccine: RNA-pulsed DCs prepared as above were collected and injected at 1x10 7 The cells were suspended in PBS at a final concentration of cells / mL. 50 μL was administered intradermally in the groin of each treated mouse.

[0184] Immunofluorescence DC2.4 were imaged in PBS 24 hours after incubation with Cy3-labeled mRNA. Images were captured on an Olympus IX70 inverted fluorescence microscope.

[0185] Gene Expression Analysis BMDCs were harvested from three independent samples per treatment group 24 h after transfection with GFP mRNA via electroporation, RNA-NP, or IO-RNA-NP at 10 μg of mRNA per 2,000,000 cells. RNA was then isolated from each sample using a commercially available RNeasy mini kit (Quiagen, Cat. No. 74104) according to the manufacturer's instructions and analyzed for purity using a NanoDrop 2000 spectrophotometer (ThermoFisher Scientific) and an Agilent 2100BioAnalyzer. RNA is a part of the Interdisciplinary Center for An Illumina RNA sequencing library (polyA) from the Institute for Biotechnology Research (ICBR) was used to prepare for directional sequencing. 100 cycles of paired-end RNA sequencing were completed in two lanes using an Illumina HiSeq3000. Gene set enrichment was assessed using Gene Set Enrichment Analysis (GSEA) software available from the Broad Institute (genepattern.broadinstitute.org). Nine gene sets were selected from the C7 Immunologic Signatures gene set collection based on the hypothesis that endosomal RNA uptake initiates a toll-like receptor-dependent DC activation phenotype.

[0186] Statistical analysis Data are summarized as mean ± standard deviation for in vitro experiments and mean ± standard error for tumor growth experiments. Unpaired data were analyzed with two-tailed unpaired Student's t-test or analysis of variance with Tukey's test for multiple comparisons. Paired data were analyzed with Wilcoxon matched-pairs rank sum test for experiments with n>3 and two-tailed paired Student's t-test when n≦3. Tumor growth over time was measured with two-way analysis of variance. Survival was measured with the log-rank test. Statistical analysis was performed using GraphPadPrism version 6. Statistical significance was defined as p<0.05. Linear correlation was assessed with Pearson's correlation coefficient.

[0187] REFERENCES: The following references are cited throughout Examples 15 and 16: (1)Rosenberg, SA, et al., Clin Cancer Res 17,4550-4557(2011);(2)Schadendorf,D.,et al.,J Clin Oncol 33,1889-1894(2015);(3)van der Burg,et al.,Rev Cancer 16,219-233(2016);(4)Garon et al. al.,N Engl J Med 372,2018-2028(2015);(5)Larkin,J.,et al.,N Engl J Med 373,23-34(2015);(6)Hellmann,MD,et al.,Lancet Oncol 18,31-41(2017);(7)Grippin et al.,Translational Nanoparticle Engineering for Cancer Vaccines.OncoImmunology,00-00(2017).(8)Nishino et al.,Nat Rev Clin Oncol 14,655-668(2017);(9)Lesterhuis,WJ,et al.,Nat Rev Drug Discov 16,264-272(2017);(10)Mitchell,DA,et al.,Nature 519,366-369(2015);(11)Srinivas,M.,et al.,Adv.Drug Deliv.Rev.62,1080-1093(2010);(12)de Vries,IJ,et al.,Nat Biotechnol 23,1407-1413(2005);(13)Verdijk,P.,et al.,Int J Cancer 120,978-984(2007);(14)Noh et al.,Biomaterials 32,6254-6263(2011);(15)Cho et al.,Nat Nanotechnol 6,675-682(2011);(16)Mou et al.,Int J Nanomedicine 6,2633-2640(2011);(17)de Chickera, S., et al.,Int Immunol 24,29-41(2012);(18)Zhang,Z.,et al.,Radiology 274,192-200(2015);(19)Batich,KA,et al.,Clin Cancer Res 23,1898-1909(2017);(20),Bloodle et al.,S. 130,1713-1721(2017);(21)Wilg. enhof,S.,et al.,J Clin Oncol 34,1330-1338(2016);(22)Bol,KF,et al.,Oncoimmunology 4,e1019197(2015);(23)Aarntzen,EH,et al.,Clin Cancer Res 18,5460-5470(2012);(24)Phua,KKL,et al.,Nanoscale 6,7715-7729(2014);(25)Anselmo,AC& Mitragotri,S.Nanoparticles in the clinic.Bioeng Med Transl Transl. 1,10-29(2016);(26)Shi,J.,et al.,Nat Rev Cancer 17,20-37(2017);(27)de Vries,IJM,et al,Nat Biotech 23,1407-1413(2005);(28)Ahrens,JET & Molte Immunol Rev. 13,755-763(2013);(29)Bulte,JWMAmerican Journal of Roentgenology 193,314-325(2009);(30)Kranz,LM,et al.,Nature 534,396-401(2016);(31)Sayour,EJ. al.OncoImmunology,00-00(2016);(32)Sayour,EJ,et al.Nano Lett(2018);(33)Kauffman,KJ,et al.Nano Lett 15,7300-7306(2015);(34)Sayour,EJ,et al.Oncoimmunology. 6,e1256527(2017);(35)Soema,PC,Willems,GJ,Jiskoot,W.,Amorij,JP& Kersten,GFEur J Pharm Biopharm 94,427-435(2015);(36)Shen,Z.,Reznikoff,G.D., Immunol,J.L.G. 158,2723-2730(1997).(37)Scherer,F.,et al.Gene Ther 9,102-109(2002).(38)Mah,C.,et al.Mol Ther 6,106-112(2002).(39)Gilboa,E.&Viehol,J.Imun. 199,251-263(2004);(40)Van Tendeloo,VF,et al.Blood 98,49-56(2001);(41)Blasius,AL& Beutler,B.Immunity 32,305-315(2010);(42)Crozat, K. & Beutler, A.B.C. 101,6835-6836(2004);(43)de Lima,MC,et al.Mol.Membr.Biol.16,103-109(1999);(44)Lim,YT,et al.Small 4,1640-1645(2008);(45)Jin,Hranos,et al. 6,2000-2014(2016);(46)Mackay,PS,et al.Nanomedicine 7,489-496(2011);(47)Wang,Z.,et al.Immunity 49,80-92 e87(2018);(48)Zanganeh,S.,Nat. 11,986-994(2016);(49)Ragelle,H.,Danhier,F.,Preat,V.,Langer,R.& Anderson,DGExpert Opin Drug Deliv 14,851-864(2017);(50)Flores,C.,et al.OncoImmunology 4,e994374(2015).

[0188] All references cited in this specification, including publications, patent applications, and patents, are hereby incorporated by reference to the same extent as if each reference was individually and specifically indicated to be incorporated by reference and was set forth in its entirety herein.

[0189] As used in the context of describing this disclosure (particularly in the context of the claims that follow), The terms "a," "an," and "the" and similar referents are to be construed to encompass both the singular and the plural, unless otherwise stated herein or clearly contradicted by context. The terms "comprising," "having," "including," and "containing" are to be construed as open-ended terminology (i.e., meaning "including, but not limited to"), unless otherwise noted.

[0190] Unless otherwise stated herein, recitation of ranges of values ​​herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, and each endpoint, and each separate value and each endpoint is incorporated herein as if it were individually set forth herein.

[0191] All methods described herein can be performed in any suitable order unless otherwise specified herein or clearly contradicted by context. Unless otherwise required, any examples provided herein, or the use of exemplary language (e.g., "etc.") are intended merely to better explain the disclosure and do not pose limitations on the scope of the disclosure. No language in this specification should be construed as indicating any non-claimed element essential to the practice of the disclosure.

[0192] Preferred embodiments of the present disclosure are described herein, including the best mode known to the inventors for carrying out the present disclosure. Variations of these preferred embodiments may become apparent to those skilled in the art upon reading the foregoing description. The inventors expect those skilled in the art to use such variations as appropriate, and the inventors intend the present disclosure to be carried out in ways other than those specifically described herein. Accordingly, the present disclosure includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, the present disclosure encompasses any combination of the above-described elements in all possible variations thereof, unless otherwise indicated herein or clearly contradicted by context.

Claims

1. A liposome comprising a ribonucleic acid (RNA) molecule, a lipid mixture comprising DOTAP and cholesterol, and iron oxide nanoparticles (IONPs).

2. The liposome of claim 1, wherein each IONP in the core has a diameter of about 10 nm to about 200 nm.

3. The liposome of claim 2, wherein each IONP has a diameter of about 60 nm to about 140 nm.

4. The liposome of any one of claims 1 to 3, wherein the mass of the IONP is from about 1% to about 30% of the total liposome mass.

5. 5. The liposome of claim 4, wherein the mass of the IONP is from about 5% to about 25% of the total liposome mass, optionally from about 10% to about 15% of the total liposome mass.

6. The liposome of claim 5 , wherein the mass of the IONP is about 12%±3% of the total liposome mass.

7. 7. The liposome of claim 1, wherein the DOTAP and cholesterol are present in the lipid mixture in a mass ratio of about 3:1 DOTAP:cholesterol.

8. The liposome of any one of claims 1 to 7, wherein the IONP is present in the core of the liposome.

9. The liposome of any one of claims 1 to 8, wherein the IONPs are dispersed throughout the liposome.

10. A liposome comprising a ribonucleic acid (RNA) molecule and a lipid mixture comprising DOTAP and cholesterol, wherein the DOTAP and cholesterol are present in the lipid mixture in a DOTAP:cholesterol mass ratio of about 3:

1.

11. The liposome of any one of claims 1 to 10, having a diameter of about 80 nm to about 500 nm, optionally about 90 nm to about 300 nm.

12. 12. The liposome of any one of claims 1 to 11, having an overall surface net charge of from about 20 mV to about 50 mV, optionally having an overall surface net charge of from about 40 mV to about 50 mV.

13. 13. The liposome of claim 1, wherein the cholesterol is greater than 12% and less than 37% of the total lipid mass of the lipid mixture.

14. 14. The liposome of claim 13, wherein the cholesterol is from about 15% to about 35% of the total lipid mass of the lipid mixture, optionally from about 20% to about 30% of the total lipid mass of the lipid mixture.

15. 15. The liposome of claim 14, wherein the cholesterol is about 25%±3% of the total lipid mass of the lipid mixture.

16. 16. The liposome of any one of claims 1 to 15, wherein the DOTAP is at least 50% of the total lipid mass of the lipid mixture, optionally from about 63% to about 88% of the total lipid mass of the lipid mixture.

17. 17. The liposome of claim 16, wherein the DOTAP is about 75%±5% of the total lipid mass of the lipid mixture.

18. 18. The liposome of any one of claims 1 to 17, wherein when the lipid mixture comprises a third lipid other than DOTAP and cholesterol, the third lipid is less than about 10%, or less than about 5% of the total lipid mass of the lipid mixture.

19. The liposome of any one of claims 1 to 18, wherein the lipid mixture consists essentially of DOTAP and cholesterol.

20. 20. The liposome of any one of claims 1 to 19, comprising less than or about 10 μg of RNA molecules per 150 μg of liposomes.

21. The liposome of any one of claims 1 to 20, wherein the RNA molecule encodes a protein or is an antisense molecule.

22. 22. The liposome of claim 21, wherein the protein is selected from the group consisting of a tumor antigen, a cytokine, or a costimulatory molecule.

23. 22. The liposome of claim 21, wherein the RNA molecule is an antisense molecule, and the antisense molecule is an siRNA, shRNA, miRNA, or any combination thereof.

24. The liposome according to any one of claims 1 to 23, comprising a mixture of RNA molecules.

25. 25. The liposome of claim 24, wherein the mixture of RNA molecules is RNA isolated from cells of human origin.

26. 26. The liposome of claim 25, wherein the human has a tumor and the mixture of RNA is RNA isolated from the tumor of the human, optionally the tumor is a malignant brain tumor, optionally a glioblastoma, medulloblastoma, diffuse intrinsic pontine glioma, or a peripheral tumor with metastatic infiltration into the central nervous system.

27. The liposome of any one of claims 10 to 26, further comprising an IONP.

28. 28. The liposome of claim 27, wherein each IONP in the core has a diameter of about 10 nm to about 200 nm, optionally about 60 nm to about 140 nm.

29. 29. The liposome of claim 27 or 28, wherein the mass of the IONP is from about 1% to about 30% of the total liposome mass, optionally from about 5% to about 25% of the total liposome mass, optionally from about 10% to about 15% of the total liposome mass.

30. 30. The liposome of claim 29, wherein the mass of the IONP is about 12%±3% of the total liposome mass.

31. 31. Any one of claims 27 to 30, wherein the IONP is present in the core of the liposome. The liposome according to item 1.

32. The liposome of any one of claims 27 to 30, wherein the IONPs are dispersed throughout the liposome.

33. 1. A method for making liposomes, comprising: (A) mixing DOTAP and cholesterol in a DOTAP:cholesterol mass ratio of about 3:1 to form a lipid mixture; (B) drying the lipid mixture; (C) rehydrating the lipid mixture with a rehydration solution to form a rehydrated lipid mixture; and (D) incubating the rehydrated lipid mixture at a temperature above about 40° C. and intermittently vortexing the rehydrated lipid mixture to form liposomes.

34. 34. The method of claim 33, further comprising incubating the liposomes for more than 12 hours after step (D), optionally further comprising incubating the liposomes at about 20° C. to about 30° C. or about 2° C. to about 6° C. for more than 12 hours.

35. 35. The method of claim 33 or 34, further comprising: (i) sonicating the liposomes and / or filtering the liposomes through a filter of at least 150 nm, optionally wherein the liposomes are filtered through a 200 nm filter and / or a 450 nm filter; and (ii) incubating the liposomes with an RNA molecule.

36. 36. The method of claim 35, wherein the liposomes are filtered through a 450 nm filter and a 200 nm filter, optionally wherein the liposomes are sequentially filtered through a 450 nm filter followed by a 200 nm filter.

37. 37. The method of any one of claims 33-36, comprising: (i) mixing about 7.5 mg±0.75 mg of DOTAP and about 2.5 mg±0.25 mg of cholesterol to form the lipid mixture; (ii) dissolving DOTAP and cholesterol in chloroform to form the lipid mixture; (iii) drying the lipid mixture using nitrogen gas; (iv) the rehydration solution is a buffer, optionally phosphate buffered saline (PBS); (v) incubating the rehydrated lipid mixture in a water bath at a temperature of about 50° C. and vortexing about every 10 minutes to form liposomes; (vi) or a combination thereof.

38. 38. The method of any one of claims 33 to 37, wherein the lipid mixture or the rehydration solution further comprises iron oxide nanoparticles (IONPs), or the method further comprises adding IONPs to the lipid mixture or the rehydration solution, optionally each IONP having a diameter of about 10 nm to about 200 nm, optionally about 60 nm to about 140 nm or about 10 nm to about 30 nm.

39. The method of claim 38, wherein the lipid mixture or rehydration solution comprises at least about 1 μg IONP per 10 mg lipid mixture, at least about 100 μg IONP per 10 mg lipid mixture, at least about 1 mg IONP per 10 mg lipid mixture, or at least about 1.5 mg IONP per 10 mg lipid mixture, optionally wherein the lipid mixture or rehydration solution comprises no more than about 5 mg IONP per 10 mg lipid mixture.

40. incubating the liposomes with RNA molecules, optionally (i) incubating about 5 μg of RNA molecules for every about 75 μg of lipid of the liposomes; 40. The method of any one of claims 33-39, wherein (ii) the method comprises incubating the liposomes with RNA molecules at a mass ratio of about 1:15 RNA molecules:DOTAP, (iii) when the liposomes comprise IONPs, about 10 μg of RNA molecules are incubated for every about 150 μg of liposomes, or (iv) a combination thereof.

41. A liposome produced by the method according to any one of claims 33 to 40.

42. A cell comprising a liposome according to any one of claims 1 to 32 and 41.

43. 43. The cell of claim 42, which is an antigen presenting cell (APC), optionally a dendritic cell (DC).

44. 44. A population of cells, wherein at least 50% of the population are cells according to any one of claims 42 or 43.

45. A composition comprising a liposome according to any one of claims 1 to 32 and 41, a cell according to claim 42 or 43, a population of cells according to claim 44, or any combination thereof, and a pharma- ceutically acceptable carrier, excipient or diluent.

46. 46. ​​The composition of claim 45, comprising a plurality of liposomes, at least 50% of said liposomes having a diameter of about 100 nm to about 250 nm.

47. A method for delivering an RNA molecule to a cell, comprising incubating the cell with a liposome according to any one of claims 1 to 32 and 41.

48. 48. The method of claim 47, wherein the cell is an antigen presenting cell (APC), optionally a dendritic cell (DC).

49. 49. The method of claim 47 or 48, wherein the liposome comprises an IONP.

50. 50. The method of claim 49, wherein the cells are incubated with the liposomes in the presence of a magnetic field, optionally a static or oscillating magnetic field.

51. 51. The method of claim 50, wherein the cells are incubated with the liposomes in the presence of a magnetic field for a time period of less than about 2 hours or less than about 1 hour, optionally wherein the cells are incubated with the liposomes in the presence of a magnetic field for about 30 minutes ± 10 minutes.

52. A method of treating a subject having a disease, comprising delivering an RNA molecule to cells of said subject by a method according to any one of claims 47 to 51.

53. 53. The method of claim 52, wherein an RNA molecule is delivered to the cells ex vivo and the cells are administered to the subject.

54. 47. A method of treating a subject having a disease, comprising administering to the subject a composition according to claim 45 or 46 in an amount effective to treat the disease in the subject.

55. 55. The method of claim 54, wherein the disease is cancer, and optionally, the cancer is located across the blood-brain barrier.

56. 56. The method of claim 54 or 55, wherein the subject has a tumor located in the brain.

57. 58. The method of claim 57, wherein the tumor is a low-grade glioma or a high-grade glioma, e.g., a grade III astrocytoma or glioblastoma, a medulloblastoma or a diffuse intrinsic pontine glioma.

58. 77. The method of any one of claims 54 to 76, wherein the composition comprises a liposome.

59. 59. The method of claim 58, wherein the composition is administered to the subject intravenously.

60. 60. The method of any one of claims 54 to 59, wherein the composition comprises a cell containing the liposome.

61. 61. The method of claim 60, wherein the composition comprising the cells containing the liposomes is administered intradermally to the subject, optionally, the composition is administered intradermally to the groin of the subject.

62. 62. The method of claim 60 or 61, wherein the cell is an APC, optionally a dendritic cell (DC).

63. 63. The method of claim 62, wherein the DCs are isolated from WBCs obtained from the subject.

64. 64. The method of any one of claims 47 to 63, wherein the RNA molecule of the liposome encodes a tumor antigen and / or is isolated from a tumor cell, optionally the tumor cell being a cell of a tumor of the subject.

65. 87. The method of any one of claims 47-86, wherein the liposome comprises an IONP, and the method further comprises tracking the migration of the cells containing the liposome within the subject.

66. 66. The method of claim 65, wherein the tracking comprises magnetic resonance imaging (MRI), and optionally the tracking comprises performing an MRI on one or more lymph nodes of the subject, optionally the inguinal lymph nodes, and optionally an MRI is performed on the lymph nodes before and after administration of the composition or cells.

67. T2 of the lymph nodes containing DCs transfected with liposomes containing IONPs * Weighted MRI intensity was compared with the T2 * 67. The method of claim 66, comprising comparing with weighted MRI intensity.

68. 68. The method of claim 66 or 67, comprising measuring lymph node size of the subject via MRI, and optionally comparing the lymph node size of the lymph nodes containing DCs transfected with liposomes comprising IONPs, wherein the lymph nodes are compared to lymph node size of untreated lymph nodes of the control.

69. 11. A method of tracking migration of dendritic cells (DCs) to lymph nodes in a subject, comprising: (i) treating the subject according to the method of any one of claims 52 to 68, wherein the cells are DCs and the liposomes comprise IONPs; and (ii) performing magnetic resonance imaging (MRI) of one or more lymph nodes of the subject.

70. One or more lymph nodes * Determining the enhanced MRI intensity of the control untreated Lymph node T2 * Compared with the weighted MRI intensity, T2 * 70. The method of claim 69, wherein lymph nodes showing a decrease in weighted MRI intensity represent lymph nodes into which DCs have migrated.

71. 71. The method of claim 69 or 70, wherein one or more lymph nodes are the inguinal lymph nodes of the subject, and optionally, the composition is administered intradermally to the groin of the subject.

72. 72. The method of any one of claims 69-71, wherein an MRI is performed on the lymph nodes before and after administration of the composition or cells, optionally before administration and about 48 hours after administration, and optionally about 72 hours after administration.

73. The T2 lymph nodes containing DCs transfected with liposomes containing IONPs. * Weighted MRI intensity was compared with the T2 * A method according to any one of claims 69 to 72, comprising comparing with weighted MRI intensity.

74. 74. The method of any one of claims 69 to 73, comprising measuring lymph node size of the subject via MRI, and optionally comparing the lymph node size of the lymph nodes containing DCs transfected with liposomes comprising IONPs to the lymph node size of the control untreated lymph nodes.

75. A method for determining a therapeutic response of a subject to a dendritic cell (DC) vaccination therapy in a subject, comprising: (i) treating the subject according to the method of any one of claims 52 to 68, wherein the cells are DCs and the liposomes comprise IONPs; and (ii) tracking DC migration to lymph nodes according to any one of claims 69 to 74, wherein T2 * If the enhanced MRI intensity decreases, it is determined that the DC vaccination therapy results in a positive therapeutic response in the subject.

76. 76. The method of claim 75, wherein the positive therapeutic response comprises an increase in the subject's progression-free and overall survival for at least 4 weeks following administration of therapy.

77. 77. The method of claim 76, wherein said positive therapeutic response comprises an increase in the subject's progression-free and overall survival for at least 8-12 weeks following administration of therapy.

78. A method for monitoring a therapeutic response to a dendritic cell (DC) vaccination therapy in a subject, comprising tracking DC migration to lymph nodes according to any one of claims 69 to 74 at a first and a second time point, and measuring the T2 * The enhanced MRI intensity of the treated lymph node at the first time point is * If the compared to weighted MRI intensity is decreased, then said therapeutic response to DC vaccination therapy is effective.

79. 47. A method of delivering RNA to cells in a tumor, optionally in the microenvironment of a brain tumor, comprising intravenously administering a composition according to claim 45 or 46, said composition comprising said liposome.

80. 80. The method of claim 79, wherein the liposome comprises an siRNA targeting a protein of an immune checkpoint pathway, optionally, PDL1.

81. 81. The method of claim 79 or 80, wherein the cells in the microenvironment are antigen-presenting cells (APCs), optionally tumor-associated macrophages.

82. A method for activating antigen-presenting cells in the microenvironment of a brain tumor, comprising intravenously administering a composition described in claim 45 or 46, wherein the composition comprises the liposome.

83. A method for increasing dendritic cell (DC) migration to a lymph node in a subject, comprising administering to the subject a composition described in claim 45 or 46 in an amount effective to increase DC migration to the lymph node.

84. 47. A method of enhancing an immune response to a tumor or cancer in a subject, comprising administering to the subject a composition described in claim 45 or 46 in an amount effective to enhance the immune response in the subject.

Citation Information

Patent Citations

  • Novel liposome complexes for increased systemic delivery

    JP2000516630A

  • A tumor-targeted nanodelivery system to improve early MRI detection of cancer

    JP2009512712A

  • Magnetic nanoplatforms for theranostic and multi-modal imaging applications

    WO2011112597A1